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ABSTRACT / 
RESUMEN
The demographic trend in Europe shows a gradual aging of the population. Aging is a process 
that have been associated with the development of age-related diseases as diabetes, 
cardiovascular disease or cancer. Immune defeat, cognitive impairment or the loss of proper 
regulation of sensory pathways of metabolic state such as IGF-1/PI3K/AKT/FOXO and 
AMPK/SIRT1/mTOR pathways are other hallmarks of aging. Aging is an irreversible process, but 
it can be modulable, and it is also affected by environmental factors as diet. In this sense, a 
healthy dietary pattern as Mediterranean Diet or its specific foods and caloric restriction have 
been postulated as the most important interventions that allow increasing the expectancy and 
quality of life. MicroRNAs, short non-coding RNA sequences are key epigenetic regulators of 
these nutrient sensing pathways. This thesis is focused in the nutritional modulation of 
microRNAs related to cardiovascular disease and aging and regulating nutrient sensing 
pathways. For this purpose, we carried out different intervention studies with functional extra 
virgin olive oil enriched with its own polyphenols in healthy patients (VOHF study), beer and 
non-alcoholic beer in volunteers at high cardiovascular risk (miRoBeer study) and Mediterranean 
Diet (MD) with/without caloric restriction in late adults with metabolic syndrome (PREDIMED-
PLUS study). In addition, it has been tested the presence of exogenous microRNAs in human 
plasma. The results obtained in this thesis showed first, the non-detection of exogenous 
microRNAs in human plasma in nor in in olive oil and beer. With the VOHF study, we observed 
that functional extra virgin olive oil consistently regulated let-7e, microRNA implicated in insulin 
signaling and inflammation, miR-17-92 cluster, which is a regulator of IGF-1/PI3K/AKT/FOXO and 
AMPK/SIRT1/mTOR pathways and miR-328, implicated in hypertension and cardiovascular 
disease. In miRoBeer study we observed a downregulation after non-alcoholic beer intake and 
an upregulation after beer intake of macrophages miR-17-92 cluster, miR-26b, miR-145, miR-
223 and circulating levels of miR-17-92 cluster, miR-155 and a downregulation of miR-320 in 
both types of beer suggesting an anti-inflammatory microRNA profile but a worse glucose 
homeostasis. In additions, we observed a correlation between macrophage and circulating levels 
of miR-328, let-7e, miR-92 and miR-26b suggesting a link between both. Last, we observed a 
downregulation after 1 year of treatment with a hypocaloric Mediterranean diet with physical 
activity of macrophage miR-130a and miR-30c in MD in PREDIMED-PLUS study and a lower 
population of senescent lymphocytes. To conclude, we suggest that one of the mechanisms by 
MD and their associated foods have beneficial effects on human health could be the modulation 
of microRNAs and the observed modulation of circulating microRNAs suggest the detection of 
putative biomarkers of nutritional response, but further studies are necessary to confirm this 
effect. 
3 
ABSTRACT/RESUMEN 
ABSTRACT/RESUMEN 
Europa muestra un envejecimiento gradual de la población que tiene asociado el desarrollo de 
enfermedades como la diabetes, las enfermedades cardiovasculares o el cáncer además de la 
disfunción inmune, el deterioro cognitivo o la pérdida de la regulación de vías sensoras del 
estado metabólico, como la vía de IGF1/PI3K/AKT/FOXO y la vía de AMPK/SIRT1/mTOR. El 
envejecimiento es un proceso irreversible, pero que a su vez puede ser modulable, y que está 
afectado por factores ambientales como la dieta. En este sentido, un patrón dietético saludable 
como la dieta mediterránea o sus alimentos típicos y la restricción calórica se han postulado 
como algunas de las intervenciones más importantes que permiten aumentar la calidad y 
esperanza de vida. Los microRNAs, secuencias cortas de ARN no codificantes, son reguladores 
epigenéticos clave de estas vías sensoras de nutrientes. Esta tesis está centrada en la 
modulación de microRNAs relacionados con las enfermedades cardiovasculares, envejecimiento 
y vías sensoras de nutrientes. Para ello, hemos realizado diferentes estudios de intervención con 
aceite de oliva virgen extra funcional enriquecido en sus propios polifenoles en pacientes sanos 
(estudio VOHF), un estudio con cerveza y cerveza sin alcohol en voluntarios con alto riesgo 
cardiovascular (estudio miRoBeer) y un estudio con Dieta Mediterránea (DM) con/sin restricción 
calórica en adultos de edad avanzada con síndrome metabólico (estudio PREDIMED-PLUS). 
Además, se ha testado la presencia de microRNAs exógenos en plasma humano. Los resultados 
obtenidos en esta tesis muestran, en primer lugar, la no detección de microRNAs exógenos en 
plasma humano así como en aceite de oliva y cerveza. En el estudio VOHF observamos que el 
aceite de oliva virgen extra funcional regulaba consistentemente let-7e, microRNA implicado en 
la cascada de señalización de la insulina e inflamación, miR-17-92 cluster, regulador del IGF-
1/PI3K/AKT/FOXO y AMPK/SIRT1/mTOR y miR-328, implicado en la hipertensión y las 
enfermedades cardiovasculares. En el estudio miRoBeer se observó una sobreexpresión en 
cerveza con alcohol y una represión en cerveza sin alcohol del miR-17-92 cluster, miR-26b, miR-
145, miR-223 en macrófagos y en los niveles circulantes de miR-17-92 cluster, miR-155 siendo 
una represión de miR-320 en ambos tipos de cerveza, sugiriendo un perfil de microRNAs 
antiinflamatorio pero con una peor homeostasis de la glucosa. Además, observamos 
correlaciones entre los niveles de macrófagos y circulantes de miR-328, let-7e, miR-92 y miR-
26b, sugiriendo un vínculo entre ambos. Por último, observamos una represión de miR-130a y 
miR-30c después de 1 año de tratamiento con DM con restricción calórica en el estudio 
PREDIMED-PLUS, además de una menor población de linfocitos senescentes. Por todo ello 
sugerimos que uno de los mecanismos por los que la DM y sus alimentos asociados tienen 
efectos beneficiosos en la salud humana podría ser la modulación de los microRNAs además de 
que la modulación observada de microRNAs circulantes sugiere la detección de biomarcadores 
de respuesta nutricional, aunque son necesarios más estudios para confirmar este efecto.
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1. Aging situation of European and Spanish population
The demographic trend in Europe indicates a gradual aging of the population. According to 
Eurostat, average age of European population will increase by 4.2 years between 2014 and 2080. 
The demographic shift in European countries has been attributed to the progressive decrease in 
the levels of birth and mortality. The percentage of the population over 65 years old will increase 
from 18.5% (93.9 million people) in 2014 to 28.7% (149.1 million people) in 2080, assuming an 
increase of 55.2 million people (1). 
If we focus on elderly people (defined as people older than 80 years), the increase in this specific-
age group of population will increase from 5.1% in 2014 to 12.3% in 2080, resulting in an increase 
of more than double respect to the current proportion (from 26 million in 2014 up to 63.9 million 
in 2080). 
Regarding to the European pyramid of population in 2014 and, comparing it with the pyramid 
predicted for 2080 (figure 1), we can observe that the distribution of the population shifts from 
a rhomboidal distribution, with a majority percentage of working-age population, to a 
distribution with the form of an inverted pyramid, equilibrating the working-age population with 
the retired population. Especially relevant is the increase of centenarians, especially in women. 
Figure 1: Comparison between the European population pyramid in 2014 with the projected population 
pyramid for the year 2080 (Source: Eurostat) 
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If we look at the specific data from Spain, we can see a trend very similar to the demographic 
shift predicted in Europe, but with a more pronounced aging of the population (figure 2). The 
causes behind this demographic shift in Spain are the same that in Europe, a lower number of 
births and deaths. Especially relevant is the increase in lifespan, which will go from 80.2 years in 
men and 85.71 years in women, to a projection of 88.6 years in men and 91.6 years in women 
in the year 2060 (2). 
Figure 2: Comparison between the Spanish population in 2016 with the projected population in the year 
2031 and 2066 (Source: Spanish national statistical institute, INE) 
Not only is Europe facing a gradual aging of its population, but also all the developed or 
developing countries are facing this circumstance. However, we cannot consider the aging of 
the population as only a demographic curiosity, but it has been associated to a very significant 
economic, health and social impact, and can influence the policies that will be carried out in the 
coming years or decades. 
Aging is an irreversible biological process, but it can be modulated. An intervention on aging can 
not only increase lifespan, but also improve the quality of life, delaying as far as possible the 
appearance of physiological complications related to age. These actions are framed in the field 
of prevention, rather than treatment and it is of such importance that more and more countries 
seek new health policies in order to improve the quality of life of elderly adults. Under this 
premise, the concept of "healthy aging" describes the health status of people who, even after 
reaching an advanced age, are free of disease. Unfortunately, the current situation is far from 
reaching the ideal state of healthy aging. The increase of diseases associated with age is 
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becoming one of the main health problems in developed and developing countries. Aging is 
associated with the development of diseases such as Alzheimer's or Parkinson's diseases, Type 
2 Diabetes Mellitus (T2D), cancer or cardiovascular disease (CVD) and its associated 
complications. Definitely, the main objective of healthy aging is not just to live longer; it is to live 
longer with good quality of life. 
In the current situation, we are faced with the following question: What type of intervention is 
the most appropriate to face aging? There is no clear consensus that can answer this question, 
although we can find several promising approaches from different areas such as 
pharmacological, dietary or behavioral intervention (3). 
2. Interventions focusing on increasing longevity and promoting healthy aging
As described above, the aging process is modulable. This means that is subjected to 
environmental factors that influence it. These environmental factors are smoking, pollution, 
physical activity (PA) and diet (4). In addition to this, we have seen the influence of some drugs 
on the aging process, as well as on their associated diseases. Some of the interventions that have 
been studied in aging are pharmacological interventions, interventions on lifestyle and on diet. 
2.1 Pharmacological interventions 
It has been described that certain drugs can have a potential to enlarge lifespan. Some of the 
drugs that are thought to have the greatest influence on aging are metformin, rapamycin, statins 
or aspirin. Metformin, one of the most widely used drug for the treatment of diabetes and 
prediabetes, is a hepatic activator of AMP-activated protein kinase (AMPK), which, as 
mammalian target of rapamycin (mTOR), is a sensor of the cellular energy state signaled by the 
AMP/ATP ratio (ATP, adenosine triphosphate). In worms, rats and mice it has been described 
that metformin increases lifespan (5), whereas in humans, the treatment with metformin slows 
the development and progression of diseases associated with aging such as CVD, cancer and 
neurodegenerative diseases (6, 7). Rapamycin, whose main target is mTOR, has been described 
to have an effect on cardiac aging, as well as on inflammation, oxidative stress and cellular 
senescence (8, 9). Furthermore, in mice treated with rapamycin, an increase in lifespan and 
better general health have been observed, with a greater effect in female mice than in male 
mice (10). However, the mechanism of action by which rapamycin  increases lifespan is not clear 
because, even though there is an inhibition of mTOR expression, levels of Insulin-like growth 
factor-1 (IGF-1) decreased, levels of leptin increased and levels of insulin decreased in males and 
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are softly higher in females, and a worse glucose tolerance has been observed (11). Statins are 
used to lower blood cholesterol levels, being the drug of choice when analytical values of total 
cholesterol greater than 200 mg/dl in blood are consistently observed. Apart from the described 
effect, it has been described that AKT (AKT serine/threonine kinase) activation increases with 
statins treatment and is associated with lower mortality in elderly people (12). Finally, 
acetylsalicylic acid, known as aspirin, is used as an anti-inflammatory, analgesic and antipyretic 
treatment, in addition to its antiplatelet effect. Moreover, it has been described an increased 
lifespan in crickets and mice treated with this drug (13, 14). Table 1 shows a summary of 
pharmacological interventions. 
2.2 Interventions on lifestyle 
Although lifestyle interventions on aging have not been widely studied, a relationship between 
both can be observed. For instance, there is an important connection between the feeling of 
loneliness and healthy aging (15), demonstrating that a lifestyle that fosters social relationships 
can promote better aging. Within the scope of action on lifestyle, it should be also including the 
usual practice of PA. The benefits of sports practice on health are well-known (16), but the 
mechanisms by which PA promotes healthy aging must be studied in depth. PA has been 
postulated as the only treatment for sarcopenia, which is a disease associated with aging (17). 
In addition, PA has a protective effect on cognitive deterioration, as well as on 
neurodegenerative diseases associated with aging such as Parkinson's and Alzheimer's diseases 
(18). Some studies have shown that, the blood flow velocity in the middle cerebral artery is 
higher in people who exercise regularly than in sedentary people. This suggest a protective effect 
with respect to cerebral atrophy associated with aging (19).  Another observational study 
associated an active lifestyle with a lower incidence of neurodegenerative diseases  (20). 
Regarding the length of the telomeres, an important marker of aging, it was observed that, 
among healthy volunteers, those who were marathon runners had greater telomere length than 
sedentary volunteers (21). Table 1 shows a summary of the interventions on lifestyle. 
2.3. Nutritional interventions 
Diet is one of the most studied environmental factors given tis great impact on aging. In this 
sense, caloric restriction (CR) has been postulated as one of the most important interventions 
that allows increasing the expectancy and quality of life of the participants subjected to it (22). 
There are large number of studies showing that CR can increase lifespan as well as promote an 
improvement in the quality of life in aging. These studies range from simple animal models such 
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as Caenorhabditis elegans to more complex models such as monkeys (23). However, studies in 
humans, especially interventional studies, are scarce, mainly due to ethical and social 
considerations that can limit a sustained CR over time. 
2.3.1. Evidences from studies in animal models 
CR increases lifespan in different animal models. In 2006, Kaeberlein et al observed an increase 
in lifespan in Caernohabditis elegans nematodes, which were deprived of food (24). Other 
models in which CR has been shown to increase lifespan have been fly Drosophila melanogaster 
(25) and yeasts such as Saccharomyces cerevisiae (26). 
In the 1980s, using SPF Fischer 344 rats, Yu et al observed that 60% of the rats subjected to CR 
(40% with respect to their ad libitum feeding) significantly increased their lifespan comparing to 
control rats (27). In addition, it was observed that rats under RC had fewer diseases and age-
related deterioration (27). In another study, also conducted on SPF Fischer 344 rats, which 
underwent a smoother CR (8%) along with PA (28), authors found an improvement of muscle 
composition, oxidative stress, cell death and autophagy (28). Intermittent fasting (IF) is another 
approach for CR which limits the calories intake certain days while ad libitum food intake is 
allowed in other days (29). In the liver of rats subjected to a CR of 40% and to an IF, that provided 
access to food every other day, the sensitivity to glucagon was maintained in levels similar to 
those of young rats in the CR group while the insulin sensitivity was maintained in the IF group 
(30). 
In murine models, mice subjected to an IF with CR of 40% showed a better regulation of glucose 
homeostasis as well as a 40% reduction in IGF-1 levels. However, these mice exhibited 
hyperphagia in response to fasting periods (31).  In 2007, Varady et al presented a study in 
C57BL/6J mice subjected to different levels of CR with IF (1 day with 50% CR and another day ad 
libitum). The results showed that, although the 50% CR and fasting days modulated the function 
of adipocytes, no changes in weight or amount of adipose tissue were observed (32).  
A meta-analysis that studied CR in rat and mouse models concluded that there is sufficient 
evidence that CR influences lifespan of mice and lead to a lower rate of age-related diseases 
incidence. However, more studies are necessary because the effects of CR vary according to the 
strain of the mouse as well as the design of the intervention based on CR (33). 
Regarding more complex animal models such as monkeys, there is greater controversy about 
the effects of CR on aging. In a study carried out by the Wisconsin National Primate Research 
Center (WNPRC) on non-human primates (Rhesus monkeys) subjected to a CR of 30%, a lower 
incidence of diseases associated with aging, a smaller loss of brain gray matter, as well as an 
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increase in lifespan was observed  (34). Parallel to this study, the National Institute of Aging (NIA) 
carried out another study in the same species of monkeys that contradicted the previously 
described results, since it was not observed that CR increased lifespan (35). However, it has been 
concluded that there are evidences that CR benefits health in monkeys and that mechanisms 
explaining these benefits could be similar in humans (34-36). This disparity of results in both 
studies can be explained by the different experimental designs that were made in both studies 
(37). However, these results highlight the need to carry out more studies to elucidate the effect 
that CR has on aging. Table 1 shows a summary of the evidence in animal models regarding the 
effect of CR on aging. 
2.3.2. Evidences from studies in human populations 
2.3.2.1. Effect of CR on markers of aging and cardiovascular health 
Regarding the studies carried out in humans, most of them have been observational studies, 
due to the ethical considerations involved in the development of long-term CR trials. However, 
it is well described that CR and a healthy dietary pattern have a beneficial effect on longevity 
and age-related diseases. In the 1950s, certain regions of the world were described in which the 
number of centenarians was significantly higher. These areas, which were called "Blue Zones", 
are Sardinia in Italy, Okinawa in Japan, Nicoya in Costa Rica and Ikaria in Greece (38). 
Interestingly, all these regions are in the same geographical area, they are adjacent to the 
parallel 42, which suggests that these regions share similar climatological characteristics. It has 
been proposed the inclusion of a new blue zone that would be located on the island of Menorca 
given its higher rate of centenarians with respect to the whole Spanish population, but it would 
be necessary a deeper study of this population to elucidate  the causes behind the extreme 
longevity of this island  to consider this area as such (38). The greater longevity in these areas 
has been related to PA, an active social life, an optimistic attitude and a healthy dietary pattern 
(39). One of the most studied regions is the Okinawa region. Studying their traditional pattern 
of diet, it was observed that it has a low animal protein content and is rich in vegetables, fruits 
and fish, as well as in isoflavones from soy. Additionally, the a caloric content is 17% lower than 
the Japanese average intake (40). In addition, this dietary pattern is rich in mono and poly-
unsaturated fats (MUFA and PUFA, respectively), characteristics shared with other dietary 
patterns described as healthy, such as the Mediterranean Diet (MD). These patterns have the 
ability to modulate different molecular processes associated with aging, such as telomere length 
or oxidative stress (41, 42). 
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Currently, there are only a few studies in humans that analyze the effect of a CR on aging. 
The main CR study conducted in humans is the Comprehensive Assessment of Long- term Effects 
of Reducing Intake of Energy (CALERIE) study, in which healthy women and men with normal 
weight or overweight were recruited and divided into 4 intervention groups for 6 months: 
control group, very low calorie diet group (890 Kcal/d) to lose 15% of the weight, group with a 
CR of 25% from the diet and group with a CR of 25% achieved with a 12.5% CR diet and a 12.5% 
increase in energy expenditure through PA. The results obtained in this study showed a decrease 
in weight, body temperature,  blood glucose and insulin levels and other the decrease in other 
biomarkers such as DNA damaged, thyroid hormones T3 (Triiodothyronine) and T4 (Thyroxine) 
in the groups subjected to CR (43). In the longer term, the two-year CALERIE-2 study did not 
observe significant differences in body temperature compared to the control group (44). 
However, these results could be due to a decrease in adherence to the treatment in the CR 
group, since it was maintained for a long period. Subsequent analyzes of the CALERIE study also 
showed that CR reduces hepatic lipid levels (45) and improves the cardiovascular risk profile 
(46). On the other hand, in patients undergoing CR, the levels of ghrelin (considered the hunger 
hormone) increased, and the levels of cortisol (47) and growth hormone were not modified (48). 
In addition to these results,  a metabolic and behavioral adaptation was observed in patients 
undergoing CR that resulted in an improved physical capacity and vitality (49), without producing 
eating disorders  (50)  in a period ranging from 6 to the 12 months of intervention. 
Another study worth mentioning is the Calorie Restriction with Optimum Nutrition (CRON) study, 
which is an observational study of the members of the "Calorie Restriction Society", which 
voluntarily have undergone a CR of 30% during a period of 15 years. The members of this society 
had lower levels of LDL (low-density lipoprotein) cholesterol, triglycerides, blood pressure and 
fasting glucose and insulin, as well as higher levels of HDL (high-density lipoprotein) cholesterol 
compared with people of the same age and sex who are consumers of a normal western diet 
(51). Other markers of aging that were modified were body temperature and interleukin levels, 
which were reduced (52, 53), suggesting that CR can result in an increase in lifespan in humans. 
Although these results (one observational and one intervention study) are promising, more 
research is needed in the field of CR in order to confirm its beneficial effects. Both studies are 
carried out in healthy non-obese of overweight individuals. It would be interesting to describe 
the effect of CR in a high CVD risk population.  A meta-analysis including 42 intervention and 
observational studies concluded that CR decreases the accumulation of visceral fat, markers of 
inflammation and leptin levels and increases adiponectin levels (54). In addition, CR also 
produces a metabolic adaptation of the organism that is expressed as  a decrease in energy 
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requirements, muscle mass and strength, that is more pronounced when CR is maintained long-
term (54). Table 1 shows a summary of the evidence of CR in humans and animal models. 
2.3.2.2. Interventions based on IF 
Apart from the studies described above based on CR, the IF is another type of nutritional 
intervention studied with the aim of promoting healthy aging. This type of intervention was 
studied in the Alternate Day Fasting in Humans (FEAST) study, which recruited 8 men and 8 
healthy women who underwent fasting every other day for 22 days. After the intervention, the 
patients lost 2.5% of their basal weight as well as 4% of the fat mass. Although the feeling of 
hunger increased on the first day and remained high, there was no significant increase in ghrelin 
levels. Fasting insulin levels increased as well as the oxidation of fatty acids, while fasting glucose 
levels were not affected  (55). These results were confirmed in a subsequent study of the genes 
involved in the oxidation of fatty acids, which were over-expressed, and the genes involved in 
glucose homeostasis, which were not affected (56). However, in insulin-resistant individuals, IF 
may have a beneficial effect on this resistance (57). Another study conducted on young women 
with overweight or obesity showed that both, CR and IF, reduced weight, leptin, total cholesterol 
and LDL cholesterol levels, while increased insulin sensitivity (58). However, some disadvantages 
associated with IF such as bad mood or increased visceral fat due to inactivity associated with 
fasting days have been described (59). In summary, both, sustained CR and IF, can help increase 
lifespan as well as healthy aging, as studies in both animal and human models suggest. Table 1 
shows a summary of the evidence of IF in animal models and in humans. 
2.3.2.3. Selective nutrient restriction 
Finally, it is important to highlight some studies that propose only restricting some nutrients as 
an alternative to complete CR. Although it has been observed that diet has a very important 
effect on increasing lifespan, it is not known what type of dietary intervention is the one that 
produces a greater, safer and more sustained effect. In this regard, diets with protein restriction 
have been shown to be more effective in the repression of mTOR compared with diets with CR 
in mice (60). In this sense, a restriction of serine, threonine and valine in yeasts produces a 
resistance to stress, as well as an increase in longevity (61). However, a study carried out in 
Drosophila melanoganster showed that a CR produced a greater increase in lifespan compared 
to a carbohydrate restriction, independently of caloric intake (62). In rats, a specific restriction 
of tryptophan has been related to an increase in longevity (63, 64), as well as a restriction in the 
intake of L-methionine from 0.86% to 0.17% increased lifespan 30% in Fisher 344 rats (65). Diets 
low in methionine also decrease levels of IGF-1, glucose and insulin and confer greater resistance 
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to liver damage promoted by oxidative stress (66). Although some studies suggest that general 
control nonderepressible 2 (GCN2) protein, an aminoacid sensor, and mTOR play a role in 
mediating the beneficial effects of restricting some amino acids (67) it is not yet clear which 
molecular mechanisms are involved. 
In a murine model of breast and prostate cancer, it was observed that a protein restriction 
decreased tumor growth and mTOR activity in the tumor, also leading to lower levels of serum 
IGF-1 (68). In mice, diets low in protein and high in carbohydrates also produce a decrease in 
mTOR levels and an increase in lifespan (60). In humans, serum IGF-1 levels are not affected by 
CR, but they decrease with a low protein diet (69). Table 1 shows a summary of the evidence in 
animal models regarding the specific restriction of nutrients. 
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Intervention 
type 
Intervention Effect References 
Pharmacological 
interventions 
Metformin → AMPK ↑ Lifespan ↓ CVD, ↓Neurodegenerative diseases, ↓ Cancer (5-7) 
Rapamycin → mTOR ↓ Inflammation, ↓ Oxidative stress, ↓ Cellular senescence,  ↓ Cardiac aging (8-11) 
Statins → AKT ↓ Old mortality (12) 
Aspirin → AMPK ↑ Lifespan, ↓ Inflammation (13, 14) 
Lifestyle 
interventions 
Social ↑ Lifespan (15) 
Physical activity ↑ Telomeres length ↓ Sarcopenia, ↓ Neurodegenerative diseases,  
↓  Cerebral atrophy 
(17-21) 
Nutritional 
interventions 
Caloric restriction  Animal models C. elegans ↑ Lifespan (24) 
Flies ↑ Lifespan (25) 
S. cerevisiae ↑ Lifespan (26) 
Rats ↑ Lifespan, ↓ Age-related diseases (27, 28, 30) 
Mice ↑ Lifespan, ↓ Age-related diseases, Glucose homeostasis  (31-33) 
Monkeys 
NIA study  = Lifespan (35-37) 
WNPRC study ↑ Lifespan, ↓ Age-related diseases, ↓ Cerebral grey mass loss (34, 37) 
Humans CALERIE study ↓ Body temperature, ↓ Glucose and insulin levels, ↓Thyroid hormones, 
↓Hepatic lipids, ↓ Cardiovascular risk, ↑ Ghrelin, metabolic adaptation (43-46, 48-50) 
CRON study ↓LDL, ↓ Triglycerides, ↓Blood pressure, ↓Glucose, ↓ Insulin, ↓ Body 
temperature, ↓ Interleukins, ↑HDL, metabolic adaptation (51-53) 
Intermittent 
fasting 
Humans FEAST study ↓Weight, ↑ Insulin, ↑Fatty acid oxidation, ↑Hunger feeling (55-57) 
Premenopausal women ↓ Weight, ↓LDL, ↓ cholesterol, ↓leptin, ↑Insulin sensitivity (58, 59) 
Selective 
restriction of 
nutrients 
Animal models S. cerevisiae Serine, threonine and 
valine restriction 
↑ Lifespan, ↑ Stress resistance (61) 
D. melanogaster  Carbohydrates 
restriction 
↑ Lifespan (62) 
Rats 
Tryptophan restriction ↑ Lifespan (63, 64) 
L-methionine 
restriction 
↑ Lifespan, ↓ Insulin, ↓Glucose, ↓IGF-1, ↑Hepatic damage resistance (65, 66) 
Mice 
Proteins restriction ↓ Tumoral growth ↓ mTOR activity, ↓IGF-1 (60) 
Carbohydrates 
restriction 
↓ mTOR activity, ↑ Lifespan (60, 69) 
Table 1: Summary of all type of interventions described with an effect in healthy aging and longevity 
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3. The Mediterranean Diet: a great allied in healthy aging
3.1 MD: a healthy diet pattern 
MD is defined as the traditional diet of the countries around Mediterranean Sea. This diet is 
characterized by a high consumption of olive oil (being the main source of fat), vegetables, 
legumes, fruits and nuts, with a moderate consumption of blue fish and white meat and with a 
low consumption of other types of fat and red meat (figure 3). In addition, MD is associated with 
a moderate consumption of alcohol, usually from fermented alcoholic beverages such as wine 
or beer and with moderate PA (70). Among the beneficial properties associated to MD, it is 
worth highlighting the improvement in cognitive function, which indicates an important effect 
on the quality of life in elderly people (70). The importance of MD in maintaining an optimal 
state of health is well demonstrated. The first evidence about the benefits of MD were described 
in 1958 by Ancel Keys in the 7 countries study, tat describe a lower prevalence of CVD in 
countries around Mediterranean Sea that shared the same dietary pattern (71)  . The Prevención 
con Dieta Mediterránea (PREDIMED) study has demonstrated its clear cardioprotective profile 
with respect to the low-fat diet recommended by the American Heart Association (72). Some of 
the potential mechanisms of this effect are related to factors such as inflammation, oxidation 
and lipid profile, among others (72) . It has been described that, in these Mediterranean 
countries, the prevalence of cardiovascular disease is lower (42), a greater longevity has also 
been observed in populations with a high adherence to the MD (73, 74). These results could 
indicate that the combination of a CR together with the beneficial properties of MD could have 
a very positive effect on healthy aging. 
Figure 3: Food pyramid of the Mediterranean Diet (Source: Mediterranean Diet Foundation) 
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Although we are beginning to discern the mechanisms that could explain the effect of MD on 
aging, such as the length of telomeres (41), the effect of this diet on other markers of aging has 
not been fully deciphered. 
3.2. The role of olive oil in health 
Olive oil is one of the most representative foods of MD and to which unique health properties 
have been widely described (75-77). The formulation of olive oil can vary greatly depending on 
the type of olive used for the extraction, the variety of the climate, the soil and the extraction 
procedure. According to the extraction procedure of olive oil, during the process, it can be 
obtained extra virgin olive oil (EVOO), virgin olive oil (VOO), olive oil (OO) and refined olive oil 
(ROO) being the highest quality the EVOO (78). 
The composition of olive oil in fatty acids is oleic acid (55-85%), palmitic acid (6-20%), linoleic 
acid (2-20%), stearic acid (0.3-5%), palmitoleic acid (0.3-2%) and linolenic acid (0.1-1.5%) (79). 
Olive oil also has a large number of polyphenols that contribute to its healthful properties (80). 
The use of olive oil as a cardio protective agent has been also studied. The observational study 
"Study of Three Cities" shows a relationship between the consumption of olive oil and a lower 
prevalence of strokes in elderly adults (76). In addition to this, PREDIMED study shows a lower 
percentage of stroke in high cardiovascular risk volunteers under a MD supplemented with olive 
oil compared with the control group that consumed a low-fat diet (72).  
Oleic acid, the main fatty acid in olive oil, increases HDL cholesterol levels and decreases the 
oxidation of LDL cholesterol in humans (75, 81). Additionally, polyphenols present in olive oil 
have been shown to have a chemo-protective effect. The most important polyphenol is 
hydroxytyrosol, which is a phenolic alcohol involved in the elimination of oxygen free radicals 
species (ROS) and with an antioxidant effect (82). Moreover, hydroxytyrosol has also been 
shown to have an anti-inflammatory, antiplatelet, antiatherogenic (83), antitumor (84) or 
neuroprotective effect (85, 86). Apart from hydroxytyrosol, other polyphenols present in olive 
oil such as secoiridoids, hydroxy-isochromans, flavonoids and lignans have an effect on microbial 
activity, inflammation, oxidation, platelet aggregation and on the lipoprotein profile (87). 
However, this healthy effect of olive oil could be modified according to the amount of 
polyphenols present in it, an amount that is affected by environmental factors, type of tree and 
olive variety  (88). 
Despite these results, the effect of olive oil intake at the molecular level has not been described 
in depth. In this regard, it is unknown how it modulates gene expression in humans, even though 
this modulation has been seen in cell lines and in murine models (89). In the Virgin Olive Oil and 
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HDL Functionality (VOHF) study, the effect of different types of virgin olive oils (some of them 
enriched in polyphenols) on the modification of HDL as well as on other parameters associated 
with cardiovascular benefits was analyzed in 33 hypercholesterolemic participants. These 
patients took  three different types of oil enriched in its own polyphenols and authors observed 
that the intake of EVOO and its enriched variants modified the functionality of HDL cholesterol, 
as well as the expression of proteins related to cholesterol metabolism, response to oxidation, 
coagulation , lipid transport or immune system (81). Other postprandial study carried out  with 
6  healthy volunteers (90) and  a 3 months study with 90 healthy volunteers (91)  did a molecular 
approach analyzing the changes in the expression levels of genes involved in inflammation, 
oxidative stress, lipid metabolism, cellular apoptosis or DNA damage after an intake of EVOO, 
showing a downregulation of proatherogenic genes or upregulation of anti-inflammatory genes 
producing a cardioprotective effect (90, 91). 
3.3. The role of beer in health 
Beer is one of the most popular fermented beverages in Europe and is original of the 
Mediterranean area. Fermented drinks are those in which, during the manufacturing process, 
the food source is modified by yeasts and, as a consequence, some changes in the nutritional 
composition happen (92). This fermentation process is considered one of the oldest 
biotechnological applications in food. Moreover, appearance of beer in the human diet has been 
dated around 5000 BC. In 2016, 39,000 million liters of beer were produced in the European 
Union, with 900 million liters corresponding to the production of beer without alcohol 
(considered beer with 2% or less of alcohol). Beer is mainly composed by water, hops, yeast and 
malted cereals (usually barley but can be made from other cereals). In the brewing process, the 
grain is introduced into water where the grain germinates and enzymes break the cell wall and 
starch producing the softening of the cereal. Once the optimum point of germination is reached, 
the cooking process starts, which will stop the germination and eliminate part of the humidity 
of the grain. In this process organoleptic changes occur in the color and flavor of the grain due 
to the high temperature, turning the grain into malt, which is stored for several weeks. 
Subsequently, the malt is grinded and soaked with hot water to gelatinize it and to facilitate the 
digestion process carried out by amylases. The liquid produced is collected and boiled with the 
hops. Later, a clarification and cooling process takes place adding the yeast strain specific of the 
type of beer that is being manufactured. In the fermentation process, yeasts convert the sugars 
into ethanol and CO2. In addition, other organoleptic changes that give the final taste to beer 
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also occur. Once the beer fermentation process is complete and the yeasts are removed, the 
beer is stabilized, clarified and prepared for consumption (93). 
The nutritional composition of beer consists in carbohydrates, amino acids, vitamins (mainly 
from group B) and minerals such as selenium, potassium, zinc or magnesium (table 2). The 
nutritional composition of beer has been related to its healthy properties (94). It has been 
observed that beer consumption has an effect on factors related to cardiovascular risk such as 
higher levels of HDL cholesterol and lower levels of LDL cholesterol oxidation, as well as anti-
inflammatory properties (95, 96).  
In addition to these effects, other potentially antioxidant, anti-carcinogenic, anti-inflammatory, 
estrogenic and antiviral effects of beer have been described, mainly in in vitro models, and have 
been based on specific compounds of beer, but not on the whole drink (97-99). Many of these 
compounds are polyphenols, which come mainly from the malt (approximately 70-80%), while 
the remaining 20-30% comes from hops (100). Up to 47 different polyphenols have been 
described in beer, including simple phenolic acids, flavonols, flavones, prenylvanoxanes, 
hydroxycinnamoylquinic acids, alkylmethoxyfenols, alpha- and iso-alpha-acids (101). Among all 
polyphenols in beer, it is important to highlight 8-prenylnarigerin (8-PG) and isoxanthohumol 
Component Value Units Component Value Units
Energy 176 (42) kJ (kcal) Energy 108 (26) kJ (kcal)
Alcohol 
(ethanol)
3.96 g
Alcohol 
(ethanol)
0.33 g
Carbohiydrates 3.12 g Carbohiydrates 5.4 g
Fat 0 g Fat 0 g
Protein 0.5 g Protein 0.375 g
Water 92.4 g Water 93.9 g
Vitamin A 0 ug Vitamin A 0 ug
Vitamin D 0 ug Vitamin D 0 ug
Vitamin E 0 mg Vitamin E 0 mg
Folate 6.3 ug Folate 15 ug
Niacine 0.43 mg Niacine 0.7 mg
Riboflavine 0.033 mg Riboflavine 0.0055 mg
Tiamin 0.003 mg Tiamin 0.006 mg
Vitamin B12 0.15 ug Vitamin B12 0.1 ug
Vitamin B6 0.062 mg Vitamin B6 0.034 mg
Vitamin C 0 mg Vitamin C 0 mg
Calcium 8 mg Calcium 5 mg
Iron 0.01 mg Iron 0.02 mg
Potasium 37 mg Potasium 40 mg
Magnesium 9.6 mg Magnesium 7.7 mg
Sodium 4.4 mg Sodium 2.6 mg
Phosforus 55 mg Phosforus 20 mg
Iodine 8 ug Iodine 1 ug
Selenium 1.2 ug Selenium 1.2 ug
Zinc 0.006 mg Zinc 0.008 mg
Beer composition per  100 g
Beer Non-alcoholic beer
Table 2: Beer composition per 100 g (Source: Spanish Food Composition Database) 
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(IX) (101). 8-PG has a beneficial effect in protecting against metabolic dysfunctions associated 
with T2D in mice (102), anticancer activity in U-118 MG cells (103) or activation of PI3K, AKT, 
and p70s6k1 (ribosomal S6 kinase p70) in myotubes, leading to a better recovery from muscular 
dystrophy (104). Studies in mouse models have elucidated the molecular mechanisms 
associated with the effects of xanthohumol (XN), the precursor of IX. Thus, it has been shown 
that XN reduces the growth of the prostate tumor (105), reduces the accumulated cholesterol 
in the aortic arch and increases HDL-cholesterol, an effect that is mediated by a reduction in the 
expression of cholesteryl ester transfer protein (CETP) (106), and improves the atherogenic 
profile of mice deficient in apolipoprotein E (APOE) (107). In Zucker rats treated with XN, a 
reduction in oxidized products derived from the oxidation of fatty acids and ROS species was 
observed, mediated by an improvement of mitochondrial activity attributable to XN (108).Beer 
consumption also prevented the mitochondrial stress induced by Adriamycin in heart and liver 
mitochondria in a rat model treated with beer (109). In animal models closer to humans, such 
as pigs, it was observed that the consumption of beer improved the prognosis in post-infarction 
cardiac recovery, in addition to having other cardioprotective effects such as the greater 
antioxidant capacity of HDL, the activation of the AKT/eNOS (endothelial nitric oxide synthase) 
pathway or the greater resistance to oxidation of LDL in the coronary arteries (96, 110). 
3. Nutrient sensor pathways 
In order to carry out an effective intervention on aging, the first step that must be taken is the 
understanding of how the aging process occurs and what type of factors are associated to aging. 
Some of the processes involved in aging are: genetics factors (variants in genes involved in aging 
pathways and genomic instability), telomeres´ shortening, epigenetic alterations, loss of protein 
homeostasis, alteration of intercellular communication pathways , loss of regenerative capacity 
of stem cell tissues, cellular senescence processes, mitochondrial dysfunction and loss of 
regulation of sensory pathways of metabolic state (111).  
One of the most basic function of living organisms is nutrition, function that must respond, from 
a physiological point of view, to the fluctuation in nutrient levels. The scarcity or abundance of 
nutrients such as sugars, lipids, amino acids, vitamins, minerals, etc. is detected by multiple 
sensory pathways that trigger responses whose main function is to maintain the stability of 
these nutrients, the so-called "nutrient homeostasis". In a situation of abundance of nutrients, 
the activated pathways are anabolic and storage pathways, while in a situation of scarcity, 
catabolic pathways and mobilization of previously stored reserves will be activated (112). Less 
sensitivity to nutrient levels, as well as the deregulation of these pathways has been associated 
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with the appearance of diseases such as cancer, neurodegenerative diseases or metabolic 
syndrome and aging (113, 114). 
Some of the main nutrient sensing pathways that are affected during the aging process are: the 
IGF1/PI3K/AKT/FOXO/mTOR (PI3K, phosphatidylinositol-4,5-biphosphate 3 kinase; FOXO, 
forkhead box O) signaling pathway, whose over-expression is related to aging; and the 
AMPK/SIRT1/PGC1α (SIRT1, Sirtuin 1; PGC1α, peroxisome proliferator-activated receptor γ co-
activator 1 α) signaling pathway, which under a CR is over-expressed and may have a protective 
effect against aging (111, 115). 
4.1. Description of the IGF-1/PI3K/AKT/FOXO/mTOR and AMPK/SIRT1/PGC1α pathways and 
their role in metabolic and cardiovascular diseases 
The primary regulation of IGF-1/PI3K/AKT/FOXO/mTOR pathway is mediated by fluctuations in 
glucose levels. High blood glucose levels promote pancreatic insulin release that leads to an 
increase in IGF-1 levels. IGF-1 binds to its membrane receptor (IGF-1R) leading to its 
autophosphorylation and simultaneously activating PI3K. The activation of PI3K (in its p85 unit) 
gives rise to a conformational change that leads to the binding of the p110 catalytic subunit. 
Activated PI3K phosphorylates PIP2 (phosphatidylinositol-4,5-biphosphate) by adding a new 
phosphate group and transforming it into PIP3 (phosphatidylinositol-3,4,5-triphosphate), which 
activates AKT.  
Figure 4: Regulation and effect of nutrient sensing pathways IGF-1/PI3K/AKT/FOXO and 
AMPK/SIRT1/mTOR pathways 
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This activation produces, in turn, the activation of mTOR and the inhibition of FOXO (figure 4). 
FOXO is involved in the regulation of genes related to metabolism, apoptosis and cell cycle. This 
route is highly regulated by diet and it is modulated by CR (116). 
There is great scientific evidences supporting the notion that the reduction of mTOR expression 
is related to an increase in lifespan in animal models such as yeast, worms, fly and mouse (117). 
mTOR is a protein kinase composed of 2 complexes mTORC 1 and mTORC 2 (113). Instead of 
both complexes has different functions, both  are involved in the pathogenesis of diabetes, as 
well as in the metabolism of pancreatic β-cells (113). mTORC 1 and mTORC 2 activate 
transcription factors such as HIF1α (hypoxia inducible factor 1α) and MYC protooncogene (c-
Myc), which induce the synthesis of glycolytic enzymes (118, 119). HIF1α is related to the 
development of T2D (120) and the overexpression of c-Myc in pancreatic β cells reduces the 
expression of the insulin gene, promoting the development of diabetes (121). FOXO is a key 
transcription factor in a multitude of processes and is well conserved (122). Among the most 
relevant functions are its antioxidant activity, stress response, autophagy, apoptosis or cell 
proliferation (122). 
AMPK/SIRT1/PGC1α signaling pathway is an important regulator of energy status. High levels of 
AMP (adenosine monophosphate) indicates low cellular energy and the necessity of the 
activation of catabolic routes to increase energy availability. High levels of AMP or, more 
specifically, a low ATP/AMP ratio activates AMPK (figure 4), which regulates molecules such as 
Sirtuins, histone deacetylase enzymes that are regulated at the epigenetic level and which have 
been shown to play an important role in the regulation of nutritional status, as well as in 
longevity (123, 124). SIRT1 is  a sensor of NAD+ (nicotinamide adenine dinucleotide) levels, key 
for the regulation of energy metabolism(125). With low levels of AMP, sirtuins levels increase. 
Among the activated SIRT-1, is PGC1α which stimulates the fatty acids oxidation and 
mitochondrial biogenesis (123). In turn, AMPK inactivates mTORC1 (111), which implies an 
interrelation between both pathways of nutrient sensors with an antagonistic effect on the 
aging process. 
4.2. Relationship of nutrient sensing pathways with aging 
The regulation of nutrient sensing pathways plays a crucial role in the aging process. As 
explained in figure 5, the IGF-1/PI3K/AKT/FOXO/mTOR pathway regulates the expression of 
mTOR, whose over-expression is related to aging. On the other hand, signaling of 
AMPK/SIRT1/PGC1α, which could be regulated by CR, is also related to aging. In Caenorhabditis 
elegans, lower signaling of the insulin/IGF-1 cascade leads to a greater response to stress and 
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longevity mediated by repression of the FOXO DAF-16 family binding element (DAF-16) protein 
and an accumulation of skn1 (protein skinhead-1) in the nucleus (126). Moreover, in this animal 
model, a trial with IF in a two-day food/fasting cycle confirmed the role of DAF-16 in the increase 
in longevity (127). In this study, AP-1 (activator protein 1) was also identified as a modulator of 
longevity mediated by IF (127). In Drophosila melanoganster, it has been observed that dFOXO, 
analogous to FOXO3 in mammals, contributes to the modulation of the effect of CR, although it 
is not essential for the increase of longevity (128). In a murine model, it has been suggested that 
the increase in longevity due to CR can be mediated by FOXO3, which has an influence on 
autophagy and oxidative stress (129, 130). CR in rats and humans results in transcriptional and 
post-transcriptional modifications in genes belonging to the PI3K/AKT/FOXO signaling 
cascade(131). Moreover, the study of polymorphisms in these genes has allowed the association 
of the presence of certain polymorphisms with higher lifespan (131) as well as a lower 
prevalence of CVD (132). 
CR increases the metabolic activity of pathways such as glycolysis, gluconeogenesis, oxidative 
phosphorylation or mitochondrial function, while producing a repression of the insulin/IGF-1 
pathway in skeletal muscle in humans and rats (133) (figure 5). In Drophosila melanoganster 
subjected to a CR, mTOR activity decreased, producing an increase in longevity (134). In 
Caenorhabditis elegans, it was observed that the raptor mutation, equivalent to mTOR or 
mTORC1, can increase the lifespan (135). In this species, it was also observed that IF could 
increase the lifespan throughout the modulation of the expression of rheb-1 (Ras homolog 
enriched in brain), which activates mTORC1 (136). However, the mechanisms involved in the 
increase in lifespan in worms are not yet clear because other studies carried out by Kaeberlein 
et al and Lee et al have observed that the increase in lifespan is independent of the insulin/IGF1 
and Sirt2 (Sirtuin 2) signaling cascade (24, 137). 
In addition to this, studies on polymorphisms in the gene encoding the IGF-1 receptor have 
shown that higher levels of IGF-1 in plasma and lower activity of the IGF-1 receptor have been 
associated with extreme longevity (138). Interestingly, in another study conducted by Milman 
et al it was shown that lower levels of plasma IGF-1 were associated with greater survival in 
nonagenarian women while the effect in men was not observed  (139). 
Using samples from studies conducted in humans, it was observed that the addition of serum 
from patients of the FEAST study to HEPG2 cells resulted in a reduction in its proliferation and 
in an increase in the expression of SIRT1 (140). The increase in SIRT1 has also been observed in 
cells with serum from patients undergoing CR of the CALERIE study (140) as well as in muscle 
samples from patients in the FEAST study (56). Studies in yeasts point to the crucial role of the 
synthesis of NAD+ and SIRT2 in the increase of lifespan (141). In mice with Cockayne syndrome, 
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a disease characterized by accelerated aging, it was observed that one of the causes of 
accelerated aging is the deterioration in the DNA repair system that leads to a decrease in the 
activity of SIRT1 (142). In addition, an increase in SIRT1 has been observed in mice subjected to 
CR in certain regions of the brain (143). In addition, an increase in the expression of SIRT1 in the 
brain is related to an increase in life expectancy (144). 
Although the relationship between SIRT1 and the increase in lifespan is well described, the 
mechanism of action has not yet been correctly described. However, it has been observed that 
SIRT1 increases the expression of genes related to neuronal signaling and that an overexpression 
of SIRT1 improves neuronal activation as well as the neuronal adaptive response to CR  (143, 
144). 
All these studies demonstrate the importance of the regulation of SIRT1 to promote healthy 
aging. For this reason, the use of synthetic activators of SIRT1 has been proposed to increase life 
expectancy as well as healthy aging. However, since the molecular mechanisms by which SIRT1 
affects longevity have not been clearly described, the effectiveness of these treatments can not 
be affirmed (145). Some compounds naturally present in foods such as resveratrol activate SIRT1 
in vitro  (146) (Figure 5). 
Figure 5: Relationship between caloric restriction and aging from nutrient sensory pathways. 
Modification of Micó V. et al. (2017) (publication annex) 
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5. MicroRNAs
5.1. Synthesis and function of microRNAs 
MicroRNAs are non-coding RNA sequences with an approximate length of 22-24 nucleotides 
located in inter- or intragenic regions. Sometimes the microRNAs could be concentrated in 
certain regions of the RNA that constitute policistronic regions; being very common the 
transcription of theses microRNAs simultaneously (147). MicroRNAs could be synthesized 
through two different pathways: the canonical pathway and the non-canonical pathway, being 
the canonical pathway the most common form of synthesis in animals (148, 149). 
In the canonical pathway (figure 6a), RNA polymerase II transcribes the microRNA inside the 
nucleus, generating a precursor called pri-microRNA (primary) with a hairpin-shaped structure 
(150). The pri-microRNA goes through different maturation processes before moving on to the 
next phase of its synthesis (151). This process begins with a microprocessor complex of the pri-
microRNA that is responsible for cleaving the pri-microRNA to produce a shorter hairpin 
molecule of approximately 65 nucleotides called pre-microRNA (precursor) (152). The 
microprocessor complex of the pri-microRNA is composed by RNA III Drosha and DGCR8. RNA III 
Drosha is an nuclear endonuclease of 160 kDa approximately. DGCR8 is a protein of 
approximately 90 kDa that is found in the nucleus and nucleoplasm. This protein recognizes the 
pri-microRNA and positions the Drosha catalytic sites for the processing of the pri-microRNA 
(153). 
Pre-microRNA is exported to the cytoplasm via Exportin-5 (EXP-5) (154). This protein forms a 
complex together with the nuclear protein RAN-GTP (GTP, guanosine triphosphate)  (154). This 
protein is found in the nuclear membrane. Upon binding, GTP is hydrolyzed opening a pore from 
which the pre-microRNA exits to the cytoplasm (148, 151, 155). 
Once it is in the cytoplasm, the pre-microRNA is subsequently cleaved by Dicer. Dicer is an 
approximately 200 kDa RNase type III endonuclease (156). Dicer forms a catalytic center that 
processes the pre-microRNA to produce a double-strand sequence of approximately 22 
nucleotides (155). After this processing, both chains of the mature microRNA (3p and 5p) are 
associated with Argonaute proteins (AGO) forming an RNA-induced silencing complex (RISC) 
(148). This complex guides the mature microRNAs towards their target gene, where the 
microRNA produces translational repression and mRNA degradation (148). 
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The other pathway for the synthesis of microRNAs is the non-canonical pathway (figure 6b) that 
originates from sequences found in introns or in genes that encode proteins. These microRNAs 
are called mirtrons and they are processed directly from the gene they belong to without the 
intervention of Drosha or DGCR8. Through the excision of the gene to which the microRNA 
belongs, an intermediate precursor is generated and processed by the lariat debranching 
enzyme obtaining a pre-microRNA that is exported to the cytoplasm via EXP-5 and enters the 
canonical route (157). Recently, a third synthesis pathway called "simtrom pathway" (splicing-
independent mirtron-line microRNAs) has been described. In this pathway, the mirtrons are 
processed by Drosha and by another yet unknown protein similar to DGCR8 (157). Non-canonical 
pathways produce mature microRNAs with the same gene silencing functions as canonical 
microRNAs. 
Figure 6: Description of microRNAs synthesis. A) Description of canonical pathway and b) description 
non-canonical pathway 
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As described above, the main function of the microRNAs is to repress the expression of their 
target genes by binding specifically to them through base complementarity. However, the 
complementarity between microRNA and target mRNA is not always perfect. Depending on the 
degree of complementarity, the microRNAs can induce the degradation of their target mRNA 
(total or high complementarity), or their deadenylation or transductional repression (partial 
complementarity). The binding between the microRNA and the target mRNA sequence occur 
between the recognition region of the 3'UTR (untranslated region) of the mRNA and the 5' 
sequence of the microRNA called "seed sequence" (149, 158). However, microRNA binding to 
5’UTR and coding sequences have also been described (159) 
5.2. Relationship between microRNAs and metabolism and metabolic diseases. Modulation 
mediated by diet. 
Considering the large number of microRNAs discovered in humans, it is believed that more than 
60% of human genes have binding sites for microRNAs (160). The microRNAs have a pivotal role 
in the regulation of several biological processes as well as in the development of disorders and 
metabolic diseases. Some of the processes that have been shown to be influenced by microRNAs 
are the metabolism of glucose, lipids or amino acids and some of the diseases that have been 
associated to microRNAs are diabetes, obesity, CVD, etc.(161-164).  
The onset and progression of age-related diseases such as T2D, CVD, inflammation or cancer are 
modulated by microRNAs  (124, 161, 165, 166). Regarding to T2D, it is known that the let-7 family 
modulates glucose homeostasis and insulin sensitivity in mice (167, 168). Other microRNAs that 
regulate the insulin signaling pathway are miR-33, miR-103, miR-107 and miR-29 (124, 169-172). 
In lipid metabolism, it has been shown that several microRNAs could regulate lipoproteins. For 
example, in mice and non-humans primates, antagonism of miR-122 reduces plasma levels of 
LDL and VLDL (very-low density lipoprotein) (173, 174)and   miR-142, miR-181 and miR-383 were 
overexpressed in mice fed a high-fat diet (175, 176). In the case of miR-30c is an important 
regulator of VLDL metabolism because of it targets the microsomal transfer protein (MTP) that 
regulated VLDL production (177). In addition to this, miR-30c and miR-192 overexpression have 
an effect on the expression of genes related to lipid metabolism (178). Moreover, the expression 
of these microRNAs could be regulated by docosahexaenoic acid (DHA). Regarding to this, miR-
107, a microRNA related to circadian rhythm could be also regulated by DHA in CACO2 cell line 
model (179).  In wistar rats, a high-fat diet reduces the expression of miR-145 (180). The 
regulation of HDL by miR-33a/b has been deeply studied, being the most relevant microRNA in 
its regulation of HDL and reverse cholesterol transport (165, 171). Other microRNAs that 
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regulated HDL are miR-128-1 and miR-148a, whose overexpression results in lower levels of 
circulating HDL and ABCA1 (ATP binding cassette subfamily A member 1) expression (172). In a 
miR-223 knock out (KO) mice model, HDL levels are higher in miR-223 KO mice than in control 
mice (181). In atherosclerosis, a disorder preceding the development of CVD, the absence of 
miR-21 in macrophages results in accelerated atherosclerosis, plaque necrosis, and vascular 
inflammation (182). In healthy women who consumed a diet rich PUFA for 8 weeks, the levels 
of circulating miR-328, miR-330-3p, miR-221 and miR-125a-5p were reduced while miR-192, 
miR-486-5p, miR-19b, miR-106a, miR-769-5p, miR-130b and miR-18a were overexpressed (183). 
Other volunteers who consumed a high-protein diet showed decreased levels of HDL-associated 
miR-223  (184). 
Finally, aging is related to a low-grade level of chronic inflammation. Some microRNAs that have 
an important function as regulators of inflammation are miR-146, miR-155 and miR-21 (185). 
Table 3 shows a summary of the relationship of microRNAs and the pathways they modulate 
with their relationship with the diet. 
5.3. Circulating microRNAs: biomarkers of health status and response to treatment. 
In addition to their regulatory role in a great number of cellular processes, microRNAs have been 
detected in plasma and other biofluids (186). MicroRNAs circulate in the bloodstream associated 
with exosomes, lipoproteins or protein complexes that protect them from possible degradation 
mediated by RNAses (186). In this sense, the role of circulating microRNAs as biomarkers of 
different diseases and also of nutritional status has been postulated (187). 
Circulating miR-1, miR-208a, miR-208b and miR-133a are overexpressed within 2 hours after an 
acute myocardial infarction (AMI) (188, 189)  and circulating miR-423-5p increases its expression 
in heart failure (190, 191).Circulating levels of miR-9 and miR-126 are lower in patients with 
hypertension in comparison with healthy individuals (192). On the other hand, the levels of miR-
221 and miR-222 were significantly lower in atherosclerotic patients compared to healthy 
patients (193). Circulating miR-192, a microRNA related to inflammation, has been found 
overexpressed in patients with chronic inflammation with respect to healthy patients (194). In 
addition, circulating levels of miR-30c can also regulate macrophage-mediated inflammation 
and atherosclerotic pathways (195). Finally, a large number of microRNAs are associated with 
the initiation and progression of cancer, suggesting the possible future importance of the 
measurement of circulating microRNAs as biomarkers of cancer prognosis and treatment (196). 
miR-21-5p, miR-20a-5p and miR-223-3p have been found to be overexpressed  in lung cancer in 
stages I and II (197). 
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Not only have changes in circulating microRNAs been observed associated with disease or 
nutritional status, circulating microRNAs levels could change after performing PA. Circulating 
levels of miR-208b and miR-221 were higher after 3 months of intense basketball training (198). 
Moreover,  a battery of 12 microRNAs related to inflammation (let-7d-3p, let-7f-2-3p , miR-125b-
5p, miR-132-3p, miR-143-3p, miR-148a-3p, miR-223-3p, miR-223-5p, miR-29a-3p, miR-34a-5p, 
miR -424-3p, and miR-424-5p) were overexpressed in post-race marathon runners (199). 
The levels of circulating microRNAs can also be modified in response to a treatment. For 
instance, in a monkey model treated with simvastatin, lower levels of circulating miR-150-5p 
and miR-451 were observed as well as higher levels of miR-3613-5p compared to the untreated 
group (200). Another example can be found in mice treated with an antihypertensive agent 
(captopril) which reduced circulating levels of miR-16, miR-20b, miR-93, miR-106b, miR-223, and 
miR-423-5p with respect to untreated mice (201). 
These investigations reinforce the idea of the potential of circulating microRNAs in the diagnosis 
of CVD or other types of diseases as well as metabolic states. Moreover, circulating microRNAs 
are promising biomarkers of treatment response. 
5.4. MicroRNAs associated with aging 
The expression of many microRNAs could be affected by age. It has been described that the 
increase in aging-related stress leads to a higher expression of p53. P53, among other functions, 
has an influence on the Drosha complex, which affects the maturation of microRNAs (202). In 
addition to this, the microRNA profile (especially circulating microRNAs) also changes with age 
(203, 204). One of the main studies focusing on the circulating profile of microRNAs associated 
to aging  is the study carried out by Serna et al, who studied the circulating profile of microRNAs 
in 36 subjects (20 centenarians and 16 octogenarians) in peripheral blood mononuclear cells 
(PMBCs).They  discovered that the profile of microRNAs of centenarians was more similar to the 
profile of young adults than that of the octogenarians (203). These results could suggest that a 
specific circulating microRNA profile exists that will allow us to predict longevity. However, 
authors use all PBMCs (peripheral blood mononuclear cells) fraction to identify circulating 
microRNAs profiles, without differentiate the type of cells. This implies that the different levels 
of microRNAs observed could be mirroring an age-related change in the cellular composition of 
the blood and is not reflecting real changes in circulatory microRNAs.  Nevertheless, this study 
is a great example of how microRNA profiling could be used to categorize individuals according 
to their longevity. In this regard, the profile of circulating microRNAs could also allow us to 
discriminate between healthy and unhealthy aging, and it could be used to prevent the onset of 
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the disease before it occurs (205). A recent study in humans and mice showed that circulating 
levels of miR-34a change with the development of age-related hearing loss (AHL) (206). Another 
study carried out on Wistar rats showed that the expression of microRNAs changes during aging. 
The authors specifically found an overexpression in pancreatic islets of miR-34a, miR-124a and 
miR-383 and lower levels of miR-130b and miR-181a. These changes in the levels of microRNAs 
could contribute to the failure of pancreatic β-cells resulting in insulin resistance (207). Other 
studies have shown that circulating miR-34 is positively regulated in age-related macular 
degeneration (208). Several studies in the cell lines SH-SY5Y and SK-N-SH suggested the possible 
effects of miR-124 on neuronal apoptosis and autophagy in Parkinson's disease (209). In 
addition, miR-124 is over-expressed in the skin of elderly people compared to the skin of young 
people (209, 210).  In a study comparing miR-223 levels in young and elderly donors, they 
observed that these levels decrease in CD4+ T cells in elderly donors with respect to young 
donors (211). Finally, in human IDH4 fibroblasts, let-7 is related to the expression of p66Shc that 
is involved in cellular senescence (212). Table 3 shows a summary of the relationship of the 
microRNAs and the pathways they modulate with their relationship with aging. 
5.5. Modulation mediated by microRNAs of nutrient sensing pathways 
The role of microRNAs in aging has not yet been studied in depth as well as the role of microRNAs 
in the regulation of molecular pathways affected by the aging process. However, some recent 
studies point to the influence of microRNAs on aging-related processes, such as deregulation of 
nutrient sensing pathways, immune system dysfunction, cellular damage or age-related diseases 
(111). Table 3 shows a summary of the relationship of the microRNAs and the modulating 
pathways. 
5.5.1. Regulation mediated by microRNAs of the IGF1/PI3K/AKT/mTOR pathway 
The IGF1/PI3/AKT/FOXO/mTOR pathway is mainly regulated by let-7, a microRNA that targets 
multiple components of this route, such as the IGF1 receptor or mTOR (167, 168). In Drosophila 
melanogaster, miR-200 and miR-8 are important regulators of PI3K through Zinc finger protein 
USH/ Zinc Finger Protein, FOG Family Member 2 (USH/FOG2) (213). Another study in mouse 
myoblasts demonstrated that miR-432 is a negative regulator of myoblast proliferation and 
differentiation directed to the PI3K/AKT/mTOR pathway (214). In a murine model, regulation of 
this pathway has also been observed by miR-1 (215), a microRNA that is repressed in many 
cancers and inhibits the growth and proliferation of cancer cells, in addition to promoting 
apoptosis (215). Other studies show the role of miR-1 in aging. In a mouse model of progeria, it 
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was found that miR-1 is positively regulated in the liver, independently of the levels of growth 
hormone (GH)  (216). On the other hand, miR-223, a microRNA whose main target is  IGF1R, 
participates in the regulation of mast cell apoptosis in rat basophilic leukemic cells (217). 
Regarding the miR-17-92 cluster, in a mouse model it has been observed that alterations in the 
levels of miR-17-92 could produce the deregulation of mTOR, producing, in turn, the alteration 
of the polarity of the Sertoli cells and spermatogenesis (218). The reduction of miR-17-92 cluster 
expression has also been observed to result in more ROS and DNA damage, which increases age-
related damage (219). In liver cancer, the overexpression of miR-145 produces repression of 
IRS1 (insulin receptor substrate 1 and 2) and KIT (KIT, proto-oncogen receptor tyrosine kinase) 
(220). The expression of miR-145 also decreases in PBMCs with aging. However, higher 
expressions of miR-145 and miR-9 are related to lower levels of FOXO (221). In addition, in 
mouse skeletal muscle cells, treatment with IGF1 results in a reduction of miR-146a levels (222). 
These studies in animal models highlight the role of microRNAs in the regulation of nutrient 
sensing pathways, with a potential impact on the aging process. However, human studies 
analyzing the role of microRNAs in the modulation of these nutrient-sensing pathways and their 
variations with age are scarce. Olivieri F. et al observed a repression of miR-182, miR-223 and 
miR-142-3p in the skeletal muscle of postmenopausal women. These microRNAs regulate the 
expression of IGF-1R and FOXO3A, as well as the activation of insulin/IGF-1 signaling through 
the phosphorylation of AKT and mTOR (223). Another study in humans showed the influence of 
miR-4458 on the regulation of IGF-1. The levels of miR-4458 are higher and are inversely 
correlated with the levels of IGF-1R in patients with lumbar disc degeneration (LDD) compared 
to subjects with damage but without lumbar disc degeneration. These results suggest a 
relationship between the appearance of LDD with the levels of this microRNA (224). 
Furthermore, in humans, miR-613, which has c-MET (tyrosine protein kinase MTE) and 
PI3K/AKT/mTOR as its main targets, is repressed in osteoarcoma and its repression is associated 
with metastasis in lymph nodes (225). In human melanoma cell lines and melanoma tissues, 
miR-425 was repressed. The authors suggested that miR-425 could be a tumor suppressor by 
repressing the PI3K-AKT pathway (226). In aother human cell line, GIST882, microRNA-221 
induces apoptosis through KIT/AKT (227). In a bone marrow cell line,  it has been shown thatIGF1 
can block the processing of miR-34a (228). Finally, in the HOS, KHOS, U2OS and MG-63 cell lines, 
as well as in osteosarcoma samples from patients, it was observed that miR-16 inhibits cell 
proliferation via IGF1R (229). 
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5.5.2. Regulation mediated by microRNAs of the AMPK/SIRT1/PGC1α pathway 
The AMPK/SIRT1/PGC-1α pathway is also regulated by microRNAs. Some of them can regulate 
both, the IGF1/PI3/AKT and the AMPK/SIRT1/PGC1α pathways. For instance let-7, which targets 
different genes of the IGF-1/PI3K/AKT/FOXO/mTOR pathway, also regulates the expression of 
SIRT1 in human biliary epithelial cells (230). SIRT1 has been shown to be repressed by miR-217 
(231), modulating endothelial cell senescence, while miR-33b repressed SIRT-6 and AMPK 
expression (124). In humans, Kurylowicz A et al  demonstrated that the repression of SIRT1 is 
negatively correlated with the expression of miR-22-3p in the adipose tissue of obese individuals 
and that the overexpression of SIRT7 correlated negatively with miR-125a-5p levels in thin 
individuals (232). Another study in humans showed the importance of miR-199 as a modulator 
of SIRT1 and as a biomarker of atrial fibrillation (AF) after coronary bypass surgery (233). Lower 
miR-199 levels in the brown adipose tissue (BAT)  of Rhesus monkeys have been associated with 
age (234). Other microRNAs such as miR-19b, miR-221 and miR-222 are important regulators of 
PGC1α (235). Interestingly, miR-19b was found to be repressed in octogenarians while 
centenarians and young people maintained the same level of expression (203). In 
atherosclerosis, miR-19b, miR-221 and miR-222 can induce endothelial cell dysfunction through 
the repression of PGC-1α (235). In a transgenic mouse model without miR-455 production in 
adipose tissue, it has been shown that miR-455 activates AMPK in BAT. These results suggest 
the importance of this microRNA in the adipogenesis of BAT through the regulation of the 
AMPK/SIRT1/PGC1α pathway (236). In addition to these results, another study showed that the 
expression of miR-455 was lower in old mice compared to young mice (237). In the cell lines 
HEK-293 and HT-29, miR-451 produces an inhibition of AMPK and an activation of mTORC1 
(238). In PBMCs, a lower expression of miR-181 (associated to age) modifies the expression of T 
cells receptor due to DUSP-6 activity, gene regulated by AMPK levels via ERK (signal-regulated 
kinase) (239, 240).  
5.6. Effect of CR on the levels of microRNAs 
As explained above, there are different strategies that could delay aging or promote healthy 
aging. These strategies can be based on longevity medications or lifestyle interventions. 
Regarding to lifestyle interventions, the strategy that has been shown to be effective in different 
animal models is CR, which results in an increased lifespan and a better state of health (241). 
The molecular mechanisms by which CR has an effect on aging are not fully understood yet, but 
microRNAs could play a key role. In rats, CR reduces the expression of miR-144 in 
cerebrovascular endothelial cells (CMVEC), preventing the reduction of nuclear factor 
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(erythroid-derived 2)-like 2 (nrf2), a regulator of cellular resistance to ROS A low protein diet 
reduces the expression of miR-124 in the pancreas in pregnant rats (242). However, in old 
Rhesus monkeys, this microRNA was found to be positively regulated by CR in skeletal muscle 
(243). Other microRNAs that were also differentially modified by CR were miR-451, miR-144, 
miR-18a, miR-15a, miR-451 (overexpressed) and miR-181a and miR-181b (reduced) (243). In a 
murine model, it has been observed that miR-425, miR-196, miR-155, miR-150, miR-351, miR-
16, let-7, miR-34 and miR-138 are differentially expressed between the control group and the 
group submitted to a CR (244). Interestingly, as described above,  some of these microRNAs that 
are differentially expressed with CR have been described as regulators of nutrient-sensing 
pathways (let-7, miR-34, miR-425, miR-16, miR-155, miR-144, miR-451). Other microRNAs have 
been also described to be modulated by CR. For isntance, CR produces a repression of the miR-
17-92 cluster in a mouse model of breast cancer (245). However, the effect of CR on the profile 
of microRNAs is not yet clear due to lack of studies. For this reason, studies in humans are 
needed that combine the CR with the modification of the expression of microRNAs. In fact, the 
potential of microRNAs as biomarkers of aging allows us to suggest the future importance of 
microRNAs as biomarkers of the effect of moderate CR on human longevity and healthy aging. 
Table 3 shows a summary of the relationship of the microRNAs and CR. 
5.7. Exogenous microRNAs 
In 2012, an study carried out by Zhang L. et al, introduced a great controversy about the possible 
“cross-kingdom” effect of the intake of microRNAs coming from other species  and their possible 
regulatory effect on the gene expression of the persons or animals that ingests them (246).  In 
this study, they detected exogenous plants microRNAs from rice (Oryza sativa). They detected 
specifically high levels of miR-168a in serum of Chinese volunteers whose diet is rich in rice. They 
also detected it in the serum and tissues of mice after oral intake of rice. Moreover, they 
observed that this exogenous microRNA was able to repress human LDLRAP1 (low density 
lipoprotein receptor adaptor protein 1), a gene related to the regulation of cholesterol in the 
liver (246). Since the publication of this study, many researches have tried to replicate these 
results, obtaining different conclusions. Some authors have detected the presence of microRNAs 
from plants in the serum of patients, such as Yang J. et al who detected the presence of miR-
2911 from  Lonicera japonica in the serum of healthy individuals (247). However, this microRNAs 
was removed of miRBase database due to the fact that it is not a real microRNA, it was found to 
be a ribosomic RNA. Beatty M. et al detected different microRNAs from the order Hypocreales 
in plasma (248). Chin AR. et al detected the presence of miR-159, a microRNA widely conserved 
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in plants of the order Brassicales in human serum, microRNA that has been observed that can 
produce an inhibitory effect in the progression of breast cancer (249). Lukasik A. et al, 
performing in silico studies, detected microRNAs from plants in milk exosomes of mammals 
(250). On the other hand, other authors have not been able to detect any type of microRNAs 
from one species in another (251-253) and technical artifacts have been considered the cause 
of the detection of exogenous plant microRNAs in human and animal tissues.  
The confirmation of whether exogenous microRNAs could be detected in the blood or other 
biofluids of another species is vital to advance in the understanding of how diet can influence 
the health status of the individual. The confirmation of these results could change the current 
conception that we have about the diet since not only would the nutrients have an effect on the 
organism but the genetic material of the food would also influence their properties.  In addition, 
these discoveries would have a great influence on the development of functional foods and 
transgenic foods due to the genetic modification that is sometimes made in the brewing of these 
foods. 
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MicroRNA Aging relationship Regulated pathways Diet effect References 
let-7  Cellular senescence IGF1/PI3 /AKT/mTOR , 
AMPK/Sirtuinas/PGC1α, Inflammation  Differentially expressed in RC 
(167, 168, 199, 212, 
213, 230, 244) 
miR-1 Overexpressed in liver in progeria model IGF1/PI3 /AKT/mTOR  Inhibited in adipose tissue in mice with high fat diet (189, 215, 216) 
miR-155 Overexpressed in pancreatic  β cells IGF1/PI3 /AKT/mTOR  Differentially expressed in RC (185, 244) 
miR-16 Overexpressed in pancreatic  β cells IGF1/PI3 /AKT/mTOR  Differentially expressed in RC (201, 229, 244) 
miR-34a 
Higher circulating levels in macular degeneration 
and   age-related hearing loss. Overexpressed in 
aging 
IGF1/PI3 /AKT/mTOR , 
AMPK/Sirtuinas/PGC1α, Inflammation  Differentially expressed in RC 
(199, 206, 207) (228) 
miR-124a Related to Parkinson disease and overexpressed in old skin 
IGF1/PI3 /AKT/mTOR , 
AMPK/Sirtuinas/PGC1α 
Low protein diet reduce its  expression in pancreatic cells of 
pregnant rats (207, 209, 210, 242) 
miR-383 Overexpressed in aging IGF1/PI3 /AKT/mTOR  Reduced in pancreatic cells after high fat diet (175, 207)  
miR-130b Inhibited in aging IGF1/PI3 /AKT/mTOR  Higher circulating levels after polyunsaturated  fat intake in women (183, 207) 
miR-181 Inhibited in aging IGF1/PI3 /AKT/mTOR  Overexpressed in skeletal muscle of monkeys with CR (175, 176, 207, 239, 243) 
miR-223 Reduced in CD4+T in ancient and postmenopausal women IGF1/PI3 /AKT/mTOR  High protein diet reduce it level 
(184, 199, 201, 211, 
217, 223) 
miR-17-92 cluster Inhibited in aging IGF1/PI3 /AKT/mTOR , AMPK/Sirtuinas/PGC1α Inhibited in RC of breast cancer mouse model (218, 219, 245) 
miR-145 Reduced in PBMCs in aging IGF1/PI3 /AKT/mTOR  Overexpressed in high fat diet in Wistar rats (180, 220-222)  
miR-19b Lower levels in octogenarians compared to young and centenarians AMPK/Sirtuinas/PGC1α Higher circulating levels after polyunsaturated  fat intake in women (183, 203, 235) 
miR-451 Overexpressed in old monkeys IGF1/PI3 /AKT/mTOR , AMPK/Sirtuinas/PGC1α Overexpressed in skeletal muscle of monkeys with CR (200, 238, 243, 244) 
miR-142 Inhibited in postmenopausal women  IGF1/PI3 /AKT/mTOR  Overexpressed in high fat diet in mice (175, 176, 223) 
miR-182 Inhibited in postmenopausal women IGF1/PI3 /AKT/mTOR  Overexpressed in high fat diet in mice (176, 223) 
miR-144 Overexpressed in skeletal muscle in old rhesus monkeys 
IGF1/PI3 /AKT/mTOR , 
AMPK/Sirtuinas/PGC1α Inhibited in CR in CMEV in rats  (243, 254) 
miR-221 Inhibited in aging AMPK/Sirtuinas/PGC1α Higher circulating levels after polyunsaturated  fat intake in women (183, 193, 198, 235) 
Table 3: Summary of the reported relationships between microRNAs, nutrient sensing pathways, healthy aging and diet 
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The hypothesis proposed in this thesis is that the intake of typical Mediterranean foods as well 
as a CR based on a Mediterranean Diet will promote healthy aging through the modification of 
microRNAs modulating nutrient sensing pathways such as IGF1/PI3K/AKT/FOXO/mTOR and 
AMPK/Sirtuins/PGC1-1α. In addition, this project analyzes the existence of exogenous plant 
microRNAs in human plasma after the consumption of typical Mediterranean foods.  
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1. To study the effect of the intake of two usual foods of the Mediterranean Diet on the
expression of microRNAs associated with the aging process. Study of exogenous
microRNAs from olive oil and beer in human plasma.
a) Study of exogenous microRNAs in human plasma. Bioavailability and conservation
of microRNAs after the processing of olive oil and beer.
b) Study of the effect of olive oil intake on circulating microRNAs. VOHF study.
c) Study of the effect of alcohol ingestion with and without alcohol on circulating
microRNAs and microRNAs from macrophages associated with aging. MiRoBEER
study.
2. To study the effect of a CR based on a Traditional Mediterranean Diet, physical activity
and behavioral therapy against the same Traditional Mediterranean Diet without CR on
variables associated with a healthy aging in the individuals of the population PREDIMED-
PLUS study.
a) Study of cognitive impairment and perception of quality of life throughout the
intervention and follow-up associated with the intervention by measuring
parameters related to healthy aging.
b) Study of changes in the expression of circulating microRNAs and of and
macrophages involved in the regulation of the immune system, pathways of
nutrients and aging.
3. Analysis of the molecular mechanisms of action of microRNAs associated with
cardiovascular health and healthy aging detected in Objective 1 and 2 through the use
of bioinformatics and molecular biology techniques.
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1. Material
L-929 cells (ATCC® Number: CCL-1™) were used to activate blood monocyte-derived 
macrophages. For cell culture, we used DMEM medium with 4.5 g/L Glucose (Cultek, Madrid, 
Spain) for L-929 cells and RPMI 1640 with L-Glutamine (Cultek, Madrid, Spain) for human PBMCs. 
Both of them were supplemented with a mix of 100 U/ ml of penicillin, 100 µg/ml of gentamycin 
and 100 U/ml of streptomycin (Lonza, Basilea, Switzerland). Moreover, culture cell medium was 
supplemented with 10% of fetal bovine serum (FBS) (Gibco, Invitrogen, Carlsbad, California). 
Other materials used in cell culture were phosphate buffered saline (PBS) (Gibco, Invitrogen, 
Carlsbad, California), trypsin with ethylenediaminetetraacetic acid (EDTA) (Lonza, Basilea, 
Switzerland) and dimethyl sulfoxide (DMSO) (Scharlau, Barcelona, Spain).  
Other general material used was RNA free water (Sigma), ethanol (Scharlau, Barcelona, Spain) 
and chloroform (Scharlau, Barcelona, Spain). 
2. Study populations
2.1. Exogenous microRNAs 
Five healthy volunteers aged 25–35 years old were recruited at IMDEA Alimentación. All 
volunteers consumed 40 ml of EVOO after 12 hours fasting. Blood samples were collected at 1, 
2, 4 and 6 hours after EVOO ingestion by venous puncture. Intervention and blood collection 
were carried out at Hospital Ramón y Cajal (Madrid, Spain). The Ethics Committee of the institute 
approved the intervention protocol, and all volunteers provided written informed consent. All 
procedures were in accordance with the 19564 Helsinki Declaration and its late amendments.  
2.2 VOHF Study 
VOHF study is a postpandrial, randomly, controlled cross-over study carried out between April 
and September 2011 in Hospital Universitari Sant Joan de Reus. 12 healthy volunteers, 6 men 
and 6 women (aged 20–70 years old) were recruited through a volunteer centre database. 
Participants were considered healthy according to a physical examination and routine laboratory 
tests. Volunteers participated in three one-day experimental sessions and received, after an 
overnight fast (12 hours), a single ingestion of 30 mL of each phenol-enriched EVOO and the 
three treatment conditions were separated by a 1-week washout period. Venous blood was
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collected at baseline (0 h) and at several time points after EVOOs intake (1, 2, 4 and 6 hours after 
the ingestion). Three intervention periods were included with three different polyphenols-
enriched EVOO compounds containing 250 (L-EVOO), 500 (M-EVOO) and 750 (H-EVOO) mg/Kg 
of EVOO-derived polyphenols (255). A summary of the intervention and collection times are in 
figure 7. Phenolic composition of each functional EVOO is shown in table 4. 
Figure 7: Flow-chart of intervention (a) and samples collection (b) in VOHF study (modified of figure 1 
of Valls R-M et al (255)). 
The intervention was carried out according to the guidelines laid down in the Declaration of 
Helsinki, and all procedures involving human subjects were approved by the Clinical Research 
Ethical Committee of the Hospital Universitari Sant Joan de Reus (Ref 09-02-26/2proj2), Spain 
and was registered at ClinicalTrials.gov (Identifier: NCT01347515). 
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Table 4: Composition of functional EVOO used in VOHF study (modified of supplementary table 1 of 
Valls R-M et al (255)). All data are shown in mg/ 25 ml of EVOO 
2.3 MiRoBeer study 
The miRoBEER study is a controlled crossed-over nutritional intervention study in which 2 
different types of beer were used (alcohol and non-alcoholic beer). Male volunteers consumed 
both types of beer for 14 days, with a 1-week washout period between interventions. Volunteers 
were provided with the amount of beer needed at the start of each intervention, divided into 
individualized daily doses. The daily dose of beer was 500 ml, an amount that has been shown 
to be within a moderate consumption range and, therefore, safe for the volunteers according to 
the “Dietary Guidelines for Americans 2015-2020,” U.S. Department of Health and Human 
Services and U.S. Department of Agriculture”. Blood and urine samples were collected at the 
beginning and at the end of each intervention and washout period following the flow diagram 
in figure 8. The Ethics Committee approved the protocol for the recruitment, intervention and 
Compound (mg oil ingested dose) L-EVOO M-EVOO H-EVOO
Hydroxytyrosol 0.21 0.29 0.37
3,4-DHPEA-AC 0.16 0.60 0.90
3,4-DHPEA-EDA* 1.51 4.67 8.42
3,4-DHPEA-EA* 0.36 0.71 1.18
Total Hydroxytyrosol derivatives 2.23 6.27 10.87
p-hydroxybenzoic acid 0.00 0.02 0.03
Vanill ic acid 0.02 0.08 0.10
Caffeic acid n.d n.d n.d
Rosmarinic acid n.d n.d n.d
Total phenolic acid 0.02 0.10 0.13
Pinoresinol 0.27 0.19 0.19
Acetoxipinoresinol ** 6.95 5.98 5.81
Total lignans 7.22 6.17 6.00
Luteolin 0.17 0.28 0.57
Apigenin 0.06 0.08 0.10
Naringerin n.d n.d n.d
Eriodictyol n.d n.d n.d
Thymusin n.d n.d n.d
Xanthomicrol n.d n.d n.d
7-methylsudachitin n.d n.d n.d
Total flavonoids 0.22 0.35 0.67
Thymol n.d n.d n.d
Carvacrol n.d n.d n.d
Total monoterpenes n.d n.d n.d
Total phenols HPLC-MS/MS 9.69 12.89 17.67
* Quantified with calibration curve of hydrocytyrosol ** Quantified with calibration curve of
pinoresinol   n.d. non-determined
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follow-up of the miRoBEER project (Ref: IMD: PI-016.) and all procedures were done according 
to the Declaration of Helsinki. All volunteers signed an informed consent to participate in the 
study. 
Figure 8: Intervention design flow-chart for miroBEER study 
Seven participants were recruited with the following inclusion criteria: 
• Male
• Age between 25-65 years
• Non-smoker
• 2 or more cardiovascular risk factors:
o Family history of Early Coronary Disease: documented myocardial infarction or
sudden death before 55 years of age in first-degree male relatives or before 65
years of age in first-degree female relatives.
o High blood pressure (≥ 130/85 mm Hg) or taking antihypertensive medication.
o Body mass index (BMI)  ≥ 25 kg / m2
o HDL-cholesterol ≤ 40 mg / dl, LDL-cholesterol ≥ 160 mg / dl without taking
medication for hypercholesterolemia.
o Increased triglycerides (> 150 mg /dL) without taking medication for its
reduction.
Exclusion criteria were: 
• Documented history of CVD, such as coronary disease (angina, myocardial infarction,
coronary angioplasty techniques or abnormal Q on the electrocardiogram (ECG)), stroke
(both ischemic and hemorrhagic, including transient vascular accidents), and
symptomatic peripheral arteriopathy diagnosed by imaging techniques.
• Serious medical illness that prevents the patient from participating in a nutritional
intervention study.
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• Immunodeficiency or HIV infection.
• Toxic abuse or chronic alcoholism.
• Impossibility to continue the intervention for religious reasons or for mastication or
swallowing disorders.
• History of food allergy with hypersensitivity to any of the components of beer.
• Participation in pharmacological clinical trials or taking any investigational drug in the
last year.
• Volunteers admitted to institutions.
• Diabetes.
• Chronic illness, without autonomy, unable to walk or without a fixed postal address.
• Illiteracy.
The participants in the study also had to fill-in the following questionnaires at each control point: 
• 3-day diet registry.
• CAGE questionnaire to detect alcohol risk consumption (256).
• Intervention compliance questionnaire.
Participants’ recruitment flowchart is present in figure 9. 
Figure 9: Participants recruitment flow-chart for miroBEER study 
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The intervention was performed with two washout periods of 7 days each and two intervention 
periods (alcoholic and non-alcoholic beer) of 14 days each (figure 8). During the washout period, 
the participants were not allowed to consume any type of fermented beverages while in the 
intervention period participants only could consume the beer proportionated by the clinical 
trial. In every collection time, blood and urine samples were collected. Blood was collected by 
venous puncture. Recruitment, intervention and sample collection was carried out at IMDEA 
Food. 
2.4. PREDIMED-PLUS 
PREDIMED-PLUS project is a multidisciplinary, multicentre study formed by a consortium of 23 
research groups from more than 7 autonomous communities that has recruited a total of 6874 
volunteers. Our group is a recruitment and intervention group that has recruited 174 
participants. The protocol of recruitment, intervention and monitoring of the PREDIMED-PLUS 
project has been approved by the Clinical Research Ethics Committee of the Sant Joan de Reus 
University Hospital (Ref .: 13-07-25 / 7proj2) and by the Ethics Committee of the IMDEA Food 
Research (Ref: IMD: PI012). This study will last for 6 years but this thesis will only take the 
corresponding data up to 1 year of intervention. 
Recruitment of volunteers has been carried out from April 2015 to December 2016. Our 
recruitment node has recruited 174 participants with the collaboration of the Primary Care 
Centres of the Community of Madrid. The volunteers were recruited with the help of medical 
and nursing staff belonging to different centres. These health centres have been: 
• Buenos Aires Primary Care Centre
• Bustarviejo Primary Care Centre
• Colmenar Viejo Primary Care Centre
• Fuencarral Primary Care Centre
• Ibiza Primary Care Centre
• Aquitania Primary Care Centre
• Hospital La Paz
The recruitment process began with a 4-week run-in period that included 2 individual visits 
where the commitment of the patients and their ability to complete the study were evaluated. 
The visits carried out during the screening period were: 
• Selection visit 1: During this visit, the potential participant received the information of
PREDIMED-PLUS study and the inclusion criteria were checked. The participant was asked to 
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keep a weight, waist and hip perimeter record of 4 weeks. The participant was instructed to 
perform the measurements and was given a tape measure. A 3-day dietary record was also 
requested. On this visit the signature of the informed consent was requested. 
• Selection visit 2: a telephone call was made to the participant to follow up on the weight, waist, 
hip and diet registration tasks and he/she was reminded of the date of the next visit. 
• Selection visit 3: An evaluation was made that included: i) the verification of the correct
performance of weight, waist, hip and diet recording as a way to evaluate their ability to follow 
the intervention instructions throughout the study and its implication and ii) the inclusion and 
exclusion criteria. On this visit, his/her inclusion was decided. 
The inclusion criteria were: 
• Men between the ages of 55 and 75 and women aged between 60-75 years.
• BMI ≥ 27 and <40 kg / m2.
• Meet at least 3 of the following criteria for metabolic syndrome:
o Waist circumference ≥102 cm (men) and ≥88 cm (women).
o Triglycerides> 150 mg / dL or taking medication for its treatment.
o HDL cholesterol ≤40 in men and ≤50 mg / dL in women or taking medication for
its treatment.
o High blood pressure (≥130 / 85 mm Hg) or taking medication for its treatment.
o High fasting blood glucose (≥100 mg / dL) or taking medication for its treatment.
Exclusion criteria: 
• Illiteracy or inability/unwillingness to give written informed consent or communicate
with study staff.
• Institutionalization (the participant is a permanent or long-stay resident in a care home).
• Documented history of previous CVD, including: angina; myocardial infarction; coronary
revascularization procedures; stroke (ischemic or hemorrhagic, including transient
ischemic attacks); symptomatic peripheral artery disease that required surgery or was
diagnosed with vascular imaging techniques; ventricular arrhythmia; uncontrolled AF;
congestive heart failure (New York Heart Association Class III or IV); hypertrophic
myocardiopathy; and history of aortic aneurism >=5.5 cm in diameter or aortic aneurism 
surgery.
• Active malignant cancer or history of malignancy within the last 5 years (except
nonmelanoma skin cancer).
• Inability to follow the recommended diet (for religious reasons, swallowing disorders,
etc.) or to carry out PA.
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• A low predicted likelihood to change dietary habits according to the Prochaska and
DiClemente Stages of Change Model.
• Inability to follow the scheduled intervention visits (institutionalization, lack of
autonomy, inability to walk, lack of stable address, travel plans, etc.).
• Inclusion in another program that provides advice on weight loss (> 5 kg) in the six
months before the selection visit.
• History of surgical procedures for weight loss or intention to undergo bariatric surgery
in the next 12 months.
• History of small or large bowel resection.
• History of inflammatory bowel disease.
• Obesity of known endocrine origin (except for treated hypothyroidism).
• Food allergy to any component of the Mediterranean diet.
• Immunodeficiency or HIV-positive status.
• Cirrhosis or liver failure.
• Serious psychiatric disorders: schizophrenia, bipolar disorder, eating disorders, or
depression with hospitalization within the last 6 months.
• Any severe co-morbidity condition with less than 24 months’ life expectancy.
• Alcohol abuse or addiction (or total daily alcohol intake >50 g) or drug abuse within the
past 6 months.
• History of major organ transplantation.
• Concurrent therapy with immunosuppressive drugs or cytotoxic agents.
• Current treatment with systemic corticosteroids.
• Current use of weight loss medication.
• Concurrent participation in another randomized clinical trial.
• Patients with an acute infection or inflammation (e.g. pneumonia) will be allowed to
participate in the study 3 months after resolution of their condition.
• Any other condition that may interfere with adherence to the study protocol.
The final number of volunteers recruited at the end of this period was 174 patients. Participants’ 
recruitment flowchart is present in figure 10. 
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Figure 10: Participants recruitment flow-chart for PREDIMED-PLUS study 
The recruited volunteers were randomly divided into a control group or an intervention group. 
Randomization was carried out with a software application using a multiple randomization 
method stratified by age and sex. The members of the same family unit were assigned to the 
same group. The family unit group was randomly selected by randomizing one member of the 
family unit and assigning the other members of the family to the same group. 
The control group received general advice on adherence to MD without any objective of weight 
loss or intervention with PA. The control protocol included an individual visit and a group session 
every 6 months in the first year and one individual visit every year a group visit every 6 months 
from year one up to the end of the study. 
In the intervention group, an intensive intervention was carried out on participants the lifestyle 
with a hypocaloric diet based on T2DM, PA and behavioral therapy, with a goal of 8% weight 
loss to be reached in the first 6 months of interventions. The intervention protocol included an 
individual visit, a reinforcement telephone call and a group visit per month during the first year. 
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From the first year, individual visits were every 3 months with a call for intermediate 
reinforcement and group visits were held on a monthly basis. 
During the study, different questionnaires of food consumption, cognitive assessment, quality 
of life, PA and anthropometric measurements were collected. These questionnaires are: 
• 3-day dietary record
• Food consumption frequency questionnaire (FFQ) (137 items).
• Adherence questionnaire to a MD of 14 and 17 items.
• PA and physical condition questionnaires:
o Minnesota PA questionnaire in the free time.
o PAR-Q, RAPA Questionnaires (RAPA1 and RAPA2).
o NHS sedentarism questionnaire.
o Chair Stand Test.
• Accelerometry.
• Electrocardiogram.
• Measurement of blood pressure.
• Cognitive-neuropsychological tests:
o Mini-Mental State Examination (MMSE).
o Clock-drowing test, verbal and phonological verbal fluency (animals + P) and
Digit Span test (WAIS-III)
o Trail Making Test (TMT)
o Psychopathological Questionnaire:
o Beck Depression Questionnaire (BDI-II)
o Multidimensional scale of control locus on weight and diagnostic criteria of
eating disorders (ACT)
o Health-Related Quality of Life Questionnaire (SF-36)
At the basal time, as well as at 6 and 12 months from the time of patient recruitment, a blood 
sample collection was carried out, as well as a follow-up of clinical events and progression of 
health status. Blood collection was performed by venous puncture at primary care centers or at 
IMDEA Food. 
2.5  Data and samples management 
The collected samples were stored in a biobank according to the law 14/2007 of bio-sanitary 
research and by Royal Decree RD 1716/2011 on the operation of biobanks. In addition, a 
collection of our own samples has been made and stored in our research center in order to use 
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them for the analyses. The collection of samples and their associated data were registered in a 
file in the Spanish Data Protection Agency according to the UE regulation 2016/976. Data 
management and storage are in accordance to RGPD (05/25/2018), Ley Orgánica 15/1999, de 
13 de diciembre de protección de datos de carácter personal and LEY 14/2007 de 3 de julio, de 
Investigación Biomédica.  
3. Plasma, urine and PBMCs collection
3.1. Plasma and urine collection 
Fasting blood samples were taken from the participants of all studies in each collection 
time-point. Blood was collected in a 10 ml Vacutainer tubes with K2EDTA anticoagulant. Blood 
samples were centrifuged at 1500 x g for 15 minutes and plasma were finally recovered. A spot 
urine sample was collected in the morning (08:00). All samples were stored at -80°C until 
processing. Biochemistry analyses in miRoBEER and PREDIMED PLUS were carried out by CQS 
laboratories (Madrid. Spain). 
3.2. PBMCs isolation and macrophage selection 
Fasting blood samples were collected in a 10 ml Vacutainer tubes with K2EDTA anticoagulant. 
Total blood was mixed with 10 ml of complete RPMI complete medium. The sample was passed 
to another tube with 10 ml of LYMPHOPREPTM (STEMCELL Technologies. Grenoble. France). The 
mixture was centrifuged at 900g during 40 minutes and the intermediated cell layer containing 
the PBMCs was carefully collected. The purified PBMCs were washed 3 times with PBS. Two 
different protocols were carried out depending of the study. In miroBEER study, PBMCs were 
cultured in RPMI complete medium in a non-treated plate during 4 hours and incubated at 37ºC 
5% C02 conditions. After that, non-adherent and adherents cell (macrophages) were picked up 
separately and cryopreserved in RPMI medium with 10% DMSO and 10% FBS. Cryopreserved 
cells were stored in liquid nitrogen until its use. Adherent cells were used without any other 
processing. For PREDIMED-PLUS Study, all PBMCs were cryopreserved in cryopreservation 
medium.  We defrosted cells and they were cultured in non-treated plates with RPMI complete 
medium during 24 hours. After that, we separated adherent and non-adherent cells. Non-
adherent cells were processed, and adherent cells were cultured during 6 days with activating 
medium (complete medium with 15 % of L-929 culture medium filtered) to promote the 
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conversion of monocytes into macrophages and their activation. Only cells adhered to the plate 
were picked and processed.  
4. MicroRNAs extraction
4.1 Oil 
Two methods were carried out.  In one method, 100 µl of EVOO was extracted using miRCury 
RNA Extraction Kit – Cell & Plants (Exiqon A/S, Vedbaek, Denmark) with minor modifications: 
Addition of Additive Buffer, and MS2-RNA-carrier (Roche, Barcelona, Spain) to optimize sample 
homogenization and microRNA precipitation. 
In the second method, 30 ml of EVOO were centrifuged at 16,000g during 10 minutes at room 
temperature following the procedure reported by Rossi and colleagues for DNA purification 
adapted to microRNA purification (257). After that, we discarded the supernatant and kept the 
pellet. Then, we added 500 µL of TRIPURE (Roche Life Science, Barcelona, Spain) and continued 
the extraction according to the manufacturer’s instructions with minor modifications. To 
optimize the precipitation of microRNAs we incubated samples with the TRIPURE during 24 
hours at -80ºC before phase separation, we also increased the isopropanol precipitation period 
to 24 hours at -80ºC and we washed samples with 85% ethanol instead of 70% ethanol. For 
sequencing purposes, three samples were extracted simultaneously, pooled and concentrated 
to reach a concentration of ≈ 30 ng/µl using a CentriVap Centrifugal Vacuum Concentrator 
(Labconco). 
4.2. Beer 
500 mL of beer was subjected to lyophilisation in a freeze dryer LYOBETA-15 (Telstar).  200 mg 
of lyophilized beer was diluted in 400 µL of RNase free water and used for RNA isolation. Total 
RNA was isolated using TRIPURE (Roche Life Science, Barcelona, Spain) according to the 
manufacture´s instruction with the same modifications described above. 
4.3. Milk 
5 ml of fresh, non-pasteurised milk was used for RNA isolation using TRIPURE with the same 
protocol and modifications used for beer and olive oil. All samples were diluted in 50µl of RNAse 
free water.  
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4.4. Plasma 
Plasma microRNAs were isolated with miRCURY™ RNA Isolation Kit – Biofluids (Exiqon A/S, 
Vedbaek, Denmark) from 200 µL of plasma. In VOHF and miroBEER study 5fmol of two single 
strand spike-in controls were added to check the quality of the extraction. These spike-in 
controls were ce-miR-34 and ce-miR-238. However, during the extraction process these 
microRNAs were degraded due to their single-strand conformation. In PREDIMED-PLUS study 
the spike-in controls used were 75fmol ce-miR-67 and ce-miR-34. In this case, we used double 
strand spike-in controls to avoid degradation. All samples were diluted in 50µl of RNAse free 
water. 
4.5 Cellular fraction 
For isolation of microRNAs from the cellular fraction, we used miRCURY ™ RNA Isolation Kit -Cell 
& Plant (Exiqon A/S, Vedbaek, Denmark, No. 300121). As well as for the 5 plasma samples, we 
used the same spike-in controls described before for miroBEER samples and PREDIMED-PLUS 
samples. All samples were diluted to 50 µl. RNA was quantified and integrity was assessed with 
a Nanodrop 2000 spectrophotometer (Thermo Scientific, Grand Island, NY). 
5. Next generation sequencing (NGS)
LifeSequencing (Valencia, Spain) performed NGS in plasma samples using the Ion PGM System 
(LifeTechnologies, California, United States). Sequencing adapters were trimmed and only reads 
with a mean Phred quality score higher than 20 were retained. The Phred quality score is a 
logarithmic measure of the base-calling error probability. A Phred value ≥20 indicates a ≥ 99% 
accuracy in the base-calling. Reads were aligned end-to-end against the reference microRNA 
sequences running the Bowtie2 aligner with the very sensitive option and setting the length of 
the seed substrings parameter –L to 6 for microRNA’s detection.  Reads aligning against the MS2-
RNA carrier were removed and runs from duplicated reads were combined. The remaining reads 
were aligned against a reference set build upon the Viridyplantae clade microRNAs, to which 
Olea europaea belongs. We allowed a maximum of 3 mismatches in the alignment procedure. 
Sequencing data have been deposited in the GEO database (GSE76735). 
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6. MicroRNAs selection
For VOHF and miroBEER study we selected a panel of 53 microRNAs related to CVD  using 
prediction algorithms such as miRWalk (258) and miRbase (259) and a literature search (table 
6). For PREDIMED-PLUS study we selected a list of genes which are related to IGF-
1/AKT/FOXO/mTOR pathways and AMPK/SIRT1/PGC1α pathway. Then, we used different 
microRNAs prediction algorithms to select microRNAs that target most of the common genes in 
these pathways. The used algorithms were Target Scan (using a threshold  of PCT > 0.8 and a 
context+ score < 0.4 and a context score percentile rank  > 80%), miRWalk (using the list of genes 
validated and predicted for at least 7/9 algorithms), miRanda-SUR (using the threshold of SUR < 
0.5, energy = -14 and an alignment score threshold of 120). In addition to this, we used 
bibliography resources to select a list of potential microRNAs and, after an enrichment analysis, 
we finally selected a panel of 53 microRNAs with 3 spike-in controls (figure 11). The selected 
microRNAs are shown in table 5 
Figure 11: Flow-chart microRNAs selection for PREDIMED PLUS study 
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Table 5: MicroRNAs selected for PREDIMED-Plus study 
cel-miR-67 hsa-miR-21 hsa-miR-15b hsa-miR-221
cel-miR-34 hsa-miR-22 hsa-miR-182 hsa-miR-27b
cel-miR-54-5p hsa-miR-98 hsa-miR-183 hsa-miR-29b
dme-miR-7 hsa-miR-138 hsa-miR-195 hsa-miR-301
hsa-let-7a hsa-miR-145 hsa-miR-19a hsa-miR-30b
hsa-miR-16 hsa-miR-152 hsa-miR-20a hsa-miR-30c
hsa-miR-30d hsa-miR-424 hsa-miR-106a hsa-miR-181b
hsa-miR-30e hsa-miR-449 hsa-miR-130a hsa-miR-196b
hsa-miR-33a hsa-miR-454 hsa-miR-133a hsa-miR-200a
hsa-miR-34a hsa-miR-497 hsa-miR-135a hsa-miR-200c
hsa-miR-34c hsa-miR-506 hsa-miR-148b hsa-miR-216a
hsa-miR-373 hsa-miR-92a hsa-miR-181a hsa-miR-302c
hsa-miR-520a hsa-miR-30a-5p mmu-miR-93 mmu-miR-153
hsa-miR-17-5p hsa-miR-520c-3p mmu-miR-96 mmu-miR-124a
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miRNA Function Olive oil component up/downregulated References
cel-miR-238 spike in
cel-miR-34 spike in
cel-miR-54 spike in
let-7e Muscle glucose metabolism/Hypertension (let-7e) Oleic acid (let-7f) up J Nutr. 2014 May;144(5):575-85
miR-103 Adipocyte/hepatic glucose metabolism Conjugated l inoleic acid PLoS ONE 5, e13005.
miR-106b Reverse cholesterol transport Palmitic acid up J Nutr. 2014 May;144(5):575-85
miR-107 Adipocyte/hepatic glucose metabolism Conjugated l inoleic acid PLoS ONE 5, e13005.
miR-10a Angiogenesis and inflammation Retinoic Acid up BMC Cancer. 2015 May 2; 15():345.
miR-10b Reverse cholesterol transport
miR-122 Lipid metabolism/Heart failure Oleic acid/vitamin E up Mol Med Rep. 2014 Jul;10(1):292-300. 
miR-124a Pancreas development
miR-125 Angiogenesis and inflammation Vitamin E (miR-125a) up FEBS Lett. 2008 Oct 15;582(23-24):3542-6. 
miR-126 Angiogenesis and inflammation/Heart failure/Coronary arery disease HFD up Mol Med Rep. 2017 Sep;16(3):3061-3068.
miR-129-5p Heart failure
miR-130 Adipocyte glucose metabolism PUFA up J Nutr Biochem. 2015 Oct; 26(10):1095-101.
miR-133 Cardiac hyperthrophy and fibrosis/coronary artery disease
miR-143 Adipocyte/Hepatic glucose metabolism Conjugated l inoleic acid PLoS ONE 5, e13005.
miR-145 Endothelial function/hepatic glucose metabolism Olea europea  extract up J Cancer Res Clin Oncol. 2012 Nov;138(11):1831-44
miR-146a Angiogenesis, inflammation and pancreas development hydroxytyrosol down Int Immunopharmacol. 2017 Feb; 43():147-155.
miR-155 Angiogenesis and inflammation/Coronary artery disease PUFA/Vitamin D down Int J Mol Sci. 2017 Jan 29; 18(2):./ J Immunol. 2014 Mar 1; 192(5):2349-56.
miR-15a Insulin production and secretion/caardiomyocyte survival
miR-17 Coronray artery disease Palmitic acid up J Nutr. 2014 May;144(5):575-85
miR-182 Insulin production
miR-184 Insulin production oleic acid down Gene. 2018 Jun 30;661:126-132.
miR18b Heart failure PUFA up J Nutr Biochem. 2015 Oct; 26(10):1095-101.
miR-192 lipid metabolism Oleic acid down J Nutr. 2014 May;144(5):575-85
miR-199b Cardiac hyperthrophy and fibrosis
miR-208 Cardiac hyperthrophy and fibrosis/Coronary artery disease RvD1 (EPA derivate) up FASEB J. 2011 Feb; 25(2):544-60.
miR-20a Coronray artery disease
miR-21 Endothelial function, angiogenesis and inflammation. Cardiac hyperthrophy and fibrosis olec acid down Mol Med Rep. 2014 Jul;10(1):292-300. Hepatology. 2009 Apr;49(4):1176-84
miR-214 CAD Vitamin D down Exp Cell  Res. 2016 Nov 15;349(1):15-22
miR-22 Aging/ischaemia Vitamin D down Cell Physiol Biochem. 2017;42(1):145-155.
miR-221/222 Endothelial function, angiogenesis and inflammation Conjugated l inoleic acid down PLoS ONE 5, e13005.
miR-223 Muscle glucose metabolism
miR-23a Angiogenesis and inflammation
miR-24 Insulin production/Angiogenesis and inflammation/muscle glucose metabolism Vitamin E down Oxid Med Cell  Longev. 2014;2014:725929.
miR-26b Reverse cholesterol transport/insulin production
miR-27b Adipocyte glucose metabolism/angiogenesiis and inflammation Palmitate up J Mol Cell Cardiol. 2016 Jan; 90():38-46.
miR-296-5p Hypertension
miR-29b Cardiac hyperthrophy and fibrosis/Insulin secretion/Muscle, adipocyte and hepatic glucosezinc down Proc Natl Acad Sci U S A. 2011 Dec 27; 108(52):20970-5.
miR-30c lipid metabolism Oleic acid up J Nutr. 2014 May;144(5):575-85
miR-320 cardiomyocyte cell  survival/Adipocyte glucose metabolism
miR-328 Cardiac rhythm PUFA down J Nutr Biochem. 2015 Oct; 26(10):1095-101.
miR-33 Lipid metabolism/hepatic glucose metabolism
miR-34a Pancreas development/hepatic glucose metabolism Palmitic acid/vitamin E up Chin Med J (Engl). 2012 Dec;125(23):4202-8. /Int J Cancer. 2012 Dec 1;131(11):2668-77
miR-375 Insulin production and secretion
miR-423-5p Heart failure
miR-499 Heart failure/Acute myocardial infarction Linoleic acid up Redox Biol. 2013 Nov 7;2:1-7. 
miR-503 Angiogenesis and inflammation
miR-622 Heart failure Unknown
miR-7 aging (in vitro) Linoleic Acid down J Dermatol Sci. 2013 May;70(2):88-93. 
miR-758 Reverse cholesterol transport
miR-9 Insulin secretion
miR-92a Angiogenesis and inflammation/Coronary artery disease
miR-96 Insulin secretion Saturated fatty acids up PLoS ONE. 2016;11:e0169039
miR-98 Cardiac hyperthrophy and fibrosis
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Table 6 MicroRNAs selected for VOHF and miRoBEER studies 
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7. Selection of patients of PREDIMED-PLUS study for microRNA analysis
After a year of patient follow-up, a total of 20 patients from the intervention group and 20 
patients from the control group were selected who were representative of their group to 
analyze changes in circulating microRNAs as well as microRNAs in macrophages. For this, the 
following criteria were: 
• Patients who have not abandoned the intervention corresponding to their group.
• Patients in whom blood samples have been collected.
• Weight differences between baseline visit and 1 year
o Weight loss between baseline and 1-year time in the control group: 0 ± 1kg
o Weight loss between baseline and 1-year time in the intervention group: - 3.5kg
± 1kg (representative of the mean weight loss in the intervention group
throughout the study)
8. Analyses of microRNAs concentration and integrity using bioanalyzer
MicroRNAs extracted from beer (200 mg), milk (5 mL) and EVOO (30 mL) were measured and 
the integrity analyzed with a Bioanalyzer 2100 (Agilent Technologies, Inc, California, EEUU) using 
an Agilent Small RNA kit to specifically measure small RNA molecules (4-150 nt). This technique 
provides an electrophoretic-based automated sizing and quantitation method of small RNAs. 
Purified samples are separated on a Chip for Electrophoretic Assay and results are shown as 
electropherograms showing fluorescence intensity vs migration time in the electrophoretic gel. 
Small RNA concentration is calculated from the area under the curve of the electropherogram 
and converted to concentration values by normalization with a ladder. The concentration of 
microRNAs was calculated from the area under the curve corresponding to RNA molecules of 8-
40 nt. The ratio of microRNAs/small RNAs was also calculated. 
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9. Changes in microRNAs expression analysis
MicroRNA levels were analysed by Real-Time quantitative PCR (RT-qPCR). Isolated microRNAs 
were retro-transcribed with the TaqMan® MicroRNA Reverse Transcription Kit (Applied 
Biosystem, Waltham, MA, USA). Before retrotranscription, 5fmol of ce-miR 54 was added to 
control for retrotranscription variability in VOHF and miroBEER study and 75 fmol in PREDIMED-
PLUS study. In plasma samples, 5 µl of RNA were 
used as template and 50 ng of RNA was used from 
macrophages samples. Resulting cDNA was pre-
amplified with the TaqMan® PreAmp Master Mix 
(Applied Biosystem, Waltham, MA, USA). 
Preamplification product was diluted 1:20 and 3 µl 
of diluted preamplification product was amplified 
by RT-qPCR with TaqMan OpenArray PCR Master 
Mix (Applied Biosystem, Waltham, MA, USA) in a 
TaqMan custom OpenArray chip (figure 12) 
loaded using an OpenArray® AccuFill™ System 
(Thermo Fisher Scientific; formerly Life 
Technologies, Grand Island, NY). The RT-qPCR was run in a QuantStudio™ 12K Flex Real-Time 
PCR System with OpenArray® Block  (Thermo Fisher Scientific; formerly Life Technologies, Grand 
Island, NY). The fold-change in circulating microRNAs levels was measured as relative 
quantification using the 2-ΔΔCt method comparing each time-point to basal point and was Log2 
transformed. In all cases, a blank sample was added as a negative control. 
Due to the degradation of spike-in controls added to the samples of VOHF and miroBEER study, 
the NormFinder algorithm (260) was used to select the best two endogenous reference 
microRNAs in each case (miR-192 and miR-221 for L-EVOO, miR-221 and miR-320 for M-EVOO 
and miR-223 and miR-92a for H-EVOO). The quadratic average of the two endogenous controls 
plus the exogenous ce-miR-54 control was used for normalization. In the case of PREDIMED-
PLUS study, the quadratic average of all three spike-in controls was calculated for normalization. 
Efficiency of all probes was assessed with a calibration curve using a control RNA from plasma. 
All microRNAs with an efficiency below 80% were discarded. Two non-template controls (NTC) 
were included in each plate and all microRNAs with CTs over the NTC were also discarded. RT-
qPCR was made in duplicate and all microRNAs with >10% of inconsistent technical replicates 
were discarded.  
In the study of exogenous microRNAs, we added 200 ng of the hsa-miR-23a mimic and 200 ng 
of the single-stranded sequence of the osa-miR168a (Oryza sativa) during the extraction process 
to check the potential loss of endogenous miRNAs of the food during the extraction process. 
Figure 12: OpenArray plate used in 
analysis of microRNA expression. 
Source: Applied Biosystems 
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Subsequently, the samples were processed for the isolation of microRNAs as described above, 
retro-transcribed with the miScript RT II kit (QIAGEN GmbH, Hilden, Germany). hsa-miR-23a and 
osa-miR168a were amplified by real-time quantitative PCR (RT-qPCR) with the miScipt SYBER 
Green master Mix kit (QIAGEN GmbH, Hilden, Germany) in a QuantStudio 12KFlex device 
(Applied Biosystems, California, USA). Absolute quantification was carried out comparing CT of 
the samples with and without the exogenous controls. In all cases, a blank sample was added as 
a negative control. 
10. Gene expression analysis
For mRNA quantification, total RNA was reverse transcribed with PrimeScript Reverse 
Transcription kit (Takara, California, USA) and the resulting cDNA was amplified by RT-qPCR with 
FastStart Universal SYBR Green Master (Roche, Barcelona, Spain). Specific forward and reverse 
primers were designed using NCBI gene webpage (https://www.ncbi.nlm.nih.gov/gene), 
Jellyfish software (261)and PrimerBank. We choose a sequence located in an exon with an 
amplicon size between 100 and 200 nucleotides. Specific primers were provided by Isogen 
Lifesciences (Barcelona, Spain) (table 7) and efficiency was assessed in all cases with a calibration 
curve. mRNA levels were calculated using the relative quantification method normalizing with 
RN18S or RLP0. 
Table 7: Primer sequences 
Primer name Sequence
hCD68 Fw GCTACATGGCGGTGGAGTACAA
hCD68 Rev ATGATGAGAGGCAGCAAGATGG
hCD14 Fw CCGCTGTGTAGGAAAGAAGCTA
hCD14 Rev CGCTTTAGAAACGGCTCTAGGT
hCD16 Fw CCTCCTGTCTAGTCGGTTTGG
hCD16 Rev TCGAGCACCCTGTACCATTGA
hCD28 Fw GTTTGAGTGCCTTGATCATGTGC
hCD28 Rev GGCGACTGCTTCACCAAAATC
hCD57 Fw CCTGGCGTGGTCTACTTCG
hCD57 Rev GCAGGTTGACGGCAAATCC
hRPLP0 Fw CCTCATATCCGGGGGAATGTG
hRPLP0 Rev GCAGCAGCTGGCACCTTATTG
18S Fw TAAGTCCCTGCCCTTTGTACACA
18S Rev GATCCGAGGGCCTCACTAAAC
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11. Beer polyphenols analysis
First, we did a calibration curve of the specific polyphenols of beer: IX and 8-PG. Then, we 
measured these polyphenols in the original beer samples (alcoholic and non-alcoholic beer) that 
the patients drank during the study. 
The analysis of plasma and urine samples was carried out using 500 µL of plasma or urine. 
Samples were centrifuged at 15,000 x g for 15 min at 4°C and 353 µL of the supernatant was 
diluted (1:1) with phosphoric acid 4% and spiked with standard mix (50 nM) as an internal 
standard. 600 µL were loaded on a 96 well µ-SPE HLB plate, washed with 200 µL of water and 
200 µL of 0.2% acetic acid and finally eluted with 60 µL of methanol. Extracted and concentrated 
plasma samples were purified with a solid-phase extraction using Oasis® HLB µElution plate. This 
process allows 5-times concentration of the initial sample to improve the polyphenols detection. 
Analyses were carried out using a Thermo Scientific™ Exactive™ Plus Orbitrap (Thermo 
Scientific). The results were analyzed using Xcalibur software. 
12. In silico functional analyses
MicroRNAs significantly modified in, at least, one time-point in each treatment were selected 
for further functional analyses. Experimental validated targets of these microRNAs were 
identified using miRWalk tool (258). Predicted targets were analysed with miRWalk comparing 
9 algorithms (miRanda, TargetScan, miRDB, PITA, MicroT4, miRMap, miRNAMap and miRWalk) 
using stringent criteria in all of them. Predicted targets by, at least, 7 algorithms were selected 
for further analysis. Both, experimental and predicted targets were analysed for functional 
enrichment analysis of GO annotation terms, KEEG pathways and protein-protein interaction 
using Babelomics 5 and String Software (262, 263). In addition to this, hierarchical cluster 
analysis with heat map were carried out using TMeV software (264) 
Venn diagrams were done with Bioinformatics and Evolutionary Genomics application using 
default settings (http://bioinformatics.psb.ugent.be/webtools/Venn/)  
13. Statistical analysis
The quantitative variables are expressed as mean ± standard deviation (SD) or standard error of 
the mean (SEM), while qualitative variables are expressed as frequencies or percentages of the 
total.  
In VOHF study, the changes in microRNAs levels along the postpandrial curve were analysed by 
repeated-measurements ANOVA with Bonferroni correction for multiple testing. The interaction 
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with the type of oil was included in the analysis. Two-tailed p value of 0.05 was considered 
significant. 
Missing values were imputed using a multivariate linear regression model. Imputed values 
accounted for less than 10% of all values.  
In miroBEER study, the changes in microRNAs levels between every time point (wash out vs 
intervention points) were analyzed by t-student test. Missing values were imputed using a 
multivariate linear regression model. Imputed values accounted for less than 10% of all values. 
The interaction with the type of beer (alcoholic and non-alcoholic beer) was included in the 
analysis. Two-tailed p value of 0.05 was considered as significant.  In addition to this, we did 
correlation analyses between microRNAs levels in plasma and macrophages and nutrients intake 
and health parameters. We used Pearson correlation in parametric variables and Spearman 
correlation with non-parametric variables. A Saphiro-Wilk normal test was carried out to test 
the normal distribution of the variables. Two-tailed p value of 0.05 was considered as significant. 
In PREDIMED-PLUS study, we used the same methodology than in miroBEER study adding new 
correlations and associations with biochemical (cholesterol, LDL, HDL, glucose), anthropometric 
(blood pressure, weight, waist, hip, muscular mass, fat mass, visceral fat), diet (14 points MD 
questionnaire) and lifestyle parameters (PA) obtained during the different time-points. In 
addition to this, the comparison between mRNA levels of selected genes at the different time-
points and among groups was done with t-student test, considering significant a two-tailed p 
value of 0.05. We performed a paired significance analysis for microarray (SAM) test with 
hierarchical clustering of significant microRNAs applying a FDR using TMEV software. 
All comparisons were carried out using SPSS program version 24.0. 
Statistical significance for enriched GO biological processes and KEGG pathways were analysed 
with Babelomics 5 and Software String applications applying a False Discovery Rate adjustment 
for multiple testing correction. Overrepresented KEGG pathways are shown in bar charts 
representing the –log10 of the p value in the X axis.  
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1. Exogenous microRNAs
1.1. MicroRNA analysis in EVOO, Beer and milk samples 
We first analyzed the presence of microRNAs in the EVOO samples extracted with the miRCury 
RNA Extraction Kit specific for cells and plants. The results obtained from the bioanalyzer 
showed a concentration of approximately 40 % of short sequences of 20–40 nucleotides (figure 
12a). However, the absolute concentration of short RNAs was very low (2.5 ng/μL). After that, 
the sample was sequenced and we obtained 1.886.007 reads of 8–71 nucleotides. 78.55 % of 
these reads were less than 20 nucleotides long, but we found a high number of duplicated reads 
(duplication rate was higher than 80 %). Duplicated reads were similar sequences with different 
length that had been detected as different sequences. As a quality control step, we filtered reads 
with a mean Phred quality score lower than 20 (QC20) and therefore 48.27 % of the reads were 
removed (figure 12b and c). Reads aligning against the MS2 RNA carrier were also removed. The 
remaining reads were aligned against microRNAs of the Viridiplantae clade identifying 9 
different sequences putatively corresponding to Viridiplantae microRNAs. However, the number 
of reads of these sequences was very low. The most concentrated sequence, 
GTCGTTGTAGTATAGTGG, identical to the gma-miR-6300 from soybean, presented only 16 reads 
(table 7), although with a good mapping quality score.  
Figure 12: MicroRNAs detection in EVOO a) Electropherogram of 100 μl of EVOO. miRCury Extraction Kit 
specific for plants was used to extract microRNAs from100 μL of EVOO and the resulting microRNA 
enriched RNA was analyzed using a bioanalyzer. b) NGS average QC value of the EVOO sequences before 
quality filtering c) NGS average QC value of the EVOO sequences after filtering by a threshold of 20.  [nt], 
nucleotides; [FU], fluorescence. 
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Table 7: Viridiplantae microRNA sequences identified in EVOO samples by NGS 
Then, we repeated the extraction increasing the starting EVOO sample by 300-fold (30 mL) and 
we included a lyophilized beer sample of 200 mg and a positive control (5 mL of bovine milk). 
The presence of microRNAs in bovine milk is well documented, although their absorption 
through the human gut is also under debate (265-268). The extraction was replicated 15 times 
for EVOO, 12 times for beer and 8 times for milk. The average amount of RNA obtained was 8335 
ng ± 3864 ng and 8585 ng ± 3434 ng in 30 mL of EVOO and 200 mg of lyophilized beer, 
respectively.  
The average RNA amount obtained in 5 mL of milk was 4560 ± 905.5 ng (table 8). 260/280 ratios 
ranged from 1.49 to 1.65, and 260/230 rations were below 0.5, which is indicative of a certain 
grade of contamination with proteins or solvents.  
Table 8: RNA quantification with Nanodrop 2000 
Since Nanodrop measurements do not allow to specifically quantifying microRNAs and we 
cannot rule out the possibility of an artefactual measurement, we performed bioanalyzer 
analyses. Bioanalyzer results showed a relative high concentration of small RNAs and microRNAs 
in the milk sample (48 ng/5 ml) and a microRNA/small RNA ratio of 90 % (figure 13). However, 
the presence of small RNAs in beer and EVOO samples was lower than expected (20.5 ng/ 200 
mg of lyophilized beer and 1.6 ng/30 ml of EVOO, respectively). The ratio of microRNA/Small 
RNA was 30 % (figure 13) and 16 % in beer and EVOO, respectively (figure 13). 
Sample Replicates number RNA quantification (ng) 260/280 260/230 Starting material
EVOO 15 8335 ± 3864 1.65 ± 0.08 0.25± 0.09 30 ml
Beer 12 8585 ± 3434 1.49 ± 0.04 0.29 ± 0.05 200 mg (lyophilized beer)
Milk 8 4560 ± 905.5 1.51 ± 0.14 0.34 ± 0.19 5 ml
Sequence ID miRNA Read sequence Mismatches Reads Specie
1Q0C3:00392:02459 gma-miR6300 GTCGTTGTAGTATAGTGG 0 16 soybean
1Q0C3:01101:00721 gma-miR396i-5p TTCCACAGCTTTCTTGAACTG 0 2 soybean
1Q0C3:02727:02326 csi-miR396a TTCCACAGCTTTCTTGAACTG 0 2 orange tree
1Q0C3:02971:01796 csi-miR396b TTCCACAGCTTTCTTGAACTG 0 2 orange tree
1Q0C3:02612:02476 gma-miR166h-3p TCTCGGACCAGGCTTCATTCC 0 1 soybean
3MFN1:02624:01184 gma-miR1529 TTCAAGGAAACACTTAATCTT 0 7 soybean
1Q0C3:02633:00397 gma-miR5675 TAGAGACGACAACCATGCA 2 1 soybean
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Figure 13: Electropherogram of samples extracted using the phenol-chloroform method. 5 mL of milk, 
200 mg of lyophilized beer and 30 mL of EVOO were used to extract microRNA-enriched RNA that was 
subsequently analyzed using a bioanalyzer. [nt], nucleotides; [FU], fluorescence 
To check if microRNAs were lost during the purification procedure, we repeated the EVOO and 
beer extraction adding two spike-in controls (human miR-23a mimic and plant osa-MIR168a) 
and analyzed them by RT-qPCR (figure 14). We observed that Cts of samples without the spike-
in controls were similar to that of the NTC. However, both sequences were amplified in those 
samples with the spike-in controls with lower Ct values ranging from 5 to 13 cycles lower than 
the samples without the spike-ins. These results suggest that our method is useful to purify 
microRNAs from these samples, but they also suggest that the absence of microRNAs in our 
samples could not be attributed to the extraction method. However, we should keep in mind 
that our methods could be further optimized to yield higher amounts of microRNAs. 
Figure 14: Ct values of hsa-miR-23a and osa-MIR168a spike-in controls measured by RT-qPCR. 200 ng of 
both, hsa-miR-23a mimic and osa-miR168a sequence were added to the EVOO and beer samples before 
microRNA extraction. Both microRNAs were measured by RT-qPCR and the Ct values are shown. Beer and 
EVOO negative samples (neg) refers to samples without the spike-ins.NTC, Non-template control. Data 
represent mean ± SEM 
1.2. Presence of exogenous microRNAs in human plasma samples 
Although we did not confidently detect microRNAs in beer and EVOO, we searched for the 
presence of plant microRNAs in plasma samples after the ingestion of 40 mL of EVOO. 40 mL is 
the usual daily EVOO intake within the frame of the Mediterranean diet and the PREDIMED study 
showed that this amount is able to reduce cardiovascular mortality (72). All volunteers usually 
follow a diet close to the Mediterranean pattern and consume EVOO as the usual source of fat 
in their diet. Thus, the basal amount of EVOO microRNAs in their plasma was expected to be 
Ct
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high enough to be detected by NGS. However, we followed additional strategies to further 
increase the amount of EVOO microRNAs present in plasma and maximize their detection using 
NGS. First, our human study followed a postprandial charge design (microRNAs measured 2 h 
post-ingestion of 40 mL of EVOO). Second, we measured microRNAs in a concentrated pool of 
plasma from all volunteers. 
Bioanalyzer results showed that 67 % of the sample corresponded to microRNAs (372.23 ng/μl) 
(figure 14). NGS returned 2,178,271 reads of 8–76 nt, 81.46 % of them corresponded to reads 
of <20 nt, 89.79 % of them were duplicated. After filtering and aligning against Viridiplantae 
clade allowing a maximum of three mismatches (269), we obtained six different sequences that 
could be identified as plant microRNAs (Table 3). We only obtained one sequence that could be 
aligned with Viridiplanae microRNAs with 0 mismatches: vvi-miR3623-3p (grape). However only 
one read was detected. When we repeated the analysis allowing one mismatch, we did not 
identified any additional plant microRNA. However, we identified three microRNAs (Medicago 
trunculata, grape and Brachypodium distachyon), but with only 1–2 reads. When we allowed 
three mismatches, we identified two other microRNAs from grape. 
Figure 14: Electropherogram and Quality Control analyses of the NGS of 200 μl of plasma. miRCury 
Extraction Kit specific for biofluids was used to extract microRNAs from 200 μL of plasma. a. Bioanalyzer 
electropherogram. b. Upper panel shows the average QC value of the sequences before quality filtering. 
Lower panel shows the average QC value of the sequences after filtering by a threshold of 20. 
Specifically, we detected 109,296 reads mapping to the gmamiR1529 sequence, 1088 of them 
aligned with ≥19 nucleotides. However, this finding should be cautiously interpreted because 
sensibility score of this alignment was low, it presented three mismatches and this sequence 
also corresponded to the endogenous human miR-302a/b-3p.Moreover, all the read sequences 
presented missing nucleotides when comparing with the canonical sequence (table 9). 
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Table 9: Viridiplantae microRNA sequences identified in plasma samples after consumption of 40 mL of 
EVOO 
2. VOHF Study
2.1. Postpandrial modification of plasma microRNA levels with functional olive oils 
Four microRNAs were significantly modulated by L-EVOO (figure 15). Let-7e showed a bimodal 
distribution with two peaks of repression at 1 and 4 hours. miR-17 and miR-20a were 
upregulated after consumption of L-EVOO along the whole postpandrial curve with a maximum 
at 4 and 1 hours, respectively. On the other hand, miR-328 was downregulated after intake of 
L-EVOO with a minimum of expression at 1h.  
Figure 15. microRNAs modulated by L-EVOO. Box plots showing Log2 transformed relative quantification 
levels of indicated microRNAs along the postprandial phase. Plasma microRNA levels were calculated with 
the 2-ΔΔCt method comparing with 0h time-point. P value refers to the intra-subjects comparison of the 
paired-repeated measures ANOVA with Bonferroni correction. * p<0.05. Data represent mean ± SEM 
Sequence ID miRNA Read sequence Mistmatches Reads Specie
Read sequence TGGTGCTTGGACGAATTTGCT 0 1 grape
vvi-miR3623-3p TGGTGCTTGGACGAATTTGCTa
Read sequence TTAAGGTGATTATTGCGGC 2 1 Medicago trunculata
mtr-miR2590b aatcTaAAGGTGATTATTGtGCc
Read sequence GTAGTCGATGGGAAATTG 2 1 grape
vvi-miR3626-5p gGTAGTCGcTGtGAAATTGaa
Read sequence TCGAGTCGGCCTGCGCGG 2 2 Brachypodium distachyon
bdi-miR7778-5p gagcaTCGtGTCGGCgTGCGCGGc
Read sequence TTAATGGAAACACTTAATCTT 3 8 soybean
gma-miR1529 TTAAtGGAAACAaTTAATCgTta
Read sequence TTCATGGAAACACTTAATC 3 109,296 soybean
gma-miR1529 TTaAaGGAAACAaTTAATCgtta
3MFN1:02913:01878
3MFN1:03137:01810
2DHGC:00857:00054
3MFN1:02730:01211
2DHGC:02083:01146
3MFN1:01049:00156
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Figure 16. microRNAs modulated by M-EVOO. a) Box plots showing Log2 transformed relative 
quantification levels of let-7e, miR-17 and miR-192 along the postpandrial phase. Plasma microRNA levels 
were calculated with the 2-ΔΔCt method comparing with 0h time-point. P value refers to the intra-subjects 
comparison of the paired-repeated measures ANOVA with Bonferroni correction. * p<0.05. b) Box plots 
showing Log2 transformed relative quantification levels of miR-328 and miR-20a along the postpandrial 
phase. Plasma microRNA levels were calculated with the 2-ΔΔCt method comparing with 0h time-point. 
Data represent mean ± SEM 
Three microRNAs were modulated by M-EVOO (figure 16A). Let-7e showed a similar 
modification pattern than with L-EVOO (p = 0.025), although these results were not significant 
after Bonferroni correction in intra-subjects comparisons. miR-17 linear trend was not 
significantly modified, although we observed a significant overexpression at 6h when comparing 
with 2 hours. Finally, miR-192 was significantly upregulated by the M-EVOO. We observed that 
miR-328 and miR-20a showed the same trend than with L-EVOO although this trend did not 
reach statistical significance (figure 16B).  
H-EVOO modified significantly the expression of 4 microRNAs (figure 17). All of them were 
downregulated after 2 hours of the H-EVOO ingestion. The expression of let-7e increased up to 
basal levels at 4 hours, whereas the expression of the others remained downregulated.  
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Figure 17. microRNAs modulated by H-EVOO. A. Box plots showing Log2 transformed relative 
quantification levels of indicated microRNAs along the postpandrial phase. Plasma microRNA levels were 
calculated with the 2-ΔΔCt method comparing with 0h time-point. P value refers to the intra-subjects 
comparison of the Paired-repeated measures ANOVA with Bonferroni correction. * p<0.05. Data 
represent mean ± SEM 
2.2. In silico functional analyses 
We performed a functional analysis of the microRNAs differentially expressed in order to define 
the pathways and biological processes that they regulate. For that purpose, we used miRWalk 
database to select the genes that are predicted or validated targets of at least 2/4 microRNAs in 
L-EVOO, 2/3 microRNAs in M-EVOO and 2/4 microRNAs in H-EVOO. 
Functional analyses showed that 1361 genes were targets of microRNAs modulated by L-EVOO 
(figure 18a). between them 1070 genes are common for miR-17 and miR20a, that belongs to 
the same cluster. Targeted genes were mainly related to different types of cancer and related 
processes (p-53 signalling and cell cycle progression) (table 18b). But among the enriched 
pathways, we also observed MAPK signalling, considered an aging pathway involved in the 
regulation of the cellular energetic state and nutrient metabolism. 
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Figure 18. Functional analysis of microRNAs modulated by L-EVOO.  a) Venn Diagram showing common 
targets of the modulated microRNAs and b) Bar chart of the top 15 most represented KEGG pathways (-
log10 p value adjusted by FDR) for L-EVOO. 
Fourteen genes were predicted or validated targets of all those microRNAs (figure 18a). Among 
them, we found PRKCB (protein kinase C, beta subunit), involved in endothelial cell proliferation, 
intestinal sugar absorption, insulin signalling and B-cell activation (figure 18b and table 9) (270). 
We also found CRY2 (cryptochrome 2), with a well-known role in the circadian system, and SCD 
(stearoyl CoA desaturase), involved in monounsaturated fatty acid synthesis. Interestingly, 30 
genes were predicted or validated targets of let-7e and miR-328, both downregulated at 1h 
(figure 18a and table 9). 
381 genes were validated and predicted targets of microRNAs modulated by M-EVOO (figure 
19a). They were involved in different types of cancer and related processes (DNA replication, 
cell cycle progression and apoptosis) (table 10). Interestingly, those genes were also involved in 
insulin signalling (figure 19b). 25 target genes were predicted targets for all three microRNAs. 
Among them, we found PRKAA2 (protein kinase AMP-activated catalytic subunit alpha 2), the 
catalytic subunit of the AMPK cellular energetic sensor (figure 19b, and table 10).  
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Table 9: Genes commonly targeted by, at least, two microRNAs modified by L-EVOO 
Gene symbol Gene name GO Biological Process
IPO9 Importin 9 binding and protein transporter activity
PRKCB Protein Kinase C Beta transferase activity, transferring phosphorus-containing 
groups and protein tyrosine kinase activity.
ANKRD52 Ankyrin Repeat Domain 52 protein binding
RAB11FIP4 RAB11 Family Interacting Protein 4 calcium ion binding and Rab GTPase binding
RAB22A Member RAS Oncogene Family GTP binding and GDP binding.
HMGB1 High Mobility Group Box 1 chromatin binding
CRY2 Cryptochrome Circadian Regulator 2 protein kinase binding and kinase binding.
USP24 Ubiquitin Specific Peptidase 24 binding and cysteine-type peptidase activity.
SCD Stearoyl-CoA Desaturase iron ion binding and stearoyl-CoA 9-desaturase activity
TXLNA Taxilin Alpha  cytokine activity and high molecular weight B cell growth factor 
receptor binding
AFF2 AF4/FMR2 Family Member 2 G-quadruplex RNA binding.
ZNF280B Zinc Finger Protein 280B DNA and metal ion binding
HIF1AN Hypoxia Inducible Factor 1 Alpha Subunit Inhibitor protein homodimerization activity and oxidoreductase activity
CRK CRK Proto-Oncogene, Adaptor Protein tein domain specific binding and SH3/SH2 adaptor activity
UNC5A Unc-5 Netrin Receptor A plasma membrane
MED13L Mediator Complex Subunit 13 Like RNA polymerase II transcription cofactor activity
SEC14L5 SEC14 Like Lipid Binding 5 transporter activity
KATNB1 Katanin Regulatory Subunit B1  protein heterodimerization activity
SLCO2A1 Solute Carrier Organic Anion Transporter Family 
Member 2A1
 transporter activity and prostaglandin transmembrane transporter 
activity
YWHAQ Tyrosine 3-Monooxygenase/Tryptophan 5-
Monooxygenase Activation Protein Theta
protein domain specific binding and protein N-terminus binding
AHCYL2 Adenosylhomocysteinase Like 2 NAD binding and adenosylhomocysteinase activity
STK40 Serine/Threonine Kinase 40 transferase activity, transferring phosphorus-containing 
groupsand protein tyrosine kinase activity
RUNX1T1 RUNX1 Translocation Partner 1 DNA binding transcription factor activity and identical protein binding
DTX4 Deltex E3 Ubiquitin Ligase 4 ligase activity
PLXNA4 Plexin A4 receptor activity and semaphorin receptor activity
IQGAP3 IQ Motif Containing GTPase Activating Protein 3 calmodulin binding and Ras GTPase binding.
UROC1 Urocanate Hydratase 1 urocanate hydratase activity
EN2 Engrailed Homeobox 2 sequence-specific DNA binding
SEMA3F Semaphorin 3F receptor activity and chemorepellent activity.
ATXN2L Ataxin 2 Like RNA Binding
STARD7 StAR Related Lipid Transfer Domain Containing 7 lipid binding
CHST3 Carbohydrate Sulfotransferase 3 sulfotransferase activity and chondroitin 6-sulfotransferase activity
ZNF609 Zinc Finger Protein 609 nucleic acid and metal ion binding
AEBP2 AE Binding Protein 2
RNA polymerase II proximal promoter sequence-specific DNA 
binding and transcriptional repressor activity, RNA polymerase II 
proximal promoter sequencespecific DNA binding.
PAPPA Pappalysin 1 metalloendopeptidase activity and endopeptidase activity
SMC1A Structural Maintenance Of Chromosomes 1A chromatin binding
ZCCHC24 Zinc Finger CCHC-Type Containing 24 nucleic acid binding.
SLC38A2 Solute Carrier Family 38 Member 2 symporter activity and amino acid transmembrane transporter activity
ARHGAP19 Rho GTPase Activating Protein 19 GTPase activator activity
DIAPH1 Diaphanous Related Formin 1 nucleotide binding
IGF1R Insulin Like Growth Factor 1 Receptor identical protein binding and protein kinase activity
SNX30 Sorting Nexin Family Member 30 phosphatidylinositol binding
OTUD5 OTU Deubiquitinase 5 thiol-dependent ubiquitin-specific protease activity
SERBP1 SERPINE1 MRNA Binding Protein 1 mRNA 3-UTR binding
let-7e + miR-17 + miR-20a + miR-38
let-7e + miR-328
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Figure 19. Functional analysis of microRNAs modulated by M-EVOO:  a) Venn Diagram showing common 
targets of the modulated microRNAs and b) Bar chart of the top 15 most represented KEGG pathways (-
log10 p value adjusted by FDR) for M-EVOO. 
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Table 10: Genes commonly targeted by all the 3 microRNAs modulated by M-EVOO.
454 genes were validated and predicted targets of microRNAs modulated by H-EVOO (figure 
20a). They were involved in different types of cancer and related pathways (p53 signalling, focal 
adhesion), but they were also associated with PIK3/AKT signalling (figure 20b). YOD1 gene was 
the only predicted target of all four microRNAs. YOD1 is a protein deubiquitinase involved in 
many cellular processes including cell cycle, signal transduction and inflammation (271).  
Gene symbol Gene name GO Biological Process
NHLRC3 NHL Repeat Containing 3 extracellular exosome
RACGAP1 Rac GTPase Activating Protein 1 protein kinase binding and microtubule binding
NCOA3 Nuclear Receptor Coactivator 3 chromatin binding and transcription coactivator activity
XIAP X-Linked Inhibitor Of Apoptosis ligase activity and ubiquitin protein ligase activity
SLC30A7 Solute Carrier Family 30 Member 7 cation transmembrane transporter activity
NPHP3 Nephrocystin 3 protein binding
TMEM167A Transmembrane Protein 167A Golgi apparatus
SGCD Sarcoglycan Delta cytoplasm
MKI67 Marker Of Proliferation Ki-67 protein C-terminus binding
DNAL1 Dynein Axonemal Light Chain 1 motor activity
EEA1 Early Endosome Antigen 1 protein homodimerization activity and 1-phosphatidylinositol binding
ZNF652 Zinc Finger Protein 652 nucleic acid binding
DCBLD2 Discoidin, CUB And LCCL Domain Containing 2 protein binding
KATNAL1 Katanin Catalytic Subunit A1 Like 1 microtubule binding and microtubule-severing ATPase activity
SCD Stearoyl-CoA Desaturase  iron ion binding and stearoyl-CoA 9-desaturase activity
GABPB1 GA Binding Protein Transcription Factor Beta Subunit 1
DNA binding transcription factor activity and transcription regulatory 
region DNA binding
POLQ DNA Polymerase Theta nucleic acid binding and damaged DNA binding
MAP3K1 Mitogen-Activated Protein Kinase Kinase Kinase 1
transferase activity, transferring phosphorus-containing 
groups and protein tyrosine kinase activity
PRKAA2 Protein Kinase AMP-Activated Catalytic Subunit Alpha 2
transferase activity, transferring phosphorus-containing 
groups and protein tyrosine kinase activity
SLC1A4 Solute Carrier Family 1 Member 4 chloride channel activityand L-serine transmembrane transporter activity
PLAGL2 PLAG1 Like Zinc Finger 2
RNA binding transcription factor activity and transcriptional activator 
activity, RNA polymerase II proximal promoter sequence-specific DNA 
binding
NIPA1 Non Imprinted In Prader-Willi/Angelman Syndrome 1 magnesium ion transmembrane transporter activity
CRK CRK Proto-Oncogene, Adaptor Protein protein domain specific binding and SH3/SH2 adaptor activity
UBE2V2 Ubiquitin Conjugating Enzyme E2 V2 ubiquitin protein ligase binding and acid-amino acid ligase activity
MDM4 MDM4, P53 Regulator enzyme binding
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Figure 20. Functional analysis of microRNAs modulated by H-EVOO.  a) Venn Diagram showing common 
targets of the modulated microRNAs and b) Bar chart of the top 15 most represented KEGG pathways (-
log10 p value adjusted by FDR).for H-EVOO.  
2.3. MicroRNA levels according to type of functional oil 
Then, we performed interaction analyses to compare microRNA levels across functional olive 
oils (figure 21a). Interestingly, let-7e showed the same bimodal behaviour in all the functional 
oils, although the trend seems to be delayed 1 hour with the H-EVOO. At 1 hour, plasma let-7e 
levels were 4.608-fold downregulated after ingestion of L-EVOO, compared with the levels at 1h 
after ingestion of H-EVOO (p<0.001). At 4 hours, plasma levels of let-7e after ingestion of L-EVOO 
were 3.364-fold downregulated when comparing with levels after ingestion of H-EVOO (p = 
0.032). Interaction analyses for miR-126, miR-24 and miR-328 levels were not significant.  
However, it is worth mentioning that circulating levels with L-EVOO and M-EVOO showed a more 
similar trend between them than with H-EVOO. When we performed pair comparisons, we 
observed that miR-126 plasma levels after 4 hours of the ingestion of M-EVOO were 1.541-fold 
downregulated as compared with the ingestion of H-EVOO at the same time (p=0.047). miR-24 
levels 1 hour after the ingestion of L-EVOO were 1.862-fold lower than after the ingestion of H-
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EVOO at the same time-point (p=0.016), whereas miR-328 levels 1 hour after the ingestion of L-
EVOO were 2.604-fold lower than after the ingestion of H-EVOO at the same time-point 
(p=0.017). Interaction between circulating miR-26b levels and the type of functional oil was 
significant (p=0.043) with a more similar dynamics between low and medium EVOO than with 
H-EVOO. More specifically, miR-26 circulating levels barely changed along the postpandrial 
phase with low and medium EVOO, while they are significantly downregulated after 2 hours of 
the ingestion of H-EVOO. The positive fold change of miR-26b levels after 2 hours of the 
ingestion of L-EVOO and M-EVOO as compared with H-EVOO was 2.369 (p=0.031) and 2.32 
(p=0.051), respectively.  Circulating levels of miR-192 were modified by M-EVOO and H-EVOO in 
an opposite manner. While M-EVOO lead to a postpandrial increase, H-EVOO resulted in a 
postpandrial decrease of circulating miR-192 (FC (2h) =2.025; p=0.041). Finally, miR-20a plasma 
levels were similarly modified by L-EVOO and M-EVOO. However, the early increased observed 
was more pronounce with L-EVOO, while the late decrease was more pronounce with M-EVOO. 
After 6 hours, levels had come back to basal levels in the two cases.  
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Figure 21:  Differentially modulated microRNAs according to the type of functional oil. a) Interaction 
plots showing Log2 transformed relative quantification levels of indicated microRNAs along the 
postpandrial phase in the three functional olive oils. Plasma microRNA levels were calculated with the 2-
ΔΔCt method comparing with 0h time-point. P value refers to analyses of the paired-repeated measures 
ANOVA with Bonferroni correction with oil type as interaction parameter. * p<0.05, ** p<0.001. b) Venn 
Diagram showing common targets of the modulated microRNAs in the three functional oils. 
We then performed an in silico analysis to define which genes are common targets of microRNAs 
modulated be the three functional oils (figure 21b). 44 genes were predicted and validated 
targets of microRNAs modified by all three oils. Those genes were involved in different types of 
cancer as well as in AMPK, MAPK and FOXO signalling and the circadian system (figure 22 and 
table 11). Only two genes, NUFIP2 (FMR1 interacting protein 2) and ABCG2 (ATP binding cassette 
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subfamily G member 2), were common targets among microRNAs modified by L-EVOO and H-
EVOO. NUFIP2 is a RNA binding protein that regulates RNA degradation (272) and whose 
intracellular location is cell cycle-dependent. ABCG2 is an ABC xenobiotic transporter with a role 
in multi-drug resistance (273). In addition to this, CCND1, STAT3, NCOA3, MYC, SIAP and 
TNFRSF108 conform an interaction core of genes involved in Jak-STAT signaling pathway, 
immunity, cell division, cell death and tumour formation (274). 
Figure 21:  Biocomputational analyses of predicted and validated gene targets of microRNAs modulated 
by all three functional oils. A. Bar chart of the top 15 most represented KEGG pathways (-log10 p value 
adjusted by FDR). B. Protein-protein interaction network of genes targeted by microRNAs modulated by 
all three functional oils. 
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Table 11:  Genes targeted by microRNAs common to all the three functional oils 
3. MiRoBEER study
3.1. Characteristics of the population 
During the intervention none of the biochemistry or diet parameters were significantly modified 
except MUFA consumption, that decreased in every intervention period (p=0.02) (table 12). 
Interestingly, we can see a tendency to decrease cholesterol levels and PCR levels in every 
intervention period while we observed an increase of triglycerides in intervention periods. 
Regarding to diet changes, we observed a lower caloric intake, less carbohydrates, less fat and 
Gene symbol Gene name GO Biological Process
PRKAA2 Protein Kinase AMP-Activated Catalytic Subunit Alpha 2
transferase activity, transferring phosphorus-containing 
groups and protein tyrosine kinase activity
KPNA4 Karyopherin Subunit Alpha 4 binding and protein transporter activity
CHD9 Chromodomain Helicase DNA Binding Protein 9  nucleic acid binding and helicase activity
CRY2 Cryptochrome Circadian Regulator 2 protein kinase binding and kinase binding.
PPP1R15B Protein Phosphatase 1 Regulatory Subunit 15B protein serine/threonine phosphatase activity
YOD1 YOD1 Deubiquitinase
thiol-dependent ubiquitin-specific protease activity and Lys48-specific 
deubiquitinase activity
MAP3K2 Mitogen-Activated Protein Kinase  2
transferase activity, transferring phosphorus-containing 
groups and protein tyrosine kinase activity
USP24 Ubiquitin Specific Peptidase 24 binding and cysteine-type peptidase activity
RACGAP1 Rac GTPase Activating Protein 1 protein kinase binding and microtubule binding
TNFRSF10B TNF Receptor Superfamily Member 10b  receptor activity and TRAIL binding
EPHA4 EPH Receptor A4 identical protein binding and protein kinase activity
RAB22A Member RAS Oncogene Family 22A GTP binding and GDP binding
MGAT4A
Mannosyl (Alpha-1,3-)-Glycoprotein Beta-1,4-N-
Acetylglucosaminyltransferase, Isozyme A
transferase activity, transferring hexosyl groups and alpha-1,3-
mannosylglycoprotein 4-beta-N-acetylglucosaminyltransferase activity
MSMO1 Methylsterol Monooxygenase 1 oxidoreductase activity and C-4 methylsterol oxidase activity
ANKRD52 Ankyrin Repeat Domain 52 protein binding
OPA3
Outer Mitochondrial Membrane Lipid Metabolism 
Regulator 3
mitochondrion
NIPA1 Non Imprinted In Prader-Willi/Angelman Syndrome 1 magnesium ion transmembrane transporter activity
NCOA3 Nuclear Receptor Coactivator 3 chromatin binding and transcription coactivator activity
CRK CRK Proto-Oncogene, Adaptor Protein  protein domain specific binding and SH3/SH2 adaptor activity
SCD Stearoyl-CoA Desaturase  iron ion binding and stearoyl-CoA 9-desaturase activity
STAT3 Signal Transducer And Activator Of Transcription 3
 DNA binding transcription factor activity and sequence-specific DNA 
binding
XIAP X-Linked Inhibitor Of Apoptosis ligase activity and ubiquitin protein ligase activity
FZD3 Frizzled Class Receptor 3 G-protein coupled receptor activity and PDZ domain binding
KIAA0319L KIAA0319 Like protein binding
GRPEL2 GrpE Like 2, Mitochondrial protein homodimerization activity and chaperone binding
CCND1 Cyclin D1 protein kinase activity and enzyme binding
SLC30A7 Solute Carrier Family 30 Member 7 cation transmembrane transporter activity
CBX5 Chromobox 5 protein homodimerization activity and histone deacetylase binding
UBE2V2 Ubiquitin Conjugating Enzyme E2 V2 ubiquitin protein ligase binding and acid-amino acid ligase activity
EIF4G2 Eukaryotic Translation Initiation Factor 4 Gamma 2 binding
RBM12B RNA Binding Motif Protein 12B RNA and protein binding
MYC MYC Proto-Oncogene, BHLH Transcription Factor
DNA binding transcription factor activity and RNA polymerase II proximal 
promoter sequence-specific DNA binding
AGMAT Agmatinase agmatinase activity
KLF9 Kruppel Like Factor 9 DNA binding transcription factor activity
TXLNA Taxilin Alpha
cytokine activity and high molecular weight B cell growth factor receptor 
binding
MAP3K1 Mitogen-Activated Protein Kinase Kinase Kinase 1
transferase activity, transferring phosphorus-containing 
groups and protein tyrosine kinase activity
RPRD2 Regulation Of Nuclear Pre-MRNA Domain Containing 2 DNA-directed RNA polymerase II, holoenzyme
IGF2BP1 Insulin Like Growth Factor 2 MRNA Binding Protein 1 nucleic acid binding and RNA binding
HMGA2 High Mobility Group AT-Hook 2
enzyme binding and transcriptional activator activity, RNA polymerase II 
proximal promoter sequence-specific DNA binding
MDM4 MDM4, P53 Regulator enzyme binding
HMGB1 High Mobility Group Box 1 chromatin binding
ZNF652 Zinc Finger Protein 652 nucleic acid binding
NAP1L1 Nucleosome Assembly Protein 1 Like 1 RNA and protein binding
DCAF8 DDB1 And CUL4 Associated Factor 8 protein binding
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saturated fatty acids (SFA) in every intervention point while the vegetal fiber increased, although 
these changes were not significant (table 12) 
Table 12: Population description and biochemistry and diet parameters measured during the clinical 
trial. Values are expressed in mean ± SEM. 
3.2. Beer polyphenols measurements 
IX has been described as a sensitive and specific urine marker of beer consumption (275) In order 
to confirm that all volunteers carried out the intervention properly, we measured the levels of 
IX and 8-PG  in plasma and urine samples of volunteers.  
For this purpose, we first measured the levels of these 2 polyphenols in beer samples used in 
this study. We obtained that IX levels are 5 times higher in beer compared to non-alcoholic beer 
while levels of 8-PG are 2.5 times higher in non-alcoholic beer compared to regular beer (figure 
22). 
WO1 Beer WO2 Non-alcoholic beer p value
Height (m) 1.70 ± 0.05 1.70 ± 0.05 1.70 ± 0.05 1.70 ± 0.05 n.s.
Weight (kg) 90.36 ± 12.46 90.57 ± 11.84 90.57 ± 11.84 90.69 ± 12.07 n.s.
BMI (kg/m2) 31.07 ± 2.6 31.13 ± 2.61 31.13 ± 2.61 31.03 ± 2.48 n.s.
Fat mass (%) 32.61 ± 3.33 32.56 ± 4.17 32.56 ± 4.17 32.64 ± 3.5 n.s.
Muscular mass (%) 30.87 ± 1.76 30.63 ± 2.20 30.63 ± 2.20 30.6 ± 1.7 n.s.
GEB (kcal) 1853.09 ± 177.88 1848.43 ± 169.57 1849.53 ± 171.45 1850.86 ± 170.17 n.s.
Visceral fat 15.86 ± 2.27 15.71 ± 1.98 15.8 ± 2 16 ± 2.16 n.s.
Cholesterol (mg/dl) 214.61 ± 43.21 203.56 ± 31.58 210.71 ± 34.99 205.94 ± 25.76 n.s.
HDL cholesterol (mg/dl) 49.19 ± 13.41 45.17 ± 11.71 56.73 ± 21.6 45.64 ±10.93 n.s.
LDL cholesterol (mg/dl) 134.63 ± 28.41 123.70 ±18.93 136.3 ± 24.86 130.38 ±14.27 n.s.
Triglycerides (mg/dl) 136.14 ± 108.2 187.43 ± 149.67 132.43 ± 68.88 169.86 ± 165.07 n.s.
Apolipoprotein B (mg/dl) 118.03 ± 28.83 112.29 ± 20.52 113.5 ± 21.5 117.83 ± 16.86 n.s.
C reactive protein (mg/dl) 0.28 ± 0.19 0.23 ± 0.14 0.23 ± 0.13 0.23 ± 0.16 n.s.
Energy (kcal) 2412.33 ± 450.68 2318.71 ± 419.30 2489.71 ± 406.32 2095.71 ± 383.15 n.s.
Protein (g/d) 130.18 ± 34.26 103.56 ± 20.88 118.21 ±25.65 94.34 ± 28.58 n.s.
Carbohydrates (g/d) 252.5 ± 49.81 248.43 ± 53.42 266.71 ± 61.89 250.29 ± 43.14 n.s.
Sugar (g/d) 112.6 ± 27.32 111.97 ± 36.34 121.83 ± 29.41 123.51 ± 19.78 n.s.
Starch (g/d) 109.67 ± 29.94 122.39 ± 29.19 120.86 ± 18.2 112.1 ± 32.38 n.s.
Vegetal fiber (g/d) 18.68 ± 5.95 20.14 ± 3.96 20.7 ± 7.55 20.51 ± 8.47 n.s.
Lipids (g/d) 91.63 ± 19.50 81.50 ± 27.32 96 ± 23.23 70.7 ± 18.71 n.s.
SFA (g/d) 34.85 ± 9.98 29.24 ± 14.03 34.47 ± 12 25.59 ± 7.27 n.s.
MUFA (g/d) 34.15 ± 7.19 26.33 ± 7.20 33.74 ± 1.39 22.01 ± 4.87 0.02
PUFA (g/d) 11.23 ± 0.86 13.24 ± 5.31 14.1 ± 1.93 10.27 ± 4.59 n.s.
WO1: wash-out 1 ; Beer: alcoholic beer ; WO2: wash-out 2 ; Non-alcoholic beer; BMI: Body mass index, GEB: 
basal metabolic rate; SFA: saturated fatty acid; MUFA: monoinsaturade fatty acid; PUFA: poliinsaturated fatty 
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Figure 22: Measurement of beer polyphenols in beer and non-alcoholic beer. IX: Isoxanthohumol 8-PG: 
8-Prenilnarigerin. Data represent mean ± SEM 
After that, we analysed polyphenols levels in plasma and urine samples. Regarding to IX, we 
observed a non-significant tendency to increase IX levels in urine after intervention phases 
(figure 23a).  In plasma samples, we observed a significant increase of IX levels after beer 
ingestion (p=0.001), but not after non-alcoholic beer ingestion (figure 23b).  
Figure 23: Measurement of IX in plasma and urine samples. p value refers to the intra-subjects 
comparison of the Paired-repeated measures T-student test. * p<0.05. IX: Isoxanthohumol, WO1: 
washout 1, Beer: alcoholic beer intervention, WO2: washout 2, non-alcoholic beer: non-alcoholic beer 
intervention. Data represent mean ± SEM 
We did not observe an increase in urine or plasma 8-PG levels. On the contrary, we observed a 
non-significant decrease in urine 8-PG levels after beer consumption and a non-significant 
decrease in plasma after, both, beer and non-alcoholic beer consumption.  (figure 24 a and b). 
A reason for this variability could be that 8-PG is a secondary metabolite of IX with a great intra-
subject variability in the metabolization of this compound. 
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Figure 24: Measurement of 8-PG in urine (a) and plasma (b) samples. 8-PG: 8- Prenylnaringenin, WO1: 
washout 1, Beer: alcoholic beer intervention, WO2: washout 2, non-alcoholic beer: non-alcoholic beer 
intervention. Data represent mean ± SEM 
3.3. Post-intervention modification of plasma microRNA levels with alcoholic and non-alcoholic 
beer intake. 
4 circulating microRNAs were significantly modulated by beer intake (figure 25). miR-155 levels 
increase after beer ingestion and decrease after non-alcoholic beer ingestion. Although these 
changes were not statistically significant, we observed that levels of miR-155 were significantly 
lower after non-alcoholic beer intake comparing to alcoholic beer intake (p= 0.036). A similar 
response was observed for miR-328 (p= 0.036) and miR-92a (p= 0.039). Finally, miR-320 was 
repressed after both interventions, but only non-alcoholic beer intervention was significant 
(p=0.022). 
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Figure 25. Circulating microRNAs modulated by beer intake. Box plots showing Log2 transformed relative 
quantification levels of indicated microRNAs along the intervention. Plasma microRNA levels were 
calculated with the 2-ΔΔCt method comparing with each WO time-point. P value refers to the intra-subjects 
comparison of the paired T-student test. * p<0.05. WO1: washout 1, Beer: alcoholic beer intervention, 
WO2: washout 2, non-alcoholic beer: non-alcoholic beer intervention. Data represent mean ± SEM 
Additionally, we observed a borderline significant modulation of two microRNAs, miR-107 and 
miR-17 (figure 26). miR-17, a microRNA belonging to miR-17-92 cluster was repressed after both 
interventions (p= 0.076).  However, moiR-107 levels increased after every intervention (p= 
0.066) 
p = 0.036 
* 
p = 0.022 * 
p = 0.036 * 
p = 0.039 
* 
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Figure 26. Circulating levels of miR-17 and miR-107 after by beer intake. Box plots showing Log2 
transformed relative quantification levels of indicated microRNAs along the intervention. Plasma 
microRNA levels were calculated with the 2-ΔΔCt method comparing with each WO time-point. P value 
refers to the intra-subjects comparison of the paired T-student test. * p<0.05. WO1: washout 1, Beer: 
alcoholic beer intervention, WO2: washout 2, non-alcoholic beer: non-alcoholic beer intervention. Data 
represent mean ± SEM 
3.4. Post-intervention modification of macrophages microRNA levels with alcoholic and non-
alcoholic beer intake. 
Several microRNAs present interesting responses to alcoholic and non-alcoholic beer intake with 
an opposite response to every type of beer in macrophages (figure 27a). MiR-145 is highly 
overexpressed after alcoholic beer ingestion while it does not change after non-alcoholic beer 
intake (p=0.038) (figure 27b).  On the other hand, we observed that the expression of miR-17 
(p=0.05), miR-20a (p= 0.03), miR-223 (p=0.011) and miR-26b (p=0.05) increased after alcoholic 
beer intake while decreased after non-alcoholic beer intake (figure 27b). 
p = 0.066 p = 0.076 
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Figure 27. microRNAs modulated by beer intake in macrophages. a) Heat map showing the clustered 
expression changes after every time-point. b) Box plots showing Log2 transformed relative quantification 
levels of indicated microRNAs along the intervention. Macrophages microRNA levels were calculated with 
the 2-ΔΔCt method comparing with each WO time-point. P value refers to the intra-subjects’ comparison 
of the paired T-student test. * p<0.05. WO1: washout 1, Beer: alcoholic beer intervention, WO2: washout 
2, non-alcoholic beer: non-alcoholic beer intervention. Data represent mean ± SEM 
In addition to this, we observed a similar trend in 3 microRNAs, although their changes did not 
reach statistical significance.  Let 7-e showed a trend to increase its expression after alcoholic 
beer intake while it does not present changes after non-alcoholic beer intake. In miR-146a we 
observed a trend to decrease its expression after alcoholic beer intake while miR-30c showed a 
non-significant increase after alcoholic beer intake and a non-significant decrease after intake 
of non-alcoholic beer (figure 28). 
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Figure 28. Non-significantly modulated macrophages microRNAs. Box plots showing Log2 transformed 
relative quantification levels of indicated microRNAs along the intervention. Plasma microRNA levels were 
calculated with the 2-ΔΔCt method comparing with each WO time-point. P value refers to the intra-subjects’ 
comparison of the paired T-student test. WO1: washout 1, Beer: alcoholic beer intervention, WO2: 
washout 2, non-alcoholic beer: non-alcoholic beer intervention. Data represent mean ± SEM 
3.5. Correlation between circulating microRNAs levels and macrophages microRNAs levels 
We performed different correlation analyses to detect relationships between plasma and 
macrophage microRNAs modifications after interventions. We obtained interesting positive 
correlations in miR-328 (p = 0.047 / R2 = 0.143), let-7e (p = 0.032 / R2 = 0.165) and miR-26b (p = 
0.028 / R2 = 0.172) (Figure 29). 
Figure 29. Correlation between microRNAs levels in plasma and macrophages-modulation by beer 
intake. Plasma and macrophages microRNA levels were calculated with the 2-ΔΔCt method and analysis 
were performed by Pearson correlation. * p<0.05 
Other correlated microRNAs were: plasma miR-20a with macrophage miR-26b (p = 0.002 / R2 = 
0.192), plasma miR-26b with macrophage let-7e (p = 0.004 / R2 = 0.153) and plasma miR-92a 
with several macrophage microRNAs such as let-7e (p = 0.001 / R2 = 0.347), miR-26b (p = 0.001 
/ R2 = 0.335) and miR-30c (p = 0.004 / R2 = 0.271). In addition to this, it is important to highlight 
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the correlation between plasma miR-92a with macrophage miR-17 (p = 0.038 / R2 = 0.155) and 
macrophage miR-20a (p = 0.0005 / R2 = 0.263) given that these 3 microRNAs belong to the same 
cluster (figure 30). 
Figure 30:  Correlation between microRNAs levels in plasma and macrophages. Plasma and macrophages 
microRNA levels were calculated with the 2-ΔΔCt method and analysis were performed by Pearson 
correlation between macrophages and plasma microRNAs differentially expressed after treatment.             
* p<0.05
3.6. Correlation between circulating microRNAs levels and biochemistry parameters 
Finally, we performed correlation analyses between microRNA levels significantly modulated by 
beer and non-alcoholic beer intake and biochemistry and diet parameters. We only obtained 
one positive correlation between circulating miR-320 levels and blood LDL cholesterol levels (p= 
0.028, R2= 0.202) (figure 31). 
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Figure 31:  Correlation between circulating mIR-320 and blood LDL cholesterol levels. Analysis 
were performed by Pearson correlation between blood biochemistry parameters and 
microRNAs levels. * p<0.05 
3.7. Correlation between macrophages microRNAs levels and diet parameters 
Different correlations between macrophage let-7 levels and diet parameter were observed. 
More specifically, macrophage let-7a levels were negatively correlated with soluble fiber intake 
(p = 0.027 / R2 = 0.091), B1 vitamin (p = 0.029 / R2 = 0.103) and iron (p = 0.039 / R2 = 0.048) 
(figure 32). 
Figure 32:  Correlation between macrophage let-7e levels and diet parameters. microRNA levels were 
calculated with the 2-ΔΔCt method while diet parameters were measure by 3-day die questionnaire. Soluble 
fiber is expressed in grams per day and B1 vitamin and iron are expressed in milligrams per day. Analysis 
were performed by Pearson correlation between microRNA levels and micronutrients measured with 3-
days diet questionnaire.  * p<0.05. Vit B1: B1 vitamin, Fe: Iron 
3.8. In silico functional analyses 
We performed a functional analysis of the microRNAs differentially expressed in order to define 
the pathways and biological processes that they regulate after beer intake. For that purpose, we 
used miRWalk database to select the genes that are predicted and validated target of at least 
2/4 microRNAs in plasma and 2/5 microRNAs in macrophages. 
Functional analyses showed that 585 genes were targets of microRNAs modulated by beer 
intake in plasma (figure 33a). Targeted genes were mainly related to different types of cancer 
and related processes (p-53 signalling and cell cycle progression) or nutrient sensing pathways 
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as PI3K-AKT signaling pathway or AMPK signaling pathway (figure 33b). Interestingly, IGF1R, a 
gene involved in insulin signalling cascade and EEF2 (Eukaryotic Translation Elongation Factor 2) 
which is implicated in protein kinase binding were targets of 3 significantly modulated 
microRNAs (miR-155, miR-320 and miR-92) (table 13). 
Figure 33. Functional analyses of plasma microRNAs significantly modulated by alcoholic-beer:  a) Venn 
Diagram showing common targets of the modulated microRNAs and b) Bar chart of the top 15 most 
represented KEGG pathways (-log10 p value adjusted by FDR) 
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Table 13: Genes commonly targeted by at least 3 microRNAs in plasma after beer intake 
Gene symbol Gene name GO Biological Process
MYO1D Myosin ID actin binding and calmodulin binding
NUFIP2 Nuclear Fragile X Mental Retardation Protein Interacting Protein 2 RNA binding
IGF1R Insulin Like Growth Factor 1 Recepto  identical protein binding and protein kinase activity
SOX11 SRY-Related HMG-Box Gene 1
DNA binding transcription factor activity and RNA polymerase II core promoter sequence-
specific DNA binding
PAPOLA Polynucleotide Adenylyltransferase Alpha RNA binding and manganese ion binding
SLC12A4 Solute Carrier Family 12 Member 4 protein kinase binding and cation:chloride symporter activity
LGI2 Leucine Rich Repeat LGI Family Member 2 extracellular region
RAD23B RAD23 Homolog B, Nucleotide Excision Repair Protei single-stranded DNA binding and polyubiquitin modification-dependent protein binding
LCOR Ligand Dependent Nuclear Receptor Corepressor DNA binding transcription factor activityand transcription factor binding
SLC30A7 Solute Carrier Family 30 Member 7 cation transmembrane transporter activity
NFAT5 Nuclear Factor Of Activated T Cells 5 
DNA binding transcription factor activity and transcriptional activator activity, RNA polymerase II 
proximal promoter sequence-specific DNA binding
SLC7A11 Solute Carrier Family 7 Member 11 amino acid transmembrane transporter activity and cystine:glutamate antiporter activity
MYC MYC Proto-Oncogene, BHLH Transcription Factor
DNA binding transcription factor activity and RNA polymerase II proximal promoter sequence-
specific DNA binding.
CCSER2 Coiled-Coil Serine Rich Protein 2 microtubule bindin
NUCKS1 Nuclear Casein Kinase And Cyclin Dependent Kinase Substrate 1
transcriptional activator activity, RNA polymerase II proximal promoter sequence-specific DNA 
binding, chromatin binding
ANKH ANKH Inorganic Pyrophosphate Transport Regulator
inorganic phosphate transmembrane transporter activity and inorganic diphosphate 
transmembrane transporter activity
RRP15 Ribosomal RNA Processing 15 Homolog preribosome, large subunit precursor
BRWD1 Bromodomain And WD Repeat Domain Containing 1 molecular function and protein binding
CTNNBL1 Catenin Beta Like 1 binding and enzyme binding
VCPIP1 Valosin Containing Protein Interacting Protein 1 thiol-dependent ubiquitin-specific protease activity
EXOC5 Exocyst Complex Component 5  protein N-terminus binding and Ral GTPase binding
MYO6 Myosin VI actin binding and actin filament binding
TWF1 Twinfilin Actin Binding Protein 1 protein tyrosine kinase activity and phosphatidylinositol-4,5-bisphosphate binding
LARS Leucyl-TRNA Synthetase nucleotide binding and aminoacyl-tRNA editing activity.
RAB14 Member RAS Oncogene Family 14 GTP binding and GDP binding
MORC3 MORC Family CW-Type Zinc Finger 3 protein binding and zinc and metal ion binding
AKAP10 A-Kinase Anchoring Protein 10 protein binding, protein kinase A binding and kinase activity
SLC1A2 Solute Carrier Family 1 Member 2 L-glutamate transmembrane transporter activity and glutamate:sodium symporter activity
SMAD4 SMAD Family Member 4 DNA binding transcription factor activity and sequence-specific DNA binding
RP2 ARL3 GTPase Activating Protein GTP binding and GTPase activator activity
XPR1 Xenotropic And Polytropic Retrovirus Receptor 1 G-protein coupled receptor activity and transmembrane signaling receptor activity
CREB3L2 CAMP Responsive Element Binding Protein 3 Like 2
DNA binding transcription factor activity and RNA polymerase II proximal promoter sequence-
specific DNA binding
EEF2 Eukaryotic Translation Elongation Factor 2 protein kinase binding
XPO1 Exportin 1 RNA binding and transporter activity
DCP2 Decapping MRNA 2 RNA binding and manganese ion binding
EIF3C Eukaryotic Translation Initiation Factor 3 Subunit C translation initiation factor activity
NFATC2IP Nuclear Factor Of Activated T Cells 2 Interacting Protein protein binding and protein tag
CEP41 Centrosomal Protein 41 microtubule organizing center,centrosome
NAA25 N(Alpha)-Acetyltransferase 25, NatB Auxiliary Subunit peptide alpha-N-acetyltransferase activity and protein binding
BCAT1 Branched Chain Amino Acid Transaminase 1 identical protein binding and L-leucine transaminase activity
SERTAD2 SERTA Domain Containing 2 transcription coactivator activity
NKX3-1 NK3 Homeobox 1 DNA binding transcription factor activity and transcription factor binding.
TRAK2 Trafficking Kinesin Protein 2 signaling receptor binding and GABA receptor binding
SLC7A1 Solute Carrier Family 7 Member 1 
 amino acid transmembrane transporter activity and L-ornithine transmembrane transporter 
activity
PTPRJ Protein Tyrosine Phosphatase, Receptor Type J protein kinase binding and protein tyrosine phosphatase activity
SCD Stearoyl-CoA Desaturase  iron ion binding and stearoyl-CoA 9-desaturase activity
NFIX Nuclear Factor I X
DNA binding transcription factor activity and transcription factor activity, RNA polymerase II 
distal enhancer sequence-specific binding
PIKFYVE Phosphoinositide Kinase, FYVE-Type Zinc Finger Containing
phosphatidylinositol phosphate kinase activity and phosphatidylinositol-3,5-bisphosphate 5-
phosphatase activity
YWHAQ Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Theta protein domain specific binding and protein N-terminus binding
NEO1 Neogenin 1  cadherin binding
ATXN1 Ataxin 1 identical protein binding and chromatin binding
SMC1A Structural Maintenance Of Chromosomes 1A chromatin binding
SLC38A2 Solute Carrier Family 38 Member 2 symporter activity and amino acid transmembrane transporter activity
SPEN Spen Family Transcriptional Repressor nucleic acid binding and DNA binding transcription factor activity
TECPR2 Tectonin Beta-Propeller Repeat Containing 2 autophagy
TXLNA Taxilin Alpha cytokine activity and high molecular weight B cell growth factor receptor binding
EPG5 Ectopic P-Granules Autophagy Protein 5 Homolog cytoplasm
DIAPH1 Diaphanous Related Formin 1 nucleotide binding
DNAJB12 DnaJ Heat Shock Protein Family (Hsp40) Member B12 endoplasmic reticulum, membrane and nucleus
PKM Pyruvate Kinase M1/2 MHC class II protein complex binding
KIAA2018 Upstream Transcription Factor Family Member 3
RNA polymerase II transcription factor activity, sequence-specific DNA binding and protein 
binding
TMEM33 Transmembrane Protein 33 structural constituent of nuclear pore
FAM199X Family With Sequence Similarity 199, X-Linked N.A
TMOD3 Tropomodulin 3 actin binding and tropomyosin binding
DYNC1I1 Dynein Cytoplasmic 1 Intermediate Chain 1 microtubule binding and motor activity
miR-155 +  miR-320  + miR-328 + miR-92
miR-155 + miR-320 + miR-92
miR-155 + miR-328 + miR-92
miR-320 + miR-328 + miR-92
miR-155 + miR-320 + miR-328
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On the other hand, 1729 genes were targets of microRNAs significantly modulated by beer 
intake in macrophages (figure 34a). Targeted genes were mainly related to cancer but, again, 
with nutrient sensing pathways as PI3K-AKT signaling pathway or AMPK signaling pathway 
(figure 34b).  PKFB2 (6-phosfofructo-2-kinase / fructose-2,6-biphosphatase 2), with a role in 
nutrient sensing is target of 4 modulated macrophage microRNAs.  Interestingly, we also 
observed that genes implicated in immune system as CD28 (cluster of differentiation 28) and LIF 
(Interleukin 6 Family cytokine) and genes implicated in cholesterol metabolism like ABCA1 or 
ACSL4 (Acyl-CoA Synthetase Long Chain Family Member 4) are targets of these microRNAs (table 
14). 
Figure 34. Functional analyses of significantly modulated macrophage microRNAs.  a) Venn Diagram 
showing common targets of the modulated microRNAs and b) Bar chart of the top 15 most represented 
KEGG pathways (-log10 p value adjusted by FDR). 
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Table 14: Genes commonly targeted by at least 3 microRNAs in macrophages after beer intake 
3.9. Genes network analysis 
We performed interaction network analysis to check how linked are the genes targeted by the 
regulated microRNAs after beer intake. While the network analysis of genes in plasma showed 
a big cluster of related genes (figure 35a), genes targeted by modulated microRNAs in 
macrophages showed two different interaction nodes linked each other (figure 35b). The core 
of the node of genes targeted by plasma microRNAs is composed by CHD9 (Chromodomain 
helicase DNA binding protein 9), ZNF148 (Zinc finger protein 148), MEF2D (Myocyte enhancer 
factor 2D), CSNK1A1 (Casein Kinase 1 Alpha 1), CNOT6L (CCR4-NOT transcription complex, 
subunit 6-like), HDAC4 (Histone deacetylase 4), TNRC6A (Trinucleotide repeat containing 6A), 
Gene symbol Gene name GO Biological Process
MDM2 MDM2 Proto-Oncogene identical protein binding and ligase activity
DENND5B DENN Domain Containing 5B calcium channel activity and Rab guanyl-nucleotide exchange factor activity.
ANKRD52 Ankyrin Repeat Domain 52 N.A
PURB Purine Rich Element Binding Protein B RNA binding
ST8SIA3 ST8 Alpha-N-Acetyl-Neuraminide Alpha-2,8-Sialyltransferase 3 sialyltransferase activity and alpha-N-acetylneuraminate alpha-2,8-sialyltransferase activity
TMOD2 Tropomodulin 2 actin binding and tropomyosin binding
SLC1A2 Solute Carrier Family 1 Member 2 L-glutamate transmembrane transporter activity and glutamate:sodium symporter activity
SCN3A Sodium Voltage-Gated Channel Alpha Subunit 3 ion channel activity and voltage-gated sodium channel activity.
SCN2A Sodium Voltage-Gated Channel Alpha Subunit 2  ion channel activity and voltage-gated sodium channel activity
POLR3G RNA Polymerase III Subunit G DNA-directed 5-3 RNA polymerase activity and RNA polymerase III activity
FAM199X Family With Sequence Similarity 199, X-Linked N.A
PFKFB2 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 2 protein kinase binding and 6-phosphofructo-2-kinase activity
MSMO1 Methylsterol Monooxygenase 1 oxidoreductase activity and C-4 methylsterol oxidase activity
TMEM64 Transmembrane Protein 64 endoplasmic reticulum and integral component of membrane
HECA Hdc Homolog, Cell Cycle Regulator nucleus, cytoplasm and membrane
RRAS2 RAS Related 2 GTP binding and GTPase activity
SV2B Synaptic Vesicle Glycoprotein 2B transporter activity and transmembrane transporter activity
NIPA1 NIPA Magnesium Transporter 1 magnesium ion transmembrane transporter activity
F3 Coagulation Factor III phospholipid binding and cytokine receptor activity
LIF Interleukin 6 Family Cytokine signaling receptor binding and growth factor activity
ZBTB18 Zinc Finger And BTB Domain Containing 18 DNA binding transcription factor activity and sequence-specific DNA binding
BBX HMG-Box Containing RNA polymerase II transcription factor activity, sequence-specific DNA binding
C9orf40 Chromosome 9 Open Reading Frame 4 RNA polymerase II transcription factor activity, sequence-specific DNA binding
EPM2AIP1 EPM2A Interacting Protein 1
RNA polymerase II transcription factor activity, sequence-specific DNA binding and protein 
binding
MEF2D Myocyte Enhancer Factor 2D
DNA binding transcription factor activity and RNA polymerase II transcription factor activity, 
sequence-specific DNA binding
ZNF148 Zinc Finger Protein 148 nucleic acid binding and sequence-specific DNA binding
CMPK1 Cytidine/Uridine Monophosphate Kinase kinase activity and nucleobase-containing compound kinase activity
CREBRF CREB3 Regulatory Factor DNA binding transcription factor activity and sequence-specific DNA binding
BTG2 BTG Anti-Proliferation Factor 2
transcriptional activator activity, RNA polymerase II proximal promoter sequence-specific DNA 
binding
NTN4 Netrin 4 laminin-1 binding
CD28 CD28 Molecule identical protein binding and SH3/SH2 adaptor activity
FNDC3B Fibronectin Type III Domain Containing 3B RNA and protein binding
NUFIP2 FMR1 Interacting Protein RNA binding
SLC25A44 Solute Carrier Family 25 Member 44 transmembrane transporter activity
SAMD8 Sterile Alpha Motif Domain Containing 8 transferase activity
NAA50 N(Alpha)-Acetyltransferase 50, NatE Catalytic Subunit N-acetyltransferase activity and H4 histone acetyltransferase activity
SMAD4 SMAD Family Member 4 DNA binding transcription factor activity and sequence-specific DNA binding
PLAG1 PLAG1 Zinc Finger
DNA binding transcription factor activity and transcriptional activator activity, RNA polymerase II 
proximal promoter sequence-specific DNA binding
RAB11A Member RAS Oncogene Family GTP binding and microtubule binding
CNOT6L CCR4-NOT Transcription Complex Subunit 6 Like  poly(A)-specific ribonuclease activity
RNF216 Ring Finger Protein 216 ligase activity
ZNF426 Zinc Finger Protein 426 nucleic acid binding
RNF24 Ring Finger Protein 24 ubiquitin protein ligase activity, protein and metal ion binding
ZBTB25 Zinc Finger And BTB Domain Containing 25 DNA binding transcription factor activit
FBXO28 F-Box Protein 28 protein binding
ACSL4 Acyl-CoA Synthetase Long Chain Family Member 4 long-chain fatty acid-CoA ligase activity and arachidonate-CoA ligase activity
SAMD12 Sterile Alpha Motif Domain Containing 12 sequence-specific DNA binding
ABCA1 ATP Binding Cassette Subfamily A Member 1 signaling receptor binding and phospholipid binding
ABCG4 ATP Binding Cassette Subfamily G Member 4  protein homodimerization activity and ATPase activity
PBX3 PBX Homeobox 3 DNA binding transcription factor activity and sequence-specific DNA binding
HMGA2 High Mobility Group AT-Hook 2
enzyme binding and transcriptional activator activity, RNA polymerase II proximal promoter 
sequence-specific DNA binding
miR-145 + miR-17 + miR-20a + miR-223 + miR-26b
miR-145 + miR-17 + miR-20a + miR-223
miR-145 + miR-17 + miR-223 + miR-26b
miR-17 + miR-20a + miR-223 + miR-26b
miR-145 + miR-17 + miR-20a + miR-26b
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ABCA1 and PPARα (Peroxisome proliferator-activated receptor alpha) , involved in negative 
regulation of macrophage derived foam cell differentiation and in the negative regulation of 
glycolytic process and cholesterol storage.  
Figure 35 Interaction network of genes targeted by microRNAs modulated by beer. a) genes targeted by 
significantly modulated plasma microRNAs and b) genes targeted by significantly modulated macrophage 
microRNAs 
An in depth analysis of the two nodes of the macrophage network using KEGG pathways showed 
that the genes in the right node are related to immune system (T cell receptor signaling pathway 
a 
b 
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or HTLV-I infection) and axon guidance while genes in the left node are related to cancer, 
nutrient sensing pathways (PI3K-AKT, FOXO and AMPK signaling) and cell cycle. 
4. PREDIMED PLUS STUDY
4.1. Characteristics of the population 
We selected 20 patients of each group that were representative of each type of the intervention. 
The population characteristics are shown in table 15.  
We observed several changes after 1 year of intervention. We observe a significant decrease in 
weight (p < 0.001), waist (p < 0.001), hip (p < 0.001) and BMI (p < 0.001) in the intervention 
group. Waist and hip perimeters did not change significantly in the control group, whereas 
weight (p < 0.005) and BMI (p=0.028) increased. The body composition did change significantly 
except for an increase in visceral fat in control group (p= 0.028) and a decrease in intervention 
group (p= 0.047). The biochemistry parameters did not show significant changes except for a 
decrease in triglycerides levels in intervention group (p= 0.048). Finally, regarding lifestyles 
parameters, we observed that both control (p =0.001) and intervention (p =0.002) increased 
their adherence to MD. This is not surprising, as the control group is also encouraging to increase 
adherence to the MD, but without CR. However, regarding PA, which is only introduced in the 
intervention group, we found a borderline significant increase in percentage of individuals 
performing moderate and intensive PA at the expense of a decrease in the percentage of 
individuals in the low PA group (p = 0.056). 
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Table 15: Population description and biochemistry and anthropometric measured during the year of 
intervention. Values are expressed in mean ± SEM. 
4.2. Modification of plasma microRNA levels after 1 year of treatment. 
Then we analyzed the change in the circulating levels of microRNAs targeting nutrient sensor 
pathways after 1 year of intervention. We performed a paired significance analysis for 
Basal 1 year p value
Control n.s.
Intervention n.s.
Control 62.35 ± 3.55 63.35 ± 3.55 n.s.
Intervention 65.10 ± 4.71 66.10 ± 4.71 n.s.
Control 130.05 ± 17.92 129.65 ± 13.84 n.s.
Intervention 134.20 ± 13.76 132.20 ± 17.27 n.s.
Control 83.60 ± 12.09 83.65 ± 12.09 n.s.
Intervention 86.85 ± 16.19 84.95 ± 16.74 n.s.
Control 81.5 ± 12.93 82.45 ± 12.58 0.005
Intervention 82.58 ±  13.89 79.07 ± 14.32 <0.001
Control 101.91 ± 9.49 101.42 ± 9.60 n.s.
Intervention 103.41 ± 11.82 98.96 ± 12.28 <0.001
Control 104.20  ±  4.96 104.10 ± 4.65 n.s.
Intervention 107.66 ± 9.41 104.30 ± 9.69 <0.001
Control 30.10  ± 2.25 30.46 ± 2.30 0.028
Intervention 31.36 ± 3.50 29.75 ± 3.66 <0.001
Control 34.11 ± 8.64 34.53 ± 8.09 n.s.
Intervention 37.25 ± 7.95 36.83 ±8.68 n.s.
Control 28.21 ± 5.16 28.55 ± 4.23 n.s.
Intervention 27.95 ± 4.83 27.00 ± 4.32 n.s.
Control 14.45 ± 3.48 15.05 ± 3.53 0.024
Intervention 14.55 ± 4.20 13.70 ± 3.84 0.047
Control 126.00 ± 52.15 136.40 ± 67.41 n.s.
Intervention 108.65 ± 19.82 102.06 ± 31.38 n.s.
Control 191.65 ± 38.26 195.53 ± 44.77 n.s.
Intervention 188.75 ± 34.16 192.72 ± 34.03 n.s.
Control 44.74 ± 7.51 45.90 ± 7.80 n.s.
Intervention 49.05 ± 9.99 51.33 ±10.83 n.s.
Control 124.33 ± 34.41 119.35 ± 91.912 n.s.
Intervention 112.45 ± 25.10 116.97 ±26.97 n.s.
Control 143.89 ± 81.13 162.40 ± 75.48 n.s.
Intervention 139.75 ± 44.20 123.67 ± 44.53 0.048
Control 9.95 ± 1.50 11.83 ± 1.97 0.001
Intervention 9.75 ± 2.29 12.10 ± 2.36 0.002
Control
Low PA 60%  
Moderate PA 25% 
High PA 15 %
Low PA 60%  
Moderate PA 25% 
High PA 15 %
n.s.
Intervention
Low PA 95%  
Moderate PA 0% 
High PA 5%
Low PA 75%  
Moderate PA 15% 
High PA 10%
0.056
65 /35
40/ 60
Visceral fat
Cholesterol (mg/dl)
Systolic pressure 
(mmHg)
Diastolic pressure 
(mmHg)
General description and health parameters
Anthropometric measures
Biochemistry parameters
Waist (cm)
Hip (cm)
BMI (kg/m2)
Fat mass (%)
Muscular mass (%)
BMI: dody mass index, PA: physical activity, n.s.: non significant
Weight (kg)
Age (years)
Sex (men/women) (%)
PA (%)
Lifestyle parameters
17-points MD 
questionnarie
Glucose (mg/dl)
HDL cholesterol (mg/dl)
LDL cholesterol (mg/dl)
Triglycerides (mg/dl)
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microarray (SAM) test with hierarchical clustering of significant microRNAs applying a FDR using 
TMEV software.  SAM test showed 8 microRNAs modified in control group (miR-200c, miR-93, 
miR-92a, miR-15b, miR-301, miR-30b, miR-17-5p and miR-130a) and 6 microRNAs in 
intervention group (miR-195, miR-19a, miR-181a, miR-200c and miR-30b, miR-301). However, 
the FDR indicated that in control group included 2.5 possible false positives while the 
intervention group included 2 possible false positives (figure 36). 
 
 
Figure 36: Heat map showing the hierarchical clustering of SAM significant microRNAs whose expression 
changes in. a) Control group hierarchical clustering and b) intervention group hierarchical clustering. 
Hierarchical clustering was performed with Euclidean distances. Red boxes represent upregulated 
microRNAs and green boxes represent downregulated microRNAs according to the scale depictured on 
the top of each panel. 0 means basal time and 1 means 1-year post intervention.  
 
We re-analyzed data using a paired t-test. However, none of those microRNAs were found 
significantly modulated in any group, although we did observe a trend towards an increase in 
these microRNAs after 1 year of intervention (figure 37).  
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Figure 37. Non-significantly modulated plasma microRNAs. Box plots showing Log2 transformed relative 
quantification levels of indicated microRNAs along the 1-year intervention. Plasma microRNA levels were 
calculated with the 2-ΔΔCt method comparing basal and 1-year time point. MicroRNAs were analysed using 
an intra-subjects’ comparison of the paired T-student test. Data represent mean ± SEM 
7 
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4.3. Modification of macrophages microRNA levels after 1 year of treatment. 
Again, we first did a paired SAM analysis with TMEV to compare microRNA levels of basal time 
and 1-year time in macrophages. We found 6 significant microRNAs in control group with 2 
possible false positives (miR-21, miR-195, miR-16, miR-181a, miR-20a and miR-221) (figure 38a). 
In intervention group, we also observed 6 significant microRNAs (miR-30c, miR-497, miR-130a, 
miR-152, miR-27b and miR-302c) with 1 possible false positive (figure 38b). 
Figure 38: Heat map showing the hierarchical clustering of SAM significant microRNAs whose expression 
changes in macrophages microRNAs after 1 year of intervention. a) Control group hierarchical clustering 
presents 2.5 false positives and b) intervention group hierarchical clustering presents 2 false positives. 
Hierarchical clustering was performed with Euclidean distances. Red boxes represent upregulated 
microRNAs and green boxes represent downregulated microRNAs according to the scale depictured on 
the top of each panel. 0 means basal time and 1 means 1-year post intervention.  
When we re-analyzed using a paired t-test, none of the significant microRNAs in control group 
were found to be significantly modulated (figure 39). However, in intervention group, we 
observed a significant decrease of miR-130a (p<0.05) and almost significant decrease in miR-30c 
(p=0.07) while in the other 4 microRNAs the paired t-test did not support the SAM analysis 
(figure 39) 
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Figure 39. Significant and non-significant modulated macrophages microRNAs. Box plots showing Log2 
transformed relative quantification levels of indicated microRNAs along the 1-year intervention. 
Macrophages microRNA levels were calculated with the 2-ΔΔCt method comparing basal and 1-year time 
point. MicroRNAs were analysed using an intra-subjects’ comparison of the paired T-student test. *p<0.05 
Data represent mean ± SEM 
4.4. In silico functional analysis 
We performed a functional analysis of the targets of macrophage miR-130a and miR-30c in order 
to identify the pathways and biological processes that could be modulated by the intervention 
Functional analyses showed that 115 genes were common targets of both microRNAs. (figure 
40). Pathway enrichment analysis did not show any significant pathway. However, it worth 
mentioning that some of those targets belong to the nutrient sensor pathways (table 16). 
Specifically A-Kinase Anchoring Protein 10 (AKAP10), a gene related to activation of cAMP via 
PKA (protein kinase A). Interestingly, genes associated with LDL metabolism like LDL receptor 
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(LDLR) and LDL Receptor Related Protein 6 (LRP6) are also among the targets of these microRNAs 
(table 16).  
Figure 40:  Functional analyses of macrophages microRNAs significantly modulated by the intervention. 
Venn Diagram showing common targets of the modulated macrophages microRNAs. 
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Table 16: Genes commonly targeted by miR-130a and miR-30c in macrophages after 1 year of 
intervention. 
Gene symbol Gene name GO Biological Process
FAM178A
Family With Sequence Similarity 178, Member 
A protein binding, ubiquitin protein ligase binding, protein-containing complex binding
NUFIP2
Nuclear Fragile X Mental Retardation Protein 
Interacting Protein 2 RNA binding.
TAF4B
TATA-Box Binding Protein Associated Factor 
4b DNA binding transcription factor activity and NF-kappaB binding
ENPP4
Ectonucleotide 
Pyrophosphatase/Phosphodiesterase 4 sulfuric ester hydrolase activity and bis(5-adenosyl)-triphosphatase activity
DPYSL2 Dihydropyrimidinase Like 2 protein kinase binding and microtubule binding
SOX4 SRY (Sex Determining Region Y)-Box 4 DNA binding transcription factor activity and transcriptional activator activity, RNA 
polymerase II proximal promoter sequence-specific DNA binding.
NRP1 Neuropilin 1 heparin binding and growth factor binding
LYRM2 LYR Motif Containing 2 protein binding
GJA1 Gap Junction Protein Alpha ignaling receptor binding and protein domain specific binding
ATG2B Autophagy Related 2B autophagy
MAP3K5 Mitogen-Activated Protein Kinase Kinase 
Kinase 5
protein homodimerization activity and protein kinase activity
PPP1R15B Protein Phosphatase 1 Regulatory Subunit 
15B
protein serine/threonine phosphatase activity
ARHGEF12 Rho Guanine Nucleotide Exchange Factor 12 GTPase activator activity and G-protein coupled receptor binding
ZNF529 Zinc Finger Protein 529 nucleic acid binding
LCOR Ligand Dependent Nuclear Receptor 
Corepressor
DNA binding transcription factor activityand transcription factor binding
OPHN1 Oligophrenin 1 actin binding and phospholipid binding
CSF1 Colony stimulating factor 1 protein homodimerization activity and growth factor activity
SLC6A6 Solute Carrier Family 6 Member 6 neurotransmitter:sodium symporter activity and taurine transmembrane transporter 
activity
ARF4 ADP Ribosylation Factor 4 GTP binding and obsolete signal transducer activity
KBTBD6 Kelch Repeat And BTB Domain Containing 6 protein binding
SCML2 Scm Polycomb Group Protein Like 2 DNA binding transcription factor activity and sequence-specific DNA binding
RAB14 Member RAS Oncogene Family GTP binding and GDP binding
RPS27A Ribosomal Protein S27a structural constituent of ribosome
NACC2 NACC Family Member 2 protein homodimerization activity and transcriptional repressor activity, RNA 
polymerase II proximal promoter sequence-specific DNA binding
QKI KH Domain Containing RNA Binding nucleic acid binding and RNA binding
ARID5B AT-Rich Interaction Domain 5B transcription coactivator activityand RNA polymerase II regulatory region sequence-
specific DNA binding
HABP4 Hyaluronan Binding Protein 4 RNA and protein binding
HLF PAR BZIP Transcription Factor DNA binding transcription factor activity and double-stranded DNA binding
LONRF2 LON Peptidase N-Terminal Domain And Ring 
Finger 2
ATP-dependent peptidase activity
ZNF711 Zinc Finger Protein 711 sequence-specific DNA binding
ATP6V1C1 ATPase H+ Transporting V1 Subunit C1  transporter activity and proton-transporting ATPase activity, rotational mechanism
C7orf60 Base Methyltransferase Of 25S RRNA 2 
Homolog
methyltransferase activity
PFN2 Profilin 2  actin binding and actin monomer binding
CCDC6 CCDC6 SH3 domain binding and structural constituent of cytoskeleton
AKAP10 A-Kinase Anchoring Protein 10 protein kinase A binding
NHLH2 Nescient Helix-Loop-Helix 2 protein dimerization activity and RNA polymerase II activating transcription factor 
binding
LDLR Low Density Lipoprotein Receptor calcium ion binding and low-density lipoprotein particle binding
SLC1A2 Solute Carrier Family 1 Member 2  L-glutamate transmembrane transporter activity and glutamate:sodium symporter 
activity
RIMBP2 RIMS Binding Protein 2 cell junction
SAMD8 Sterile Alpha Motif Domain Containing 8 transferase activity
ABCE1 ATP Binding Cassette Subfamily E Member 1 ATPase activity and ribonuclease inhibitor activity
KIAA1244 ARFGEF Family Member 3 ARF guanyl-nucleotide exchange factor activity
TTBK1 Tau Tubulin Kinase 1 transferase activity, transferring phosphorus-containing groups and protein tyrosine 
kinase activity
SLC38A2 Solute Carrier Family 38 Member 2 symporter activity and amino acid transmembrane transporter activity
MYH11 Myosin Heavy Chain 11 calmodulin binding and motor activity
EIF5A2 Eukaryotic Translation Initiation Factor 5A2 RNA binding and translation elongation factor activity
SUN2 Sad1 And UNC84 Domain Containing 2 identical protein binding and lamin binding
SLC35F3 Solute Carrier Family 35 Member F3 integral component of membrane
SNTB2 Syntrophin Beta 2 calmodulin binding
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BEND4  BEN Domain Containing 4, n.d
ZCCHC14 Zinc Finger CCHC-Type Containing 14 nucleic acid binding and phosphatidylinositol binding
UBE2D1 Ubiquitin Conjugating Enzyme E2 D1  ligase activity and acid-amino acid ligase activity
XPR1 Xenotropic And Polytropic Retrovirus 
Receptor 1
 G-protein coupled receptor activity and transmembrane signaling receptor activity
PRKAA2 Protein Kinase AMP-Activated Catalytic 
Subunit Alpha 2
 transferase activity, transferring phosphorus-containing groups and protein tyrosine 
kinase activity
MYLIP Myosin Regulatory Light Chain Interacting 
Protein
 ligase activity and ubiquitin protein ligase activity
RMND5A Required For Meiotic Nuclear Division 5 
Homolog A
GID complex
LRP6 LDL Receptor Related Protein 6 protein homodimerization activityand signaling receptor binding
ATP6V1B2 ATPase H+ Transporting V1 Subunit B2  proton transmembrane transporter activity
NUS1 Dehydrodolichyl Diphosphate Synthase 
Subunit
 transferase activity, transferring alkyl or aryl (other than methyl) groups
USP6 Ubiquitin Specific Peptidase 6 nucleic acid binding and cysteine-type endopeptidase activity.
PLCB1 Phospholipase C Beta 1 calcium ion binding and enzyme binding
LCLAT1 Lysocardiolipin Acyltransferase 1  transferase activity, transferring acyl groups and 1-acylglycerol-3-phosphate O-
acyltransferase activity
TNRC6A Trinucleotide Repeat Containing 6A nucleic acid binding and nucleotide binding
SLC7A5 Solute Carrier Family 7 Member 5 peptide antigen binding and antiporter activity
STIM2 Stromal Interaction Molecule 2  calcium ion binding and store-operated calcium channel activity
KREMEN1 Kringle Containing Transmembrane Protein 1 integral component of membrane
CFL2 Cofilin 2 actin binding
EPG5 Ectopic P-Granules Autophagy Protein 5 
Homolog
cytoplasm
PHACTR2 Phosphatase And Actin Regulator actin binding and protein phosphatase inhibitor activity
TBL1XR1 Transducin Beta Like 1 X-Linked Receptor 1  transcription regulatory region DNA binding and histone binding
CPEB4 Cytoplasmic Polyadenylation Element Binding 
Protein 4
nucleic acid binding and RNA binding
ACVR1 Activin A Receptor Type 1 protein homodimerization activity and protein kinase activity
SIX4 SIX Homeobox 4 DNA binding transcription factor activity and sequence-specific DNA binding
HPRT1 Hypoxanthine Phosphoribosyltransferase 1 protein homodimerization activity and nucleotide binding
NFE2L1 Nuclear Factor, Erythroid 2 Like 1  DNA binding transcription factor activity and transcription coregulator activity
IKZF4 IKAROS Family Zinc Finger 4 nucleic acid binding and protein homodimerization activity
TNFRSF10B TNF Receptor Superfamily Member 10b TRAIL binding
TMEM170B Transmembrane Protein 170B plasma membrane
ZFYVE26 Zinc Finger FYVE-Type Containing 26 phosphatidylinositol-3-phosphate binding
FAM43A Family With Sequence Similarity 43 Member A n.d.
ZEB2 Zinc Finger E-Box Binding Homeobox 2 nucleic acid binding and phosphatase regulator activity
USP48 Ubiquitin Specific Peptidase 48 cysteine-type endopeptidase activity and thiol-dependent ubiquitinyl hydrolase activity
MBNL3 Muscleblind Like Splicing Regulator 3 nucleus and cytoplasm
GABRA4 Gamma-Aminobutyric Acid Type A Receptor 
Alpha4 Subunit
chloride channel activity and GABA-A receptor activity
SKIDA1 SKI/DACH Domain Containing 1 n.d.
NIPA1 NIPA Magnesium Transporter 1 magnesium ion transmembrane transporter activity
SERPINE1 Serpin Family E Member 1 signaling receptor binding and protease binding
BRWD3 Bromodomain And WD Repeat Domain 
Containing 3
nucleus 
C3orf58 Chromosome 3 Open Reading Frame 58 golgi membrane
CBY1 Chibby Family Member 1 identical protein binding and beta-catenin binding
PTGFRN Prostaglandin F2 Receptor Inhibitor protein binding
DGKE Diacylglycerol Kinase Epsilon NAD+ kinase activity and diacylglycerol kinase activity
ATXN1 Ataxin 1 identical protein binding and chromatin binding
RASA1 RAS P21 Protein Activator 1 signaling receptor binding
BTBD7 BTB Domain Containing 7 nucleus
KLHL42 Kelch Like Family Member 42 ubiquitin-protein transferase activity
CCND2 Cyclin D2 protein kinase binding
DLC1 Rho GTPase Activating Protein GTPase activator activity and SH2 domain binding
FZD3 Frizzled Class Receptor 3 G-protein coupled receptor activity and PDZ domain binding
DLG5 Discs Large MAGUK Scaffold Protein 5  beta-catenin binding and receptor signaling complex scaffold activity
PTP4A1 Protein Tyrosine Phosphatase Type IVA, 
Member 1
phosphatase activity and protein tyrosine/serine/threonine phosphatase activity
ELL2 Elongation Factor For RNA Polymerase II 2 protein binding
C16orf70 Chromosome 16 Open Reading Frame 70 protein binding
UCP3 Uncoupling Protein 3  transporter activity and oxidative phosphorylation uncoupler activity
STX16 Syntaxin 16 syntaxin binding and SNAP receptor activity
PLA2G12A Phospholipase A2 Group XIIA calcium ion binding and calcium-dependent phospholipase A2 activity
B4GALT5 Beta-1,4-Galactosyltransferase 5 galactosyltransferase activity
TRPS1 Transcriptional Repressor GATA Binding 1 DNA binding transcription factor activity and sequence-specific DNA binding
ONECUT2 One Cut Homeobox 2 DNA binding transcription factor activity and transcriptional activator activity, RNA 
polymerase II proximal promoter sequence-specific DNA binding
UBE2D2 Ubiquitin Conjugating Enzyme E2 D2  ligase activity and acid-amino acid ligase activity
TAOK1 TAO Kinase 1  transferase activity, transferring phosphorus-containing groups and protein tyrosine 
kinase activity
MSANTD4 Myb/SANT DNA Binding Domain Containing 4 nucleus
MIB1 Mindbomb E3 Ubiquitin Protein Ligase 1  ligase activity and ubiquitin-protein transferase activity
SCN9A Sodium Voltage-Gated Channel Alpha Subunit 
9
ion channel activity and sodium ion binding
BRWD1  Bromodomain And WD Repeat Domain 
Containing 1
protein binding
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4.5. Senescence analysis 
We hypothesized that a hypocaloric MD together with PA promotes a better aging profile in late 
adulthood, and I showed that the intervention is associated to a decrease in miR-130a and miR-
30c. Both microRNAs have been associated with aging before (276, 277).   
Then, we analyzed monocytes senescence. For this purpose, we first measured CD28 and CD57 
gene expression. It has been reported that CD28 expression is reduced (278) and CD57 is 
increased in senescent monocytes (279).  We observed that CD28 levels are higher (p = 0.0709 
and that CD57 levels are lower in the intervention group that control group. Although these 
results are not significant, probably because of the small size of the population, they suggest 
that intervention is delaying monocyte senescence. (figure 41).  
Figure 41: Changes in relative expression of CD28 and CD57 in monocytes after 1 year of intervention. 
p value refers to the intra-subject’s comparison of the paired-repeated measures t-student test. Data 
represent mean ± SEM 
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It is well known that food intake is one of the most important environmental factors affecting 
human health. Nutrients are needed to maintain cellular processes. But nutrients are not only 
mere energy providers, they  are also key regulators of gene expression and they interact with 
our genome to modulate a plethora of biological processes (280). For this reason, understanding 
how human being could be affected by specific foods or dietary patterns, specifically in relation 
to gene expression, has a key role in nutrition research field. In the last years, epigenomic has 
emerged as an interesting mechanism of gene expression regulation with a great potential to be 
used as therapeutic target. Not only nutrients interact with our genome, they also do that with 
the epigenome. MicroRNAs have been recently unraveled as important fine-tune modulators of 
gene expression. Previous studies in cell and animal models have shown how different fatty 
acids modulate the expression of different microRNAs (178, 179). This thesis aimed to describe 
how Mediterranean foods and the MD pattern modulate the expression of microRNAs in human 
interventional trials.  
1. Extraction and detection of exogenous microRNAs
One of the most intriguing result of the last decade is the detection of plant microRNAs in human 
plasma (246). We aimed to elucidate if Mediterranean foods also provided microRNAs as new 
micronutrients. We analyzed the presence of microRNAs in beer and EVOO samples. According 
to our bioanalyzer results, we extracted microRNAs from beer and EVOO, although at a very low 
concentration that could be due to the processed nature of these materials. A previous study 
failed to detect  substantial levels of microRNAs in fruits usually consumed by humans (281). 
Besides, olive microRNAs have been described before from growing and dormant lateral bud 
samples using NGS (269). The discordance between Donaire and colleagues (269) results and 
ours could be due to the different sample used. Instead of leaves, roots or the olive fruit, we 
used EVOO, a mechanically processed product from olives. Additionally, EVOO is an extremely 
fatty liquid. Although we introduced modifications in the protocol to cope with this limitation, 
some technical caveats could be influencing our yielded RNA. On the other hand, beer is also a 
processed liquid submitted to a fermentation process that generates alcohol. It has been 
described that plant microRNAs are resistant to different conditions that contribute to nucleic 
acid degradation, including heat, acid pH and enzymatic lysis (246).However it is possible that 
microRNAs from the olive oil and beer were degraded in such fatty compound and in the 
fermentation process of beer production, respectively. However, our spike-in analysis showed 
that a plant single-strand microRNA exogenously added to the sample could be detected by RT-
qPCR suggesting that, although some technical limitations exist, the technique is sensitive 
enough to measure plant microRNAs.  
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We then analyzed the presence of plant microRNAs in the plasma of healthy volunteers after 
intake of 40 ml of EVOO. Interestingly, we found 109,295 molecules of the miR-1529 belonging 
to soybean. However, all the read sequences presented missing nucleotides when comparing 
with the canonical sequence and 3 mismatches (table 9). We also failed to identify any of the 
sequences reported by Donaire and colleagues (269). These results do not support the results 
reported by Zhang et al, although we used healthy volunteers that usually consume EVOO.  
On the other hand, the results obtained by Zhang et al are very controversial due to a great 
number of papers supporting and refusing the hypothesis of these authors. For instance, 
Dickinson B. et al tried to replicate the experiments without success (251). On the other hand, 
some other authors support this hypothesis. In ghtis regard, Chin AR et al that detect plant miR-
159 in human serum (249). However, the number of copies was very low and when they tried 
to replicate the experiment in cell and animal models the amount of mimic miR-159 that they 
proportionated was not physiological. It is better established in the case of microRNA 
transference from breast milk to breast milk-fed infants (282). In other animals models as pigs, 
who were fed with 1 kg of maize, Yi L. et al detected maize-microRNAs in pig serum (283). In the 
case of miR-451 KO mice model Wang W. et al detected dietary miR-451 in blood of these 
animals (284). Other authors refused this hypothesis due to the degradation and low 
bioavailability of dietary microRNAs (285). In our study, we supposed that the levels of EVOO 
microRNAs in the plasma of our volunteers would reach a peak after 2 h. Baier et al (286) showed 
a maximum increased of milk-derived microRNAs between 4 and 8 h post-ingestion, although a 
significant increase could also be observed after 2 h with the maximum dose. However, Zhang 
et al (246) detected exogenous plant microRNAs in overnight-fasted animals. We analyzed the 
plasma of five volunteers that usually consume EVOO, so we expected to detect EVOO 
microRNAs, even if after 2 h of the EVOO ingestion the levels of EVOO microRNAs did not 
reached their peak. We must bear in mind that although NGS using Ion Torrent technology offers 
a high microRNA detection rate that is really useful for challenging samples like EVOO, such 
exceptional high sensitivity may be partly related to library contamination and should be 
interpreted cautiously (287-289). Thus, we cannot rule out the possibility that the detection of 
plant microRNAs in EVOO and plasma samples was the result of a technical artifact, likely due to 
a library contamination. Thus, despite our strategies to maximize the presence of EVOO 
microRNAs in the plasma of the volunteers we could not confidently detect them.  
In summary, our results contribute to the current controversy about the presence and the 
dietary uptake of plant microRNAs by adding experimental evidences that suggest that plant-
based processed products, like beer and EVOO do not contain microRNAs or they are not 
consumed through the diet. Specifically, we did not detect substantial quantities of plant 
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microRNAs in the EVOO and beer samples. Furthermore, we did not detect plant microRNAs in 
the human plasma after the ingestion of an acute dose of EVOO. 
2. VOHF study
EVOO intake, the main fat source in MD, is well described as a beneficial food with multiple 
effects, including anti-oxidant, anti-inflammatory and anti-microbial activities (88). Additionally, 
results from the VOHF study have shown a dose-dependent effect on HDL proteome (81). 
However, the effect of OO on gene regulation has not been well described so fare. 
Nutrigenomics studies related to OO are mainly focused in the effect of its bioactive compounds, 
as hydroxytyrosol (83) or oleic acid (290) although there are a few studies about the 
nutrigenomic effect of OO (90, 290). Other studies have explored the effect of an acute ingestion 
of VOO in gene expression of health volunteers (90). Authors observed differences in insulin-
related genes such as O-linked-N-acetylglucosamine transferase (OGT) and arachidonate-5-
lipoxygenase-activating protein (ALOX5AP) (90). Other study showed the effect of VOO 
combined with MD in healthy volunteers during 3 months in gene expression related to 
inflammation as INF-gamma (INFgamma), Rho GTPase-activating protein15 (ARHGAP15), and 
interleukin-7 receptor (IL7R) or oxidative stress such as adrenergic as beta (2)-receptor (ADRB2) 
and polymerase (DNA-directed) kappa (POLK) (91). All these studies point towards and anti-
inflammatory and cardioprotective impact of OO on gene expression.  
Such impact could be mediated by an effect of OO on some related microRNAs. However, studies 
focusing on the analyses of epigenetic regulation mediated by VOO intake still lack.  
2.1 Circulating microRNAs regulation with L-EVOO intake 
We observed differences in the regulation of n microRNA expression depending of polyphenol 
enrichment of each type of VOO. In L-EVOO (EVOO supplemented with 250 mg/Kg of its own 
polyphenols) let-7e, miR-17, miR-20 and miR-328 were differently modulated (figure 15). Let-7e 
expression showed a bimodal distribution with two downregulation peaks at 1 hour and 4 hours 
(being non-significant at 4 hours), suggesting a short-term effect at 1 hour and a mid-term effect 
at 4 hours. Let7-e is a well-known microRNA, involved in many processes, like IGF-1 regulation 
(168), and inflammation, where has been reported that its upregulation inhibited inflammatory 
responses (291) , a recognized effect of VOO ingestion (292). Circulating let-7e has been found 
strongly dysregulated in atherosclerotic disease (293) and its levels are higher in patients with 
ischemic stroke  (294). Moreover, in hypertensive patients, let-7e was also found upregulated 
comparing to healthy volunteers (295) and let-7e levels has been negatively correlated with HDL 
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levels and  positively correlated with the number of metabolic syndrome criteria in school-age 
children (296) . Thus, these results suggest that a downregulation of let-7e could be a positive 
effect of EVOO intake and that a mechanism whereby EVOO has this effect could be the 
regulation of this microRNA.  
After L-EVOO intake, miR-17 and miR-20a levels were increased at all time-points, being 
significant at 4 hours in miR-17 and at 1 and 2 hours in miR-20a. Both microRNAs showed the 
same tendency, as expected, due to the fact that they belong to the same cluster (miR-17-92 
cluster). This cluster is related to IGF1/PI3K/AKT/mTOR and AMPK/SIRT1/PGC1α pathways (217, 
218). MiR-17 overexpression leads to the activation of AKT/mTOR, promoting cell adhesion, 
migration and proliferation (297); and expression of the miR-17-92 cluster impairs AMPK 
activation in mantle cell lymphoma (MCL) cells (298). Moreover, miR-17-92 cluster is highly 
expressed in endothelial cells (299) and the overexpression of miR-92a in human umbilical vein 
endothelial cells (HUVECs) and mice impaired angiogenesis in vivo and in vitro (300). In addition, 
the reduction of miR-17-92 cluster expression has also been observed to result in more ROS and 
DNA damage, which increases age-related damage (219). Interestingly, the levels of circulating 
miR-17-92 cluster were significantly reduced in coronary artery disease patients compared with 
healthy controls (301). A reduction in circulating levels of miR-20a has also been found in South 
African Women with Gestational Diabetes Mellitus (GDM) (302). Moreover, circulating miR-20a 
has been also linked to aging as it was found more abundant in young donors comparing to old 
donors after a resistance exercise in male volunteers (303). On the other hand, Ye D. et al 
observed that levels of miR-17 and miR-20a were upregulated in T2DM patients with non-
alcoholic fatty liver disease (NAFLD). In addition, GLUT4, a glucose transporter with a key role in 
peripheral tissues glucose uptake, is a direct target of miR-17 and a critical regulator of glucose 
metabolism (304). Therefore, the role of miR-17-92 cluster in human health is controversial with 
studies showing a benefit derived from its overexpression and studies showing a detrimental 
effect. In summary, the increase in miR-17-92 cluster levels could protect against ROS and DNA 
damage and could promote healthy aging through this protection. However, an increase in the 
levels of microRNAs from this cluster could also promote the development of T2D. It is likely that 
the effect of miR-17-92 cluster could be different in different tissues, in response to different 
environmental exposures or in different ages. More studies are needed to clarify if non-enriched 
EVOO also increases circulating levels of these microRNAs and if this L-EVOO mediated increase 
is related to a better aging profile or to a poorer glucose control. It would be notice that the 
studies carried out by Keita H et al. showed an insulin resistance in mice fed a high fat diet based 
in EVOO (305), but, in human intervention studies, an improvement in insulin resistance with 
EVOO intake has been observed (306). 
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Finally, miR-328 is repressed at 1 hour and its levels increase after then to reach back to basal 
levels (figure 15). Increased levels of miR-328 have been suggested to be predictive of AMI (307) 
and are associated to AF, even after the adjustment for risk factors like hypertension. This 
miRNA has been also found to promote atrial electrical remodeling by reducing L-type Ca (2+) 
channel density (308). These results suggest that the reduction of circulating miR-328 levels by 
L-EVOO could have a beneficial effect on CVD. 
As it has been described before, an over expression of IGF-1/PI3K/AKT/FOXO/mTOR pathway is 
related to aging. Additionally, higher levels of plasma IGF-1 and lower activity of the IGF1R are 
negatively associated  with longevity (138), whereas lower levels of plasma IGF-1 were 
associated with greater survival in nonagenarian women (139). Our in silico analysis have shown 
that these microRNAs could regulate mechanisms associated to insulin sensitivization via IGF1 
and IGF1R regulation. On the other hand, greater longevity has also been observed in 
populations with high adherence to the MD (73, 74) for which the main fat is EVOO. The 
modulation of let-7e, miR-17, miR-20 and miR-328 by L-EVOO could explain the protective effect 
of EVOO regarding ROS damage and endothelial function that could be part of the  mechanism 
whereby MD increased longevity.  
2.2. Circulating microRNAs regulation with M-EVOO intake 
MiR-17 and let-7e were also modulated by M-EVOO. Let-7e showed the same bimodal response 
to M-EVOO than observed with L-EVOO. This suggest that this microRNAs is a primary target of 
enriched EVOO and deserves further consideration to elucidate the mechanisms behind the 
EVOO-mediated modulation of let-7e. miR-17 and miR-20a levels also responded similarly to L-
EVOO as they were also increased by M-EVOO, although the increase in miR-20a was not 
significant. Again, these results point to the miR-17-92 cluster as one of the main targets of EVOO 
intake and one of the epigenetic mechanisms by which EVOO intake modulate cellular 
physiology. Moreover, these results suggest that miR-17 and miR-20a could be potential 
biomarkers of EVOO intake, although, we did not observe a dose-dependent response in relation 
to the higher polyphenol content of M-EVOO comparing to L-EVOO. Further studies with larger 
sample sizes are needed to confirm the modulation of the miR-17-92 cluster by EVOO and the 
impact of such modulation.  On the other hand, we observed that miR-192 was upregulated at 
6 hours by M-EVOO. Circulating miR-192 levels have been suggested as potential biomarker of 
ischemic cardiomyopathy (ICM) survival. The median age at time of death was 84 years in 
patients with low miR-192 expression but 67 years with high miR-192 expression. However, 
miR-192 levels in non-ICM patients is not associated with survival (309). Another study 
suggested that increased levels of circulating miR-192 might be a conserved biomarker for 
obesity or metabolic state  in a murine model where authors observed an increase in circulating 
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miR-192 levels in response to a high-fat / high-fructose diet (310). The role of miR-192 in cancer 
has been deeply studied, but little is known about its role in CVD, diabetes or aging and most 
studies have been carried out in animal models or in individuals with CVD, while our study was 
carried in healthy volunteers.  Therefore, it should be defined if an increase in circulating miR-
192 levels in healthy individuals have a short-term beneficial effect. But, for that purpose, a new 
study designed to directly asses that hypothesis is needed. 
2.3. Circulating microRNAs regulation with H-EVOO intake 
Interestingly, let-7e was also downregulated by H-EVOO following a bimodal distribution (figure 
17), although an inverse response was observed when comparing with L-EVOO and M-EVOO 
(figure 21). This point to let-7e as the most consistently modified microRNA by EVOO intake and 
suggest it is a good biomarker of EVOO intake and a potential mediator of the effects of EVOO. 
We also observed a down regulation of miR-10a with a greater effect at 2 hours (figure 17). It 
has been shown that miR-10a represses the expression of proteins that destabilize IκB/NF-κB–
mediated inflammation in cultured human aortic endothelial cells (HAEC) (311). Simionescu N. 
et al observed that circulating miR-10a was upregulated in hyperlipidemic patients and it is 
positively correlated with serum lipids and inflammatory parameters (312). Thus, a decrease in 
miR-10a levels mediated by H-EVOO intake could explain the beneficial effect on lipid levels and 
inflammation attributed to EVOO and its polyphenols (313-315).  
MiR-21 and miR-26b were also downregulated with a minimum at 2 hours (figure 17). miR-21 
ablation in macrophages of atherogenic mice has been found to increase apoptosis, plaque 
necrosis, and vascular inflammation, promoting plaque instability and atherosclerosis 
progression (182). However, circulating miR-21 has been found downregulated after an acute 
exercise in basketball athletes (198). Moreover, miR-21 levels have been related to aging, 
specifically, lower levels of miR-21 are related to healthy aging and it has been postulated as a 
biomarker of healthy aging (316, 317). These results suggest that H-EVOO mediated modulation 
of miR-21 could link EVOO intake and healthy aging, although high levels of polyphenols are 
needed to modulate this microRNAs as it did not change with L-EVOO and M-EVOO. In this 
regard, a further analysis of the link between miR-21, EVOO and aging is guaranteed.  
Finally, miR-26b is decreased in cardiac death or recurrent myocardial infarction, but it has  been 
also shown that its low levels are associated to the prevention of  adverse cardiomyocyte 
hypertrophy (318) and it has been observed that its overexpression produces enhanced 
endothelial cells proliferation, migration, and tube formation and its downregulation 
suppressed the proliferative and angiogenic capacity of endothelial cells (319). On the other 
hand, levels of circulating miR-26b of hypertensive patients with left ventricular hypertrophy 
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(LVH) are higher compared to healthy subjects (320). It should be studied the effect of the H-
EVOO mediated downregulation of miR-26b on cardiovascular health in more detail.  
2.4. Functional analyses of microRNAs modulated by the enriched EVOOs 
The functional analysis shed some interesting results. For instance, PRKCB, a gene involved in 
endothelial cell proliferation, intestinal sugar absorption, insulin signalling and B-cell activation 
(270) and SCD (Stearoyl-CoA Desaturase), involved in MUFA synthesis were targets of all 4 L-
EVOO modulated microRNAs (figure 18, table 9). Also, between the common genes of let7-e 
and miR-328, two micro-RNAs with the same response to L-EVOO, we found STARD7 (StAR 
related lipid transfer domain containing 7) that mediates intracellular trafficking of lipids (321) 
and induces ROS production and reticulum endoplasmic stress (322), and IGF1R, a key regulator 
of insulin signaling pathway (138). It would be interesting to further study the link between L-
EVOO, the modulated microRNAs and the expression of PRKCB, SCD, STARD7 and IGF1R. Further 
studies are needed to elucidate the mechanisms behind such link, but these results are a primary 
mechanistic glance and suggest that fatty acid metabolism and insulin signalling could be directly 
affected by this link. 
In silico studies showed that M-EVOO modulated microRNAs were involved in cancer but also in 
insulin pathways (figure 19, table 10). Twenty-five genes are common targets of the 3 
microRNAs differentially expressed. Among them, there is PRKAA2, the catalytic subunit of the 
AMPK cellular energetic sensor. This result suggest that M-EVOO could be modulating the 
energetic status of the cell through the microRNA-mediated regulation of this gene. Such a 
modulation could have an impact in aging as it has been shown that AMPK increase is associated 
with longevity in animal models (323).  Moreover, metformin, an antidiabetic drug that targets 
AMPK has been studied because of its effect on longevity. Nevertheless, this interesting 
suggestion need to be experimentally confirmed. 
In silico analyses of microRNAs modulated by H-EVOO showed that they are mainly involved in 
cancer, but also in circadian rhythm and in one of the nutrient sensing pathways studied, 
PI3K/AKT pathway (figure 20, 21 and table 11). Only 1 gen is commonly regulated by the 4 
microRNAs, YOD1. This gene is a protein deubiquitinase involved in inflammation (271). The fact 
that this gene is a potential target of all common microRNAs modulated by H-EVOO suggest that 
the effect of this highly enriched EVOO on health could be mediated primarily by YOD1 
modification. Nevertheless, the direct targeting of YOD1 be the 4 microRNAs should be 
experimentally validated as well as the link between H-EVOO, the 4 microRNAs and YOD1. 
Finally, we searched for common targets of the microRNAs modulated by all three oils (figure 
21). Forty-four genes were targeted by common microRNAs. Among them, we found ABCG2, 
PRKAA2 (Protein Kinase AMP-Activated Catalytic Subunit Alpha 2) or SCD, all genes regulated by 
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diet (324-326). The finding of PRKAA2 as a gene targeted by common microRNAs should be 
highlighted given its link to one of the aging-related nutrient sensing pathways, AMPK, described 
above. These results could suggest that the mechanism by which these microRNAs regulates 
AMPK activity could be through PRKAA2. 
In summary, we observed that enriched EVOO consistently modified microRNAs that target 
genes related to insulin signalling pathways as well as lipid metabolism and inflammation. 
Among the nutrient sensor pathways, AMPK pathway may be the most affected by all three 
enriched EVOO. These results suggest that, providing that EVOO impact on human longevity, 
AMPK modification could be the underneath mechanism. In this regard, further studies to 
analyse this hypothesis are guaranteed.  
It is important to mention that microRNAs of the miR-17-92 cluster as well as let-7e are 
commonly modified by the different types of functional EVOOs, although we did not find a clear 
dose-dependent response. That suggests that these microRNAs could play a key role in the 
mechanisms by which EVOO exerts its protective effects, but that polyphenol supplementation 
could not have an additive effect. However, in previous studies with the VOHF intervention, 
authors detected differences between L-EVOO, M-EVOO and H-EVOO regarding the levels of 
plasma phenolic metabolites (327), enzymes related to HDL antioxidant activity, oxidative stress, 
lipid profile, fat soluble vitamins or glucose and insulin resistance (255, 328) . Our results suggest 
that a different concentration of polyphenols don’t affect circulating microRNAs expression. On 
the other hand, Pedret A et al did not observed changes in inflammation biomarkers depending 
on phenolic composition of functional EVOOs (328). Moreover, our results showed more 
similarity between L-EVOO and M-EVOO than with H-EVOO regarding circulating microRNAs. 
The explanation could be that the low or medium enrichment saturate circulating levels of these 
microRNAs. Could also be possible that a higher polyphenol enrichment had different effects on 
molecular pathways and a different impact on human aging. In this regard, it has been shown 
that an excess of polyphenols could produce pro-inflammatory effects (329). It has been also 
described that an excess of flavonoids could be associated with an oxidant effect (330). These 
results suggest that the different effect of H-EVOO on microRNA levels could be, in part, due to 
a detrimental effect of an excess of polyphenols and, thus, the polyphenol supplementation 
should be uses carefully.   
2.5. Study limitations and future perspectives 
This study has some limitations. First, the low number of participants in the study with only 12 
volunteers. In addition,  not all volunteers completed the intervention, reducing the total 
number of participants. We should also bear in mind that it is a postprandial study and some 
changes produced by EVOO intake could need a longer exposure. Moreover, participants drunk 
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30 ml of EVOO that is a dose which is not usually consumed in only one ingestion. It would be 
necessary to carry out another intervention study with regular doses of EVOO ingested in a 
regular basis (for example in one day). Furthermore, it should be analysed the effect of each 
specific polyphenol in every concentration on the expression of the modulated microRNA to 
discern if EVOO oil composition have a specific effect in microRNA regulation. Finally, some 
technical limitations linked to the detection and normalization of microRNAs in plasma could 
interfere with the results by reducing sensitivity.  
Nonetheless, this study depicts a possible mechanism that could explain the beneficial effect of 
EVOO by the consistent modulation of let-7e, and miR-17-92 cluster, microRNAs that are well 
described because of their influence in insulin signalling pathways and inflammation and 
deserve further attention. Moreover, miR-17-92 cluster downregulation has been consistently 
described as biomarker of aging in several models of aging (331), so its upregulation produced 
by EVOO intake could mediate an antiaging effect, but further studies to confirm such effect 
such hypothesis are needed. . 
3. MiRoBeer study
3.1 Analysis of polyphenols levels in plasma and urine 
First, we analyzed the presence of IX and 8-PG in plasma and urine of volunteers. Both are beer 
derived metabolites and IX has been shown to be a good marker of beer consumption (275). We 
aimed to confirm participants’ adherence to the intervention. This analysis was carried out with 
the collaboration of Dr. Ana Rodríguez Mateos through a 3-months internship in her laboratory, 
in the Division of Diabetes and Nutritional Sciences of King´s College London. First, we measured 
the concentration of both metabolites in beer and non-alcoholic beer and, as expected, beer 
presents high levels of IX, higher than non-alcoholic beer; while levels of 8-PG are higher in non-
alcoholic beer (figure 22). The possible reason for that could be the heat treatment applied to 
beer to dealcoholize it that favors the conversion of IX on 8-PG. In fact, this process is commonly 
produced in human intestine after beer intake by microbiota (332). Then, we measured them in 
plasma and urine of the participants in the study. We observed higher levels of IX after every 
intervention in plasma and urine, although it was significant only in plasma after beer 
intervention (figure 23). The increase in IX levels after beer intake suggest that participants 
adhered well to the intervention. The lack of validation of IX increase after non-alcoholic beer 
consumption is explained by the fact that IX concentration was low in non-alcoholic beer (figure 
22) but does not indicate a lack of adherence to the intervention.  However, 8-PG levels did not
increase in urine or plasma after consumption of non-alcoholic beer. One reason for that could 
be that 8-PG is a secondary metabolite of IX and have a longer half-life than IX so part of the IX 
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could be transformed in 8-PG but with intrinsic differences between patients given that this 
conversion depends of factors like the microbiota of each individual (332). In fact, different 
conversion phenotypes have been described and this could be an explanation of the great 
variability that we detect in levels of 8-PG (333). Additionally, we allowed patients to choose the 
moment of the day of beer intake to avoid problems associated to alcohol and activities like 
driving, working, etc. Participants could also choose if they drunk the 500 ml of beer in 1 or more 
intakes. Martinez SE et al studied the enantiospecific pharmacokinetics of IX and 8-PF in rats 
concluding that the rate of urinary excretion is higher the closer the time of the intake (334). 
Given that we took blood and urine samples early in the morning, after 12 hours fasting, IX and 
8-PG levels in urine or plasma could be lower than expected. The time since the last intake of 
beer could be delayed depending if the participant drunk the beer in midday or night, 
introducing a big variability in our urine and plasma measures. 
3.2 Analysis of population characteristics 
First, we analyzed if participants had modified their nutritional behavior during the intervention 
in order to control for that effect. We did not find any significant modification in anthropometric 
or body composition. We found some modifications in nutritional behavior such as a lower 
energy intake during intervention phases that was explained by a lower intake of all 
macronutrients (carbohydrates, proteins and fats), but only the decrease in MUFA intake was 
significant (table 12). This could be due to the so-called “control effect” that means that 
participants feel under supervision during intervention and, unconscienced, they improved their 
diet. Nevertheless, we considered that those weak modifications, non-significant, would not 
significantly affect circulating and macrophage microRNAs levels. Although changes in 
biochemistry parameters were not significant, we observed a tendency to reduce C reactive 
protein (CRP) levels, a classic inflammation biomarker (335) after the beer intake that continued 
lower along the whole intervention (table 12). We also observed a trend to a reduction in total 
cholesterol, LDL-cholesterol and HDL-cholesterol levels and an increase in triglycerides after 
each intervention period (table 12). It has been described the influence of beer consumption in 
inflammation. In animal model, Iso-α-acids, a component of beer produces a significant 
reduction of inflammatory cytokines like IL-1β (336). In vascular cells, IX and XN manifested anti-
inflammatory properties while 8-PG increase blood vessels formation (337). In healthy male 
runners, non-alcoholic beer reduces levels of IL-6 (338), while in elderly women whose diet were 
supplemented with 500 ml of non-alcoholic beer, inflammatory parameters did not change 
while oxidative stress parameters improved although only in participants with cholesterol levels 
higher than 240 mg/dl a significant reduction was found (339). Moreover, recent studies 
conducted by Padro T. et al observed that beer consumption did not produce an improvement 
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in anthropometric parameter as well as lipoproteins profile or inflammation biomarker while 
anti-oxidative properties of HDL and better cholesterol efflux were detected (340). These results 
agreed with our results given that we did not observed significant differences in lipid levels after 
each intervention period, but we observed a tendency to decreased CRP levels.   
3.3.Modulation of circulating microRNAs after beer intake 
Some circulating microRNAs modified by beer intake are common with EVOO. For instance, miR-
328, which was downregulated by L-EVOO, was also downregulated by non-alcoholic beer. It 
was up-regulated by beer, although not significantly and the difference in plasma miR-328 levels 
among beer and non-alcoholic beer was significant. This suggest that the alcohol content of beer 
could damper miR-328 modifications mediated by polyphenols of the beer and the EVOO. As it 
has been described before, miR-328 is a microRNA whose higher levels are correlated with CVD 
(307). Therefore, while non-alcoholic beer could be promoting a beneficial effect related to miR-
328, alcoholic beer could have the opposite effect. A similar response was found in miR-92a, 
(figure 25). In osteosarcoma patients, miR-92a regulated the expression of PTEN/AKT signaling 
pathway (341) and an inhibition of miR-92a is associated to a  better remodeling after 
myocardial infarction (342). MiR-92a is a member of the miR-17-92 cluster and, as it has been 
described before, the downregulation of this cluster could be a biomarker of healthy aging (331). 
MiR-17-92 cluster is closely linked to nutrient sensing pathways regulation (especially insulin 
signaling cascade) and inflammation (217-219). Moreover, in Rhesus monkeys a downregulation 
of miR-92 was observed with CR, a well-known intervention to promote longevity, although miR-
92 levels were dependent on bodyweight or adiposity (343). Mir-17 levels were also 
downregulated with non-alcoholic beer, but also with alcoholic beer (figure 27). These results 
point again to the cluster miR-17-92 as one important mediator of the effects of traditional 
Mediterranean foods like EVOO and beer and could be the link between these foods and aging. 
In summary, members of the miR-17-92 cluster as well as miR-328 are sensitive to nutrients and 
could be good biomarkers of food intake.  
Other circulating microRNAs modified by beer intake are miR-155 and miR-320. Regarding miR-
155, it is upregulated by beer and downregulated by non-alcoholic beer, being the difference 
between both significant. Circulating levels of this microRNA have been found downregulated 
in esophageal cancer (344) and  in diabetic patients (345). Moreover, Elgheznawy A et al 
observed lower levels of platelet miR-155 in humans and mice with T2DM (346). In addition to 
this, low levels of circulating miR-155 are associated to coronary artery disease (CAD) and has 
been suggested to be a potential risk factor of coronary heart disease (CHD). All these results 
could suggest that low levels of this microRNA could not be beneficial in the context of CVD and 
T2DM. More studies are needed to clarify the role of the biological impact of the non-alcoholic 
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beer-mediated downregulation of miR-155. Interestingly, the increase of miR-155 with beer 
could suggest that beer could affect cardiovascular health specifically through the modulation 
of this microRNA, as the effect of beer on the other microRNAs suggested a negative impact on 
human health. Finally, miR-320 was downregulated after both, beer non-alcoholic beer 
intervention, although it was significant only in the last condition. In plasma samples of diabetics 
patients, this microRNA was found downregulated (347). On the other hand, circulating miR-320 
levels are higher in Crohn's disease (CD) (348) and an overexpression of miR-320 is related to 
cardiomyocyte apoptosis and the loss of mitochondrial membrane potential in mice (349). 
Additionally,  overexpression of miR-320  in cardiomyocytes isolated from 2 months old Sprague-
Dawley rats enhanced cardiomyocyte death and apoptosis while miR-320 KO rats showed the 
opposite effect (350).  These results could suggest that the downregulation of miR-320 after 
non-alcoholic beer intervention could have a cardioprotective effect although in glucose 
metabolism could have a negative effect. 
Finally, miR-107 is overexpressed almost significantly after each intervention. MiR-107 is related 
to insulin sensitivity in liver and its silencing improved glucose homeostasis and insulin sensitivity 
(351). As the results obtained in the other described microRNAs, this result agreed with a non-
beneficial effect on glucose homeostasis after beer intake. 
In silico functional analysis of the 4 circulating microRNAs differentially expressed (miR-92a, miR-
328, mir-320 and miR-155) showed that only 4 genes are targets of all of them: IGF1R, NUFIP2, 
MYO1D (myosin ID) and SOX11 (SRY-Box 11) (figure 33a and table 13). IGF1R, the gene that 
encodes the receptor of the IGF1 is a key regulator of the insulin signaling pathway. EEF2, which 
is also regulated by 3 microRNAs (miR-155, miR-320, miR-92), is implicated in the regulation of 
protein kinase and could be regulated by diet, specifically, MD (352). The regulation of these 
genes could suggest that the microRNAs regulated by beer intake could have an effect on the 
insulin signaling pathway through the modulation of these genes. In the KEGG pathways 
analysis, some of the main pathways associated to genes targeted be these 4 microRNAs, are 
AMPK signalling pathway or PI3K-AKT signalling pathway, two nutrient sensing pathways with a 
role in aging (figure 33b). In silico analysis showed the link between beer intake and regulation 
of IGF1/PI3K/AKT/mTOR pathway and AMPK/SIRT1/PGC1α pathway via miR-92a, miR-328, mir-
320 and miR-155. 
3.4. Modulation of macrophage microRNAs after beer intake 
Macrophages microRNAs analysis after intervention showed that miR-17, miR-20a, miR-26b, 
miR-145 and miR-223 were differentially expressed (figure 27). Thus, we observed again the 
modulation of some members of the miR-17-92 cluster, miR-17 and miR-20a. This modulation 
in macrophages was similar to that found in plasma, they were upregulated by beer and 
downregulated by non-alcoholic beer. These results support this differential effect of beer and 
130 
DISCUSSION 
non-alcoholic beer on this cluster. Both microRNAs play a key role in signal-regulatory protein α 
(SIRPα)-mediated macrophage inflammatory response (353). Moreover, in THP-1 and RAW 
264.7 macrophage-derived foam cells lines, miR-20a decreased cholesterol efflux and increased 
its cholesterol content (354). Given that both are upregulated after beer intake but 
downregulated after non-alcoholic beer intake, this could suggest that alcohol could be 
mediating an inflammatory response in macrophages. However, the non-alcoholic beer-
mediated decrease of both could have an anti-inflammatory effect.  The recommendation for 
moderate alcoholic beer consumption is 2 drinks per day (355) but the current trend consider 
that the limit for alcohol consumption should be as maximum 10 g of alcohol consumption (356) 
On the other hand, miR-145, miR-26b and miR-223 showed a similar response to beer intake. It 
should be noted that miR-26b was also downregulated by H-EVOO, but not with the other less 
enriched EVOOs. As it has been described before, the reduction of its microRNA is associated to 
the prevention of adverse cardiomyocyte hypertrophy and its levels are higher in hypertensive 
patients with left ventricular hypertrophy (LVH) (318, 320). However, Zhang L. et al observed 
that an overexpression of miR-26b in bovine alveolar macrophages (bAMs) results in higher 
levels of pro-inflammatory cytokines and chemokines (357). This is consistent with an 
inflammatory effect of the alcohol of beer and an anti-inflammatory effect of non-alcoholic beer 
(358).    
On the other hand, it has been shown that macrophage miR-145 expression is associated to 
inflammatory reaction via NF-κB activation in APOE KO mice (359). However, miR-145 was found 
downregulated in M1 macrophages comparing to M2 macrophages in bone marrow-derived 
macrophages (BMDMs) (360) and miR-145 expression inhibits the secretion of inflammatory 
factors with the downregulation of ADP ribosylation factor 6 (ARF6) in THP1 cell line (361). These 
results show controversial effects of miR-145 on macrophage inflammatory response and they 
seem to indicate that a downregulation of miR-145 could not be beneficial given that it could be 
associated to a pro-inflammatory profile in cell lines although in a mouse model of 
atherosclerosis the opposite could be true. Therefore, it would be necessary to carry out more 
studies to clarify the effect of miR-145 on humans. 
The last macrophage microRNA differentially expressed is miR-223 that increased with beer and 
decreased with non-alcoholic beer. miR-223 is a key regulator of innate immunity and its 
expression could inhibit macrophage differentiation (362). Moreover, its downregulation 
increases TLR-activated inflammatory responses and promotes the production of pro-
inflammatory cytokines IL-6 and IL-1β in murine model (363, 364). These results suggest that the 
modulation of miR-223 by non-alcoholic beer could promote inflammation, which is not in 
accordance with the effect of previously described microRNAs. It has been found an increase in 
miR-223 levels in serum from alcoholic patients and in serum and neutrophils in mice with 
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chronic alcohol consumption (365), which is consistent with our increase observed after beer 
intake. So, it is possible that the increase of miR-223 observed with beer was a specific effect of 
its alcohol content, whereas the relationship between the non-alcoholic mediated increase of 
miR-223 and its pro-inflammatory role should be further elucidated.   
Finally, it is worth mentioning that let-7e, which was downregulated by all enriched EVOOs, was 
upregulated, almost significantly, by beer. As it has been described before, let-7e is involved in 
IGF-1 regulation (168). Upregulation of let-7e has been associated to stroke, atherosclerotic 
disease, hypertension and metabolic syndrome (293-296). These results could suggest that the 
beer-mediated increase of this microRNA in macrophages could be detrimental. This supposition 
needs to be directly addressed, because it has been reported that its overexpression in mice 
macrophages improve sensitivity and tolerance to lipopolysaccharides (LPS) in an AKT KO mouse 
(366). Upregulation of let-7e has also been associated to inhibited inflammatory responses in 
vascular smooth muscle cell (SMC) (291). Thus, let-7e could have tissue-specific effects and, in 
this sense, its increase in macrophages could be related, not to increase of CVD risk factors, but 
to an improvement in insulin sensitivity and a reduction in inflammation.  
3.5.Macrophage and circulating microRNAs were correlated 
Changes in circulating levels of let-7e, miR-328 and miR-26b and miR-92a correlated positively 
with changes in macrophage levels of these microRNAs (figure 29). This suggest that beer 
consumption has a similar effect in those microRNAs in macrophages and in their release to the 
circulation. We cannot assure that the origin of those microRNAs in the circulation is the 
macrophages, but such positive correlation suggest that this could be the case. It is well known 
that macrophages actively release microRNAs into the circulation (367). Thus, it is not 
unreasonable to suggest that macrophages could be, in part, the source of these plasma 
microRNAs.  
Then, we performed correlation analyses to analyze If microRNA levels were associated to the 
characteristics of the individuals. Interestingly, we observed a positive correlation between 
plasma miR-320 and LDL cholesterol (figure 31). As far as we know, this is the first study 
reporting such correlation, although Wei G. et al previously observed a negative correlation 
between hepatic miR-320 and Adiponectin receptor 1 (ADIPOR1) protein, that promotes fatty 
acid oxidation in the liver (368). Interestingly, macrophage let-7e levels were negatively 
correlated with iron, soluble fiber and B1 vitamin intake (figure 32) It has also been 
demonstrated that a low-protein diet leads to a downregulation of plasma let-7e in mice 
offspring, suggesting the influence of the diet on the expression of let-7e (369). To our 
knowledge, this is the first report showing a correlation between macrophage microRNA levels 
and dietary parameters. We cannot assure if the reduction observed in the intake of these 
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nutrients is influencing the response of let-7e to beer intake or if the effect of beer on let-7e 
levels is influencing the intake of these nutrients and new studies are needed to clarify these 
correlations. 
The gene network analysis (figure 35) showed that there is a node formed by CHD9, ZNF148, 
MEF2D, CSNK1A1, CNOT6L, HDAC4, TNRC6A, ABCA1 and PPARα as genes regulated by circulating 
microRNA modified by beer intake. They are mainly related to immune system function and 
glycolytic process and could be the mechanism by which beer intake impact on these processes. 
Future studies will be addressed to confirm the modification of the expression of those genes 
by beer intake. On the other hand, genes targeted by microRNAs modulated in macrophages 
were distributed in two different nodes involved in immune system function and nutrient 
sensing pathways. Given that nutrient sensing pathways are related to aging, the microRNA 
mediated modulation of those genes by beer could be a link between beer intake and healthy 
aging.  
To sum up, we demonstrated that beer intake modulates the microRNA profile in both plasma 
and macrophages. Some of the modulated microRNAs had been found also modulated by the 
enriched EVOOs (let-7e, miR-328 and the miR-17-92 cluster), suggesting that they are specifically 
sensitive to nutrient-mediated modulation. Moreover, we observed a difference regarding beer 
and non-alcoholic beer intake with beer having a more pro-inflammatory microRNA profile that 
is inversed in non-alcoholic beer. This is in accordance with results from Dr. Estruch and 
colleagues that have shown that nonalcoholic beer presents a better anti-inflammatory effect 
comparing to other alcoholic beverages. In addition to this, we have observed an interesting 
correlation between some circulating and macrophage microRNAs that supports the notion that 
those circulating microRNAs could be released by the macrophages. Further studies are needed 
to clarify the effect of the alcohol.  
3.6. Study limitations and future perspectives 
The short sample size is the main limitation of this study, so it would be necessary to perform 
other interventions increasing the participants as well as including women to confirm the results 
obtained in this pilot study. In addition, the measurement of IX to check the beer consumption 
depend on the time where the participants drunk the beer and its suitability as biomarker of 
beer intake is limited. We allowed the participants to choose the moment and how they wanted 
to take the dose during the day leading to a great variability in IX levels.  
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4. PREDIMED-PLUS study
4.1 Analysis of the population after 1-year treatment 
Our last objective was to analyze if a CR sustained along 1 year and based on a healthy dietary 
pattern (MD) plus PA modulated circulating and macrophages microRNAs. For that purpose, we 
selected 20 samples of each group of the PREDIMED-PLUS study. First, we observed that the 
intervention group had reduced anthropometrical parameters significantly. There was also a 
significant reduction in visceral fat, whereas the control group significantly increased visceral fat 
(table 15). This clearly suggest that the intervention is effective in the modification of obesity-
related parameters. In biochemistry parameters, we did only observe a significant reduction in 
the levels of triglycerides (table 15).  
Regarding lifestyle parameters, we observed that both groups increased the adherence to the 
MD. This is not surprising, given that participants in the control group are also encouraged to 
follow a MD. However, intervention group increased their PA level according to the specific 
recommendation that were given to each group.  
4.2 Plasma microRNAs modifications after 1 year of treatment 
SAM analysis of circulating microRNAs gave 8 microRNAs differentially expressed in control 
group and 6 in the intervention group, miR-200c, miR-301 and miR-30b were common for both 
groups. They were all upregulated after 1 year of intervention with a greater effect in the 
intervention group. However, a paired t-test did not confirm the significance. This intervention 
is not as acute as that in VOHF and miroBeer studies; instead is a chronic and multivariant 
intervention based on lifestyle instead of specific nutrients. In this sense, 1 year could be a too 
short time for a so multifactorial intervention to lead to significant changes in circulating 
microRNAs levels.  The PREDIMED-PLUS intervention based on a complete lifestyle change 
involves the variation in more than one nutrient and variable, thus it introduces a higher 
variability that may require a larger sample size to have sensitivity enough to detect small 
changes in circulating microRNAs. On the other hand, after one year of intervention, participants 
are 1 year older, and we cannot rule out the possibility of an age-related modification of these 
microRNAs independently of the intervention  (203).  
Although changes were not significant, we observe and interesting trend to an increase in some 
plasma microRNAs. For instance,  miR-30b, which is modulated by physical exercise and is 
related to cardiovascular risk in spinal cord-injured patients (370), miR-181 that belongs to a 
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family related to vascular inflammation and immunity (371) and  miR-195 and miR-19a that are 
considered to be predictive of aging and respond to resistance exercise in men (303).  
4.3. Macrophage microRNAs modifications after 1 year of treatment 
SAM analyses showed 6 differentially modulated microRNAs in macrophages of both groups 
(figure 38). However, after paired t-test none of the selected microRNAs in the control group 
remained significant.  
On the other hand, paired t-test did show a significant downregulation of miR-130a and an 
almost significant downregulation of miR-30c in intervention group (figure 39). In macrophages, 
Su S. et al observed that IL-4 and IL-13, interleukins with anti-inflammatory properties,  lead to 
a downregulation of miR-130a  (372) and, inflammatory factors as NF-ΚB increased its 
expression (373). Moreover, Sharma H et al showed that macrophages treatment with HIV and 
cocaine increased its expression (374).  These results suggest that the intervention could be 
resulting in the release of anti-inflammatory interleukins that, in turn reduces miR-130a levels 
and that this intervention-mediated downregulation could result in an anti-inflammatory profile 
of macrophages. This hypothesis needs to be further investigated. On the other hand, miR-130a 
is a negative regulator of TSC1 (TSC complex subunit 1), which is also a negative regulator of 
mTOR signaling (373). Therefore, miR-130a downregulation could be increasing TSC1-mediated 
inhibition of mTOR signaling, mirroring the effect of rapamycin, a supposed anti-aging drug (5).  
Regarding to miR-30c, as it has been described before, it is an important regulator of VLDL (177) 
and its overexpression has an effect on the expression of genes related to lipid metabolism, 
increasing accumulation of triglycerides with lower levels of miR-30c (178). Moreover, reduction 
of miR-30c levels is associated to the production of pro-atherosclerotic signals like IL-1β release, 
caspase-3 expression and apoptosis that leads to inflammation and apoptosis  in THP-1 cell line. 
(195). Additionally, Chen C et al showed that downregulation of miR-30c leads to the activation 
of BECN1 (Beclin 1) that promotes autophagy and the pathogenesis of diabetic cardiomyopathy 
in mice and HEK293 cells treated with palmitate acid (375). Therefore, our results showing a 
downregulation of miR-30c by the treatment suggest that this reduction cold have a negative 
effect in lipid metabolism, CVD and atherosclerosis. This is inconsistent with a healthier 
macrophage microRNA profile after 1 year of treatment. Following studies are needed to clarify 
this controversy and elucidate the impact of the treatment-mediated reduction of miR-30c in 
macrophages. 
The in silico functional analysis of the two macrophage microRNAs differentially expressed 
showed that they have 115 common target genes (figure 40 and table 16). Between them, the 
most relevant genes related to nutrient sensing pathways and CVD (table 16) are AKAP10, a 
gene involved in the activation of cAMP and for which polymorphisms have been found to be 
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associated with insulin resistance and T2DM (376) and PRKAA2, also involved in cAMP synthesis, 
which is 50% upregulated with an aerobic exercise intervention in dyslipemic mice (377). This is 
consistent with a potential modulation of this gene by our intervention that involves physical 
exercise. Other genes regulated by both microRNAs are LDLR and LPR6, involved in metabolism 
of LDL lipoproteins. 
4.4 Senescence analysis 
Due to the special characteristic of the recruited population, with a minimal age of 55 years old 
in men and 60 years old in women, we hypothesized that the aging of the population could be 
differential in the two groups and that such a different aging dynamic could be reflected in a 
differential progression of immune senescence. It is known that senescence is accompanied by 
a phenotypic change in the population of T cells with an increase in the ratio of senescent/non-
senescent T cells. It has been described that senescent T cells loss gene and protein CD28 
expression and become CD57 positive. Thus, the loss of CD28, coupled to an upregulation of 
CD57 has been used as biomarker of T cell senescence progression (378).  We measured changes 
in the levels of both genes after 1 year of intervention in both, control and intervention groups 
(figure 41).  We observed that intervention group presents higher levels of CD28 and lower 
levels of CD57 comparing to control. These results could suggest that the proportion of 
senescent T cells in control individuals is higher than in individuals in the intervention group. 
Therefore, this suggest that the intervention could be delaying immune-senescence. Although 
specific studies are needed, we suggest that the intervention modifies microRNAs that, through 
the regulation of nutrient sensing pathways, delay the appearance of aging hallmarks, one of 
them is immune defeat. Different molecular studies to further analyze the direct impact of the 
modulation of these microRNAs in hallmarks of aging will be conducted in the near future.  
4.5. Limitations and future perspectives 
PREDIMED-PLUS is a clinical trial aimed to analyze the long-term effect of MD and physical 
activity on CVD in high cardiovascular risk patients with a follow-up of 8 years. The specific 
characteristics of this intervention with a non-acute intervention, make us to expect small 
changes in microRNA levels and the limited number of samples we have used to analyze 
microRNA levels have added high variability to results that difficult to observe significant small 
changes. For that reason, it would be necessary to include more samples to the analysis and to 
check the changes in microRNA profile in the next years to observe more sustained changes in 
microRNA profile. However, the observed modulation of miR-130a and miR-30c in macrophages 
is promising as it is the first report showing changes in microRNA levels in macrophages in a 
human intervention study based on a multifactorial intervention.  
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CONCLUSIONS/CONCLUSIONES 
1. Substantial amounts of plant microRNAs have not been detected in EVOO and beer
samples nor in in human plasma after the ingestion of an acute dose of EVOO. Therefore, 
our results do not support a cross-kingdom regulation mediated by plant exogenous
microRNAs ingested with plant foods.
2. Different polyphenol-enriched EVOOs modulate circulating levels of microRNAs
associated with CVD, insulin signaling, inflammation and aging. Among them, Let-7e,
miR-17 and miR-20a (the two later belonging to the miR-17-92 cluster), microRNAs well
described as modulators of nutrient sensing pathways and inflammation, are modified
by the three types of functional oils.
3. A consistent dose-dependent response to polyphenol content was not observed in
circulating microRNA levels, although microRNAs modulation mediated by L-EVOO and
M-EVOO was more similar between them than with H-EVOO.
4. Circulating levels of miR-155, miR-328 and miR-92a are modulated differently by beer
and non-alcoholic beer intake, suggesting an alcohol-specific effect, whereas miR-320
and miR-17 levels are downregulated by both types of beer, suggesting an alcohol-
independent effect on these microRNAs. All of them could be good biomarkers of beer
intake and could modulate IGF-1/PIK3/AKT/FOXO/mTOR signaling pathway and
inflammation as shown by our in silico analysis.
5. Beer and non-alcoholic beer differently modulated the expression of miR-145, miR-17,
miR-20a, miR-26b and miR-223 in macrophages, suggesting an alcohol specific effect.
These results suggest that beer and non-alcoholic beer could modulate macrophage
physiology through these microRNAs, involved in IGF-1/PIK3/AKT/FOXO/mTOR signaling 
pathway and inflammation as shown by our in silico analysis.
6. The effect of beer and non-alcoholic beer on the expression of circulating and
macrophage microRNAs was different and suggests a pro-inflammatory microRNA
profile and an anti-inflammatory microRNA profile of both beer types respectively.
7. Let-7e, miR-328, miR-26b and miR-92a circulating and macrophage levels were
correlated suggesting that macrophages could be, in part, the source of these plasma
microRNAs.
8. CR achieved with hypocaloric MD plus physical activity is more effective for weight loss,
body composition balance, plasma triglycerides levels and, in general, cardiovascular
health than only MD recommendations after 1 year of intervention.
9. CR achieved with hypocaloric MD plus physical activity modifies macrophage expression
of miR-30c and miR-130a, involved in lipid metabolism and mTOR signaling regulation,
suggesting that the beneficial effect of this intervention could be epigenetically
mediated by the modulation of these microRNAs in macrophages. However, we did not
find any significant modulation of circulating microRNAs, suggested that a more acute
and long intervention is needed to detect substantial changes.
10. CR achieved with hypocaloric MD plus physical activity could delay age-related immune
system defeat, due to the observed higher CD28 and lower CD57 levels in lymphocytes
of intervention participants in comparison with control participants.
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11. In general, let-7e and members of the miR-17-92 cluster (miR-17, mir-20a and miR-92a) 
were consistently modulated by different interventions both, in plasma and 
macrophages, suggesting that they are sensitively modulated by diet in humans and 
could be mediators of the effect of nutrients on cellular physiology in different tissues. 
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CONCLUSIONS/CONCLUSIONES 
1. No se han detectado cantidades sustanciales de microRNAs de plantas en muestras de
aceite de oliva virgen extra y cerveza ni en plasma humano después de la ingestión de una
dosis aguda de aceite de oliva virgen extra. Por lo tanto, nuestros resultados no apoyan la
hipótesis de una regulación cruzada entre diferentes reinos mediada por microRNAs
exógenos de plantas ingeridas con alimentos vegetales.
2. Los diferentes aceites de oliva virgen extra enriquecidos con polifenoles modulan los
niveles circulantes de microRNAs asociados con la enfermedad cardiovascular, la
señalización de la insulina, la inflamación y el envejecimiento. Entre ellos, let-7e, miR-17 y
miR-20a (los dos últimos pertenecientes al cluster miR-17-92), han sido descritos como
moduladores de las vías sensoras de nutrientes y la inflamación y son modificados por los
tres tipos de aceites funcionales.
3. No se observó una respuesta constante dosis-dependiente respecto al contenido de
polifenoles en los niveles de microRNAs circulantes, aunque la modulación de los
microRNAs mediada por L-EVOO y M-EVOO fue más similar entre ellos que con H-EVOO.
4. Los niveles circulantes de miR-155, miR-328 y miR-92a están modulados de manera
diferente por el consumo de cerveza y cerveza no alcohólica, sugiriendo un efecto
específico del alcohol, mientras que los niveles de miR-320 y miR-17 están reprimidos por
ambos tipos de cerveza, sugiriendo un efecto independiente del alcohol en estos
microRNAs. Todos ellos podrían ser buenos biomarcadores de la ingesta de cerveza y
podrían modular la vía de señalización de IGF1/PIK3/AKT/FOXO/mTOR e inflamación como
lo demuestra nuestro análisis in silico.
5. La cerveza y la cerveza sin alcohol modularon de manera diferente la expresión de miR-145,
miR-17, miR-20a, miR-26b y miR-223 en macrófagos, sugiriendo un efecto específico del
alcohol. Estos resultados sugieren que la cerveza y la cerveza sin alcohol podrían modular
la fisiología de los macrófagos a través de estos microRNAs, que están involucrados en la
vía de señalización e inflamación de IGF1/PIK3/AKT/FOXO/mTOR como lo muestra nuestro
análisis in silico.
6. El efecto de la cerveza y la cerveza sin alcohol en la expresión de microRNAs circulantes y
de macrófagos fue diferente y sugiere un perfil de microRNAs proinflamatorio en la cerveza
con alcohol y un perfil de microRNAs antiinflamatorio en la cerveza sin alcohol.
7. Los niveles circulantes de let-7e, miR-328, miR-26b y miR-92a se correlacionaron con sus
niveles de macrófagos, sugiriendo que los macrófagos podrían ser, en parte, la fuente de
estos microRNAs en plasma.
8. La restricción calórica obtenida con la Dieta Mediterránea hipocalórica y la actividad física
es más efectiva para la pérdida de peso, la composición corporal, la disminución de los
niveles de triglicéridos en plasma y, en general, para la salud cardiovascular que las
recomendaciones del Dieta Mediterránea después de 1 año de intervención.
9. La restricción calórica obtenida con la Dieta Mediterránea hipocalórica y la actividad física
modifica la expresión de miR-30c y miR-130a en macrófagos, los cuáles están involucrados
en el metabolismo de los lípidos y la regulación de la señalización de mTOR, sugiriendo un
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efecto beneficioso. Sin embargo, no encontramos ninguna modulación significativa de 
microRNAs circulantes, lo que sugiere que se necesita una intervención más aguda y 
prolongada para detectar cambios sustanciales. 
10. La restricción calórica obtenida con la Dieta Mediterránea hipocalórica y la actividad física
podría retrasar la disfunción del sistema inmunológico relacionada con la edad, debido a
los niveles más altos observados de CD28 y CD57 en los linfocitos de los participantes de
intervención en comparación con los participantes control.
11. En general, let-7e y los miembros del cluster miR-17-92 (miR-17, mir-20a y miR-92a) fueron
modulados consistentemente por diferentes intervenciones tanto en plasma como en
macrófagos, sugiriendo que están modulados de manera importante por la dieta en
humanos y podrían ser mediadores del efecto de los nutrientes sobre la fisiología celular
en diferentes tejidos.
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